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A bstract
Syntheses of some chiral analogues of the second messenger D-myo-inositol 1,4,5- 
trisphosphate [Ins(l,4,5)P3], using carbohydrates as starting materials, are described. 
Methyl a-D-glucopyranoside was converted by an improved procedure to methyl 4,6-0- 
benzylidene-a-D-glucopyranoside and thence to methyl 3-0-benzoyl-2-0-benzyl-4,6-0- 
benzylidene-a-D-glucopyranoside without recourse to column chromatography. The 
latter compound was converted to methyl 3,4-di-0-benzoyl-2-0-benzyl-6-deoxy-a-D- 
xy/o-hex-5-enopyranoside via methyl 3,4-di-0-benzoyl-2-0-benzyl-6-bromo-6-deoxy-a 
-D-glucopyranoside. Rearrangement of the hex-5-enopyranoside with mercury (II) 
trifluoroacetate provided (25, 3R, 45, 5R)-2,3-dibenzoyloxy-4-benzyloxy-5-
hydroxycyclohexanone and (25, 3/?, 45, 55)-2,3-dibenzoyloxy-4-benzyloxy-5-
hydroxycyclohexanone. Attempts to invert the configuration at position 5 of the latter 
were unsuccessful, but provided a number of discrete products. Reduction of (25, 3R, 
45, 5R)-2,3-dibenzoyloxy-4-benzyloxy-5-hydroxycyclohexanone and saponification 
furnished D-l-0-benzyl-3-deoxy-jcy//o-inositol, which was phosphorylated and 
deprotected to give the first target compound, D-2-deoxy-myo-inositol-1,3,4,5- 
tetrakisphosphate.
Methyl a-D-glucopyranoside was protected as its 4,6-0-(p-methoxybenzylidene) 
derivative. Regioselective benzylation followed by p-methoxybenzylation and reductive 
cleavage of the acetal furnished methyl 2-0-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D- 
glucopyranoside. This compound was oxidised to the corresponding aldehyde which 
was subjected to a samarium (II) iodide-catalysed ring contraction to yield (1/?, 25, 35, 
4R, 55)-3-benzyloxy-4-hydroxy-5-hydroxymethyl-1,2-di-(p-methoxybenzyloxy)cyclo- 
pentane. This compound was benzylated and hydrolysed under acidic conditions to give 
(li?, 25, 35, 4R, 5/?)-3-benzyloxy-5-benzyloxymethyl-1,2,4-trihydroxycyclopentane, 
which was further elaborated to furnish the second target compound, (1R, 2R, 35, 4R, 
55)-3-hydroxy-5-hydroxymethyl-1,2,4-trisphosphocyclopentane.
Methyl a-D-glucopyranoside was converted to (E,Z)-methyl 6-0-acetyl-3,4-0- 
isopropylidene-2-0-(p-methoxybenzyl)-a-D-xy/o-hex-5-enopyranoside, which failed to 
yield a cyclohexanone when treated with mercury (II) acetate in aqueous acetone.
An anomeric mixture of allyl glucopyranosides was obtained by Fischer glycosylation 
and the Oranomer was isolated by crystallisation. Treatment of the anomeric mixture 
with 1.05 equiv. dibutyltin oxide followed by 2.1 equiv. of benzoyl chloride gave allyl
2.6-di-0-benzoyl-a-D-glucopyranoside, which was converted in 3 steps to allyl 2,6-di-
0-benzyl-3,4-0-isopropylidene-a-D-glucopyranoside. Alternatively, treatment of the 
pure a-anomer with 2.5 equiv. of dibutyltin oxide followed by benzyl bromide gave 
allyl 2,6-di-0-benzyl-a-D-glucopyranoside which was also converted to the 3,4-0- 
isopropylidene derivative. Allyl 2,6-di-0-benzyl-a-D-glucopyranoside was converted to
2.6-di-0-benzyl-3,4-di-0-(p-methoxybenzyl)-D-glucopyranose, a useful intermediate for 
the synthesis of adenophostin A and related compounds.
Allyl 2,6-di-0-benzyl-3,4-0-isopropylidene-a-D-glucopyranoside was elaborated to the 
phosphorylation precursor (2-hydroxyethyl) 2,6-di-0-benzyl-a-D-glucopyranoside in a 
convenient one-pot reaction, and this precursor was phosphorylated and deblocked to 
afford the third target polyphosphate (2-hydroxyethyl) a-D-glucopyranoside 2',3,4- 
trisphosphate.
Allyl 2,6-di-0-benzyl-a-D-glucopyranoside was converted in four steps to 
(2-hydroxyethyl) a-D-glucopyranoside 3,4-bisphosphate-2'-phosphorothioate, which was 
attached to a BODIPY FL fluorescent label.
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1 .1  T r a n sm em br a n e  S ig na llin g  S ystem s
Intercellular communication is essential in multicellular organisms to co-ordinate the 
diverse activities of different cell types. In mammals such communication occurs by the 
endocrine and paracrine systems, and neurotransmission. Hormones and 
neurotransmitters, once released, often bind to receptors on the outer surface of plasma 
membranes of their target cells.
With the exception of steroid and thyroid hormones, which are internalised, these 
hydrophilic transmitters are unable to cross the hydrophobic plasma membranes. 
Therefore a transduction mechanism is required to couple the incoming signal to an 
intracellular response.
Three main classes of plasma membrane receptor have been identified:
i) Those which are intrinsically ion channels. On stimulation, a dramatic alteration in 
their permeability to ions occurs within fractions of a millisecond and a rapid entry of 
ions into the cells occurs. This system is by far the fastest transduction process and has 
evolved where the swiftest response to the extracellular stimulus is required, e.g. in 
nervous impulse conduction. An example is the nicotinic acetylcholine receptor1 found 
on postsynaptic membranes of cholinergic synapses. In response to acetylcholine the 
postsynaptic neurone is depolarised and an action potential is initiated in the adjacent 
axon or muscle membrane.
ii) Those which are intrinsically tyrosine kinase enzymes. These proteins span the 
membrane and binding of the extracellular agonist alters the conformation of the kinase 
and causes pairs of receptors to dimeiise. The association of the two intracellular kinase 
domains results in autophosphorylation of tyrosine residues in these domains. The 
autophosphorylated tyrosine residues then tightly bind to phosphotyrosine residues of 
particular intracellular receptors, causing activation of enzymes or transcription factors. 
This transduction system is relatively slow and tends to be the effector for growth 
factors and the longer-acting hormones, such as insulin.
1
iii) Those whose transduction mechanism occurs via GTP-binding (“G-”) proteins. This 
class, termed “metabotropic” receptors, is schematically represented in fig. 1.1. Binding 
of an agonist (the “first messenger”) to its extracellular receptor (step 1) stimulates a G- 
protein to release a molecule of GDP and bind GTP (step 2). The G-protein then 
activates a membrane-bound enzyme to catalyse the release of the “second messenger” 
(step 3). There are many subtypes of G-protein3 and several second messengers have 
been identified. These are adenosine 3',5-cyclic monophosphate (cAMP, 1) (reviewed4) 
and guanosine S'.S’-cyclic monophosphate (cGMP, 2) (reviewed5) which activate protein 
kinases, D-myo-inositol-1,4,5-trisphosphate* [Ins(l,4 ,5)P3, 3a] which mobilises Ca2+ 
from intracellular stores,6 and diacylglycerol (DAG, 4) (reviewed7) which activates 
protein kinase C. In addition, two putative second messengers are phosphatidylinositol
3,4,5-trisphosphate [PtdIns(3,4 ,5)P3, 5] (reviewed8) and cyclic adenosine diphosphate 
ribose (cADP-ribose, 6) (reviewed9).
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Fig. 1.1 Schematic representation of G-protein-mediated transmembrane 
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Two important consequences of transduction (in addition to variation of speed of 
response) are as follows: First, one molecule of extracellular agonist can cause many 
molecules of second messenger to be produced, i.e. there is an amplification of the 
signal across the cell membrane. This amplification leads to an extremely sensitive 
system as relatively small changes in the concentration of liberated second messenger 
have an enormous impact upon cell physiology. Second, the same extracellular agonist 
can elicit a markedly different response in different tissues. This may occur either a) by 
utilisation of different classes of plasma membrane receptor, e.g. acetylcholine nicotinic 
receptors are of the ion channel type while muscarinic receptors are coupled to G- 
protein systems or b) by utilising different second messengers, e.g. the Hi-histaminic 
receptor is coupled to Ins(l,4 ,5)P3 production, whereas the H2-receptor is coupled to 
cAMP production.10 In addition, heterogeneity in G-proteins and potential functional 
differences in second messenger receptor subtypes offer many possibilities for variation 
in type and degree of response. It should be emphasised that none of these systems 
operates in isolation. In healthy cells a delicate equilibrium exists between the various 
transduction systems.
The overall project in these laboratories, of which this thesis forms a part, is concerned 
with the study of the interaction of the second messenger Ins(l,4 ,5)P3 with its 
intracellular receptor. An extensive review of the chemistry and biology of the 
Ins(l,4 ,5)P3 signalling pathway has recently been published.11 The remainder of this 
chapter will briefly introduce the phosphoinositide system. Two topics will be 
considered in detail: the Ins(l,4 ,5)P3 receptor, because many biochemical advances have 
recently been reported; and structure-activity relationships at the receptor, which form 
the most important background for the work described in this thesis.
1 .2  T he P hosphoinositide S ystem
1.2.1 Phospholipids
Inositol-containing phospholipids account for less than 10% of the total phospholipid in 

















Fig. 1.2 Metabolism of phosphatidylinositol phosphates. 
PME=specific phosphomonoesterase.
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(10) R i=PO |; R2=R3=H
(11) R!=R2=P03; R3=H
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phosphatidylinositol 4-phosphate [PtdIns(4)P, 8], and phosphatidylinositol 4,5- 
bisphosphate [PtdIns(4 ,5)P2, 9] were elucidated by Brockerhoff and Ballou12 in 1961, 
while more recently phosphatidylinositol 3-phosphate [PtdIns(3)P, 10] ,13 phosphatidyl­
inositol 3,4-bisphosphate [PtdIns(3,4)P2, l l ]14 and phosphatidylinositol 3,4,5- 
trisphosphate (5)15 have been identified. The metabolic pathway controlling the 
interconversion of these compounds is summarised in fig. 1.2. In animals, the sn-l 
glycerol carbon atom is usually linked to stearic acid and the sn-2 carbon atom to 
arachidonic acid, as shown. In plants, the sn-2 carbon is linked to linoleic acid and the 
sn-\ carbon to one of several fatty acids.11
Ptdlns, which forms about 90% of the inositol-containing phospholipid in animals, is 
chiefly located in the endoplasmic reticulum. The other phospholipids described above 
occur on the inner leaflet of the plasma membrane.
1.2.2 Discovery of the Second Messenger Role of Ins(l,4,5)P3
In 1953 Hokin and Hokin16 demonstrated that acetylcholine stimulated the incorporation 
of [32P]HPC>42- into phospholipids from pancreatic acinar cells. This was interpreted as 
acetylcholine stimulating the synthesis of phospholipid and subsequent studies indicated 
the major phospholipid to be Ptdlns. Over twenty years later, Michell17 noted that 
agonists which stimulated such phospholipid turnover also raised intracellular Ca2+ 
concentration and suggested these phenomena were linked. In 1983 Streb et a /.18 
showed that Ins(l,4 ,5)P3 was the phospholipid-derived second messenger responsible 
for mobilising intracellular Ca2+.
It is now well established that on extracellular stimulation (step 1; fig. 1.3) the receptor 
activates a G-protein(step 2), which then stimulates phospholipase C to hydrolyse the 
minor membrane phospholipid PtdIns(4,5)P2 into Ins(l,4 ,5)P3 and DAG (step 3). 
Ins(l,4 ,5)P3 diffuses into the cytosol, binds to its receptor and causes release of Ca2+ 
from the endoplasmic reticulum into the cytosol (step 4). Ins(l,4 ,5)P3 is then
inactivated by metabolism (step 5). Each of these five processes has been intensively 











Fig. 1.3 Sequence of events in signal transduction pathways involving 
phosphoinositide turnover. Most of the effects of Ca2+ result from its binding to 
calmodulin.
1.2.3 Extracellular Receptors Coupled to Ins(l,4,5)P3 Production
The fundamental importance of the phosphoinositide system is illustrated by table 1.1, 
which shows the range of different receptors known to be coupled to the pathway. All 
G-protein-linked receptors characterised so far exhibit the same general structure. They 
consist of a single polypeptide chain possessing seven regions rich in hydrophobic
7
amino acids which form the membrane-spanning domains. These transmembrane 
domains interact to provide the extracellular agonist binding site. In the case of 
phosphoinositide-coupled receptors, binding of the agonist induces a conformational 
change in the protein which causes the second and third cytoplasmic loops of the 
receptor to interact with and thereby activate an associated G-protein. The topic of 
receptor-G-protein interaction has been reviewed.19
Receptor Type Endogenous ligand(s)
oc j-adrenoceptors NA, adrenaline
Angiotensin ATj Angiotensin II
Bombesin BB} & BB2 GRP, NMB
Bradykinin B, & B2 Bradykinin, kallidin, T-kinin
Cholecystokinin & gastrin Cholecystokinin, gastrin
Endothelin ETA & ETB Endothelins 1-3
Glutamate mGluR! & mGluR5 Glutamate
Histaminic H, Histamine
5“HT2A-2C 5-HT
Leukotriene BLT & CysLTj LTB4, LTC4, LTD4, LTE4, (12R)-HETE 
(BLT), Lipoxin A4 (CysLT,)
Muscarinic Mlt M3 & M5 Acetylcholine
Neurotensin Neurotensin, Neuromedin B
Prostanoid EP, & EP3 p g e 2
FP p g f 2„
TP TxA2
PAF PAF
Purinoceptors P2Y & P2U ATP, ADP, AMP, UTP (P2U)
Tachykinin N K ^ Substance P, Neurokinins A-B, 
Neuropeptides K, y
Vasopressin V1A, V1B & OT Vasopressin
Table 1.1. Receptors known to be coupled to phosphoinositide turnover. Compiled from 
Trends Pharmacol. Sci. 1995 Receptor and Ion Channel Nomenclature Supplement.10 
Abbreviations: NA, noradrenaline; GRP, gastrin releasing peptide; HETE,
hydroxyeicosatetraenoic acid; NMB, neuromedin B; 5-HT, 5-hydroxytryptamine; LT, 
leukotriene; PAF, platelet activating factor; Tx, thromboxane.
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1.2.4 G-Proteins
Signal transducing G-proteins are of two general types. “Small G-proteins” are 
involved in regulation of cell growth, protein secretion and intracellular vesicle 
interaction. Heterotrimeric G-proteins are involved in signal transduction from cell 
surface receptors. There are several subfamilies of heterotrimeric G-proteins and that 
responsible for phosphoinositide metabolism is designated Gq. Trimeric G-proteins 
consist of a relatively large subunit (a), a slightly smaller one (p) and a much smaller 
one (y). The G-protein is attached to only the cytoplasmic side of the plasma membrane, 
as represented in fig. 1.3.
In the resting state the three subunits are bound together and a molecule of GDP is 
bound to the a-subunit. On extracellular agonist activation, the receptor’s conformation 
is altered such that it interacts with a nearby G-protein trimer. The interaction 
stimulates the dissociation of bound GDP from the a-subunit, which rapidly binds a 
molecule of GTP. The a-subunit-GTP complex dissociates from the Py-complex and 
diffuses through the membrane until it encounters a molecule of phospholipase C (PLC; 
also referred to as phosphoinositidase C), which it activates. The bound GTP molecule 
is gradually hydrolysed to GDP, i.e. the a-subunit is a GTPase. The GDP-a-subunit 
complex does not activate PLC, dissociates from it and rejoins the Py-complex, 
returning the G-protein to its resting state. G-proteins have been the subject of
3,19,20reviews.
1.2.5 Phospholipase C
“Phospholipase C” is actually a family of related phosphodiesterases. These enzymes 
require calcium to function, and are membrane-bound proteins. They will hydrolyse 
Ptdlns, PtdIns(4)P and PtdIns(4,5)P2 in vitro but PtdIns(4,5)P2 appears to be the main 
substrate in vivo.21 The specific enzyme responsible for hydrolysing PtdIns(4,5)P2 has 
been identified as phospholipase Cp.6 On activation by the GDP-a-subunit complex, 









Fig. 1.4 Site of action of Phospholipase C
DAG itself is a second messenger. It stays in the plane of the membrane and activates 
protein kinase C. This kinase phosphorylates specific serine and threonine residues in 
target proteins, including the insulin receptor. DAG can be subsequently cleaved to give 
arachidonic acid, the precursor to the eicosanoids. PLCP is therefore an important 
catalyst for the liberation of two second messengers.
The highly charged Ins(l,4 ,5)P3 molecule diffuses into the cytoplasm, crosses the 20nm 
gap separating the plasma membrane and the endoplasmic reticulum, and interacts with 
its receptor.
1.2.6 The Ins(l,4,5)P3 Receptor
The Ins(l,4 ,5)P3 receptor is situated in the lipid bilayer of the endoplasmic reticulum 
(ER). In cerebellar Purkinje cells, where it is expressed in abundance,22 the receptor 
was found to be incorporated into the smooth ER, but was also present in rough ER and 
on the outer nuclear membrane.11 Cloning of the receptor cDNA from several sources 
has confirmed that its structure is highly conserved and that it is a tetrameric ligand- 
gated ion channel, as represented in fig. 1.3. This Ca2+-channel is dissimilar to Ca2+-
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channels in the plasma membrane,11 but is both structurally and functionally similar to 
the ryanodine receptor, which is responsible for Ca2+ mobilisation in cardiac and 
skeletal muscle, and this similarity has been reviewed.6
Each of the four subunits of the Ins(l,4 ,5)P3 receptor is capable of binding one molecule 
of Ins(l,4 ,5)P3. Meyer et al.23 found evidence of cooperativity and suggested that four 
molecules of Ins(l,4 ,5)?3 had to bind sequentially for channel opening to occur, 
although other studies24,25 found no cooperativity, suggesting that a single molecule of 
Ins(l,4 ,5)P3 could open the channel. A recent study26 using the purified type I receptor 
{vide infra) found positive cooperativity and evidence that kinetically the receptor has 
two states for Ca2+ release. One has a high affinity for Ins(l,4 ,5)P3 and a low 
permeability to Ca2+ ions. This state causes a slow release of Ca2+ from the stores. The 
second has low affinity for Ins(l,4 ,5)P3 and a high permeability to Ca2+ ions, and causes 
a rapid release of Ca2+. Their data suggest that the fast phase of Ca2+-release increases 
with increasing Ins(l,4 ,5)p3 concentration, and that this receptor state is responsible for 
quantal Ca2+ release.26 The discrepancies in cooperativity results23-26 illustrate the 
difficulties biologists face in attempting to compare results from different experimental 
systems.
The receptor comprises three functional regions, the Ins(l,4 ,5)P3-binding region, the 
Ca2+-channel and a regulatory area.
i) Ins(l,4,5)Py-binding region Ins(l,4 ,5)P3 appears to bind within the amino-terminal 
20% of the receptor, based upon photoaffinity labelling studies with 
[3H](benzoyldihydrocinnamyl)aminopropyl-Ins(l,4 ,5)P327 and mutagenesis studies.28 
Structure-activity relationships at the Ins(l,4,5)P3 receptor are considered in detail in 
section 1.3.
ii) Ion channel region The 600 amino acids at the carboxyl terminus contain a
2+ 29hydrophobic transmembrane domain which is believed to constitute the Ca -channel, 
i.e. the Ca2+-channel is an intrinsic part of the receptor. There appear to be 6-8 
transmembrane units.29-31
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iii) Regulatory region Ins(l,4,5)P3-stimulated Ca2+-release is an “all-or-nothing” 
effect,6 but various processes can alter the effectiveness of Ins(l,4,5)P3 on channel 
opening. The area of the receptor which is modified to effect these changes is located 
between the N-terminus Ins(l,4,5)P3-binding region and the C-terminus channel. A 
cAMP-dependent protein kinase can phosphorylate two serine residues, although again 
there are conflicting reports of the effect. In some systems ’ a partial reduction of 
Ins(l,4,5)P3-induced Ca2+-release was found, while in others34-36 Ca2+-release was 
increased. At low concentrations ATP potentiates Ins( 1,4,5)P3-stimulated channel 
opening.11 Ca2+ itself can exert a positive feedback25 which has been reviewed.6 A 
schematic representation of the Ins(l,4,5)P3 receptor, summarising the points above, is 













Fig. 1.5 Schematic representation of the Ins(l,4,5)P3 receptor showing the functionally 
distinct regions.
Subtypes of the Ins(l,4,5)P3 receptor have been identified. It should be emphasised, 
however, that classification has not arisen on a classical pharmacological basis by
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considering differing effects of compounds on different receptor populations (e.g. 
acetylcholine receptors stimulated by muscarine or nicotine). Rather, these proteins 
contain different primary sequences as identified by molecular cloning and sequencing 
experiments. (Early purification techniques24 relied upon heparin-agarose columns, 
which, as heparin binds many receptor subtypes, provided a mixture of these subtypes).
In rat, type I, II and ID receptors have been identified, containing 2749, 2701 and 2670 
amino acids respectively and sharing 62-69% sequence homology.29,37,38 De Smedt et 
al.39 have shown that the type I receptor is present in most tissues, whereas types II and 
IQ are less widespread. Recently the human type I receptor has been purified and 
characterised from platelets.40 Putative type IV receptors from mouse placenta41 and rat 
basophilic leukaemic cells ’ and a putative type V receptor from mouse fibroblasts 
have been reported.
It was originally believed that receptor subtypes were all homotetrameric. However, it 
has recently been shown that distinct monomer subunits combine to form 
heterotetramers in many cell types where two43 or all44 of receptor types I, II and HI are 
abundantly expressed. This phenomenon could greatly increase the number of 
structurally distinct receptor types, although the observed proportions of heterotetramers 
suggest that they do not arise through random mixing.43
Any physiological significance of multiple receptor types remains to be established. 
Monkawa et al.44 noted that in voltage-dependent K+ channels and cyclic nucleotide- 
gated cation channels, hetero-oligomeric channels have different properties from the 
homo-oligomeric ones, and speculated that this could also be the case with the 
Ins(l,4 ,5)P3 receptors.
Some experimental differences between receptor subtypes have been reported:
i) The protein kinase A phosphorylation sites (vide ultra) present in receptor type I are 
not present in types II and HI.43,44
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ii) There is a calmodulin binding-site in type I and II receptors that is not present in type 
HI.44 This may be significant as most of the effects of Ca2+ arise from its binding to 
calmodulin.
iii) Binding specificities of eight inositol phosphates were determined for the type I and 
type II receptors. The compounds displayed the same rank order, but different absolute 
values, the type II receptor having the higher affinity for Ins(l,4,5)P3.37 It has been 
suggested37,44 that different receptor types may respond to different levels of 
Ins(l,4,5)P3 within the cell. This is an attractive hypothesis because it represents a 
second mechanism (in addition to the dual affinity states observed in the type I receptor) 
for different amounts of Ca2+ to be released despite the observed “all-or-nothing” 
mechanism: different receptor subtypes would release their Ca2+ stores sequentially 
depending on their variable sensitivities to Ins(l,4,5)P3.
iv) Wojcikiewicz45 has demonstrated that type I, II and ID receptors are down-regulated 
to different extents when AR4-2J cells are exposed to various extracellular agonists 
coupled to the Ins(l,4,5)P3 second messenger pathway.
1.2.7 Metabolism of Ins(l,4,5)P3
Anabolism: In mammals dietary intake is the main source of myoinositol, which 
abounds in plant material. It can also be synthesised de novo from glucose-6-phosphate 
via L-Ins(l)P by the sequential action of the enzymes L-myo-inositol-1 -phosphate 
synthase (see fig. 2.5, chapter two) and inositol monophosphatase (fig. 1.6). The latter 
enzyme also dephosphorylates Ins(4)P, Ins(5)P and Ins(6)P and is therefore an important 
component in the production of free inositol.
Lithium ions inhibit inositol monophosphatase and it has been suggested that this 
inhibition may contribute to the effectiveness of lithium salts in the treatment of manic 
depression.46 As lithium has a notoriously low therapeutic index,47 considerable effort 
has been invested in attempting to understand the mechanism of dephosphorylation and 













D-glucose-6-phosphate L-myo-inositol-1 -phosphate myo-inositol
Fig. 1.6 De novo synthesis of myo-inositol
Inositol is incorporated into the phosphatidylinositol metabolic pathway by 
phosphatidylinositol synthetase, which combines it with cytidine-phosphatidate to form 
Ptdlns (7) and cytidine 5'-monophosphate. The subsequent conversion of (7) into 
PtdIns(4,5)P2 (9) was outlined in fig. 1.2.
Catabolism: Once biological messengers have exerted their effects, they must be 
efficiently deactivated so the cell can return to its basal state. Ins(l,4,5)P3 can be 
deactivated by a low affinity, high capacity 5-phosphatase which generates Ins(l,4)P2
(12), or a high affinity, low capacity 3-kinase which produces Ins(l,3,4,5)P4 (13). Dual 
deactivation systems with these affinity/capacity differences are found throughout 
nature, for example uptake-1 and uptake-2 of noradrenaline.48 Both 5-phosphatase and







Much effort has been invested in attempting to prepare suitable inhibitors of these 
enzymes to use as pharmacological tools (reviewed11). In brief, many analogues of 
Ins(l,4,5)P3 bind to 5-phosphatase but few are substrates. Very few analogues bind to
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3-kinase with high affinity and even fewer are substrates. Inhibitors of these enzymes 
which do not themselves mobilise intracellular Ca2+ are potentially useful and several 
have been developed, e.g. L-2-deoxy-2,2-difluoro-Ins(l,4,5)P3 (14b) is a potent 






Ins(l,4)P2 has no known role in Ca2+ homeostasis, although it has been shown to 
allosterically activate 6-phosphofructo-l-kinase in vitro.51 Whether Ins(l,3,4,5)P4 has a 
physiological function is unclear and this controversy is reviewed in chapter two. 
Metabolites of Ins(l,4,5)P3 themselves undergo extensive phosphorylation and 
dephosphorylation, resulting in a plethora of naturally occurring inositol phosphates (fig. 
1.7), many of which do not have any known physiological significance. Inositol 
phosphate metabolism and potential biological functions of inositol phosphates other 
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Fig. 1.7 Metabolism of inositol phosphates.
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1.3 S t r u c t u r e - A c t t v i t y  R e la t io n s h ip s  a t  T h e  Ins(l,4,5)P3 R e c e p to r
1.3.1 General Comments
An underlying aim of the work described in the subsequent chapters of this thesis was to 
ascertain whether various structurally diverse polyphosphates based on inositol, 
cyclopentane and glucose retained sufficient of the Ins(l,4,5)P3 pharmacophore to 
mimic Ins(l,4,5)P3-stimulated Ca2+-mobilisation. A detailed understanding of structure- 
activity relationships at the Ins(l,4,5)P3 receptor leading to a tentative definition of the 
pharmacophore is therefore essential. This subject has been recently reviewed11 and 
will be considered in detail here.
The inositol polyphosphates described below have not all been tested in the same 
system. Ins(l,4,5)P3 receptors from brain, Xenopus oocytes, Swiss 3T3 cells, GH3 cells, 
hepatocytes, platelets, pancreatic and parotid acinar cells, skeletal muscle triads, SH- 
SY5Y neuroblastoma cells, rat basophilic leukaemic cells and Limulus photoreceptors 
are routinely used in pharmacological experiments. Therefore absolute values for half 
maximal concentration for calcium release (EC50) and binding affinity are not directly 
comparable. However, similar patterns emerge from all systems and it is the rank order 
of potency that is important. (Rank orders of EC50 values are rarely different from rank 
orders of binding affinities; therefore, these two parameters are broadly 
interchangeable.) Where binding affinity or EC50 values are given, they are referenced 
to the value for Ins(l,4,5)P3 from the same experiment whenever possible.
To date, no differences in rank order of affinity of a set of analogues tested in different 
purified receptor subtypes have been reported.
1.3.2 Agonists
Most active inositol phosphates and analogues examined to date are full agonists with 
respect to calcium mobilisation.
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1H, 13C and 31P NMR spectroscopic studies have established that the chair conformation 
of Ins(l,4,5)P3 containing three equatorial phosphates and two equatorial hydroxyl 
groups is anancomeric at physiological pH.53
The Ins(l,4,5)P3 receptor exhibits high stereoselectivity. In racemic mixtures, activity is 
usually attributable to one enantiomer, and eudismic ratios are high. This is exemplified 
by d -  and L-Ins(l,4,5)P3 (3a and 3b respectively); (3b) does not mobilise Ca2+ to any 
significant extent and is 1000-2000 times more weakly bound than (3a).54"56
Irvine et al.51 predicted that the minimum structural requirements for calcium release 
were trans vicinal phosphates on positions d - 4  and d -5 ,  and this is supported by the 
relative or absolute lack of activity of inter alia, myo-inositol,58 Ins(l)P,58 Ins(2)P,58 dl-  
Ins(l,4)P2,57,58 DL-Ins(l,3,5)P3,54 L-Ins(l,4,5)P3,54"56 L-2-deoxy-2,2-difluoro-Ins( 1,4,5)P3 
[ L-2,2-F2-Ins(l,4,5)P3 ] (14b)49 DL-myo-inositol 1-phosphate-4,5-pyrophosphate (16),59 
and derivatives in which all three phosphates have been replaced by sulphonamide, 
sulphate, methylphosphonate and carboxymethyl groups.60 Additionally, D-3-deoxy- 
mwa?-Ins(l,4,5)P3 (17), in which the position 4 phosphate is inverted, was found to bind 
almost 1000-fold more weakly to rat cerebellar membranes than Ins(l,4,5)P3, compared 
to a 10-fold reduction by D-3-deoxy-Ins(l,4,5)P3 (18).61 It is worthy of note that 
replacement of phosphate groups with phosphorothioates gives compounds which often 
do release calcium {vide infra).
OH
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Each ring position of Ins(l,4,5)P3 will now be considered independently.
Position 1: The presence of a phosphate group at position 1 of Ins(l,4,5)P3 appears to 
be important in increasing the affinity between the molecule and its receptor as
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Ins(4,5)P2 (19) is bound considerably less tightly than Ins(l,4,5)P3.58 Inversion of 
stereochemistry at position 1, to give D-c/zir0-Ins(l,3,4)P3 (20) resulted in only a ca. 25- 
fold reduction in potency in permeabilised rat basophilic leukaemic cells [EC50 4.2jim; 
cf. Ins(l,4,5)P3 0.17pM].62 The 1-phosphate group of Ins(l,4,5)P3 has been extensively 
modified with little effect on potency. Henne et al.63 attached various large substituents 
to this site and found that even D-./V-octylaminoethanol( 1) 1 -phospho-wyo-inositol 4,5- 
bisphosphate (21) was only about 7-fold less potent than Ins(l,4,5)P3 at mobilising 
calcium from guinea pig parotid acinar cells. Other groups have taken advantage of this 
fact to attach photoaffinity ligands and fluorescent labels to this site.64,65
OH
(20)
Potter and co-workers64 prepared a nitrobenzoxdiazole derivative (22) from d l -  
Ins(l,4,5)P3- lS  (23), while Prestwich et al.65 prepared racemic radiolabelled 
(azidosalicyl)aminopropyl (24) and (benzoyldihydrocinnamyl)aminopropyl (25) 
derivatives. All were found to be potent calcium mobilisers (EC50 for 22 0.64}Im; cf. 
Ins(l,4,5)P3 0.08|llm),66 or to display high affinity for the receptor for 24 and 25 
0.236|1m and 0.500fiM respectively; cf Ins(l,4,5)P3 O.OlpM).27
Given the above observations, it is reasonable to suggest that the 1-phosphate group 
undergoes an electrostatic interaction with a cationic residue (arginine or lysine) such 
that the molecule is tightly bound to the receptor in an orientation allowing protrusion of 
the bulky substituents away from the receptor. Ins(2,4,5)P3 (26) is only about five times 
less potent than Ins(l,4,5)P3.57 It may tentatively be proposed that transfer of the 
phosphate from position 1 to position 2 does not completely abolish interaction with this 
site.
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(23) R i= —P— O” ; R2-H
(24) R i= -
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(26) Ri=H; R2= P 0 3
HO,
NHN = N
(27) R 1= P 0 3 ;R 2=
; R2=H
D
Position 2: Hirata and co-workers67,68 have prepared many analogues of Ins(l,4,5)P3 
modified at position 2. They found that even incorporation of bulky substituents had 
little effect on calcium-releasing activity. For example, racemic (27) had an EC50 value 
of 0.3jim compared to 0.2jxm for Ins(l,4,5)P3 in permeabilised guinea pig peritoneal 
macrophages.67 Incorporation of an additional phosphate group at position 2 to give 
Ins(l,2,4,5)P4 (28) has produced a potent calcium-releasing inositol
tetrakisphosphate,69,70 which exhibited about half the potency of Ins(l,4,5)P3 in SH- 
SY5Y neuroblastoma cells [EC50 106iim; cf. Ins(l,4,5)P3 51.6 nM].70 Replacement of 
the position 3 hydroxyl group with a fluorine atom did not significantly alter Ca2+- 
mobilising potency.70






*71The fact that both hydroxyl deletion and inversion at position 2 (to give DL-2-deoxy- 
Ins(l,4,5)P3 [29] and DL-$cy//oIns(l,2,4)P3 [30] respectively) only result in an 
approximately 2.5-fold decrease in calcium mobilising activity suggests that the 2- 
hydroxyl group has only a weak interaction with the receptor.
Studies involving 2-fluorinated derivatives have helped probe the nature of this 
interaction. (The reasonable assumption is made that L-enantiomers of all the following 
analogues are inactive, as was demonstrated for DL-2,2-F2-Ins(l,4,5)P3 [14ab]).49 2- 
Deoxy-2-fluoro-Ins(l,4,5)P3 (31) was found to be equipotent with Ins(l,4,5)P3 in 
releasing calcium in SH-SY5Y cells [dl-31 EC50 104.7nM; cf. Ins(l,4,5)P3 51.6iim],72 
whereas 2F-scyllo-Ins( 1,4,5)P3 (32) was about 3-fold less potent [dl-32 EC50 0.77|llm; cf. 
Ins(l,4,5)P3 0.13p,M].73 D-2,2-F2-Ins(l,4,5)P3 (14a) was about 1.5 times less potent 
[EC50 0.21jim ; cf. Ins(l,4,5)P3 0.13|1m] 49 Both (31) and (14a) can accept, but not 
donate, hydrogen bonds;74 (32) can donate, but not accept hydrogen bonds. Thus, the 2- 
hydroxyl group of Ins(l,4,5)P3 possibly accepts a hydrogen bond from its receptor.
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Position 3: Modifications of position 3 of Ins(l,4,5)P3 have included its hydroxyl 
deletion,75 inversion76,77 and isosteric replacement with fluorine75,76 (to give 18, 33 and 
34 respectively). All these changes yielded relatively potent calcium mobilisers (e.g. 
EC50 of 33 I.OOhm; cf. Ins(l,4,5)P3 0.1 hm in SH-SY5Y cells).78 The chiral 3-C- 
trifluoromethyl analogue (35) was only threefold less potent than Ins(l,4,5)P3 in binding 
assays,79 suggesting that the receptor can tolerate some steric bulk in the axial position 3 
region of Ins(l,4,5)P3 even when the 3-hydroxyl group is retained. D-2,3-Dideoxy- 
Ins(l,4,5)P3 (36), in which hydroxyl groups at positions 2 and 3 have been deleted, still 
binds firmly and is a relatively potent calcium releasing analogue.75 These results 






(18) R =r 2=h
(33) R =H; R2=OH
(34) R =F; R2=H
(35) R =OH; R2=CF3
(37) R =C1; R2=H
(38) R =Br; R2=H
(39) R =OCH3; R2=H
(40) R =0CH2C 02 ; R2=H
(36) R=OH 
(48) R=H
It has been demonstrated, however, that this position may have poor tolerance for bulky 
groups. A smooth increase in EC50 values (Ca2+-mobilisation in SH-SY5Y 
neuroblastoma cells) was observed when replacing the position 3 hydroxyl of 
Ins(l,4,5)P3 (EC50 0.05jlim) with H (18; 0.16jxm), F (34; 0.12|1m), Cl (37; 0.64pM), Br 
(38; 1.1 ^ m) and methoxy (39; 7.7jim),80 and replacement with ethoxy or n-propoxy 
resulted in even larger increases.81 Notably, DL-3-Omethylenecarboxylate-Ins(l,4,5)P3
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(40) was more potent than this series would predict (EC50 3.5pM),82 possibly because of 
the charge on the carboxylate.81
Whether Ins(l,3,4,5)P4 can mobilise Ca2+ via the Ins(l,4,5)P3 receptor is disputed, and 
this controversy is reviewed in chapter two.
Position 4: No analogues of Ins(l,4,5)P3 modified exclusively at position 4 have yet 
been described (see above for inversion of this position in 3-deoxy analogues), but a 
derivative in which the position 4 phosphate has been conformationally restricted (with 
concomitant charge reduction) has recently been described.83 Racemic (41) (note also 
that the hydroxyl group at position 2 is inverted) was reported to possess an EC50 value 








Position 5: Potentiometric studies have shown that increase in specific binding to brain 
membranes as a function of pH coincides with increasing ionisation of Ins(l,4,5)P3,84 
and particularly of the position 5 phosphate.85 This suggests that the position 5 
phosphate is important in the binding process.
Substitution of the phosphate group at position 5 with a phosphorothioate as in d l -  
Ins(l,4,5)P3-5S (42), produced a potent agonist which could not be deactivated by 5- 
phosphatase.86 This compound was more potent than the multiply modified d l -  
Ins(l,4,5)PS3 (43) (EC50 values of 0.8pM and 2.5|!m respectively; cf. Ins(l,4,5)P3 0.1 l |l 
m ),86 which is not surprising as it more closely resembles the natural ligand.
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A chiral 5-methylenephosphonate analogue (44) of Ins(l,4,5)P3 has been synthesised 
and has been shown to be another long-lived agonist of calcium release.87 A 5-
o o
phosphonate analogue (45) has been reported to be an antagonist of calcium release; 
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Position 6: The hydroxyl group at position 6 is the most sensitive of the three
unphosphorylated hydroxyl groups in the cyclitol to modification. D-6-Deoxy- 
Ins(l,4,5)P3 (47) was found to be 400-fold less potent than Ins(l,4,5)P3 at binding to the 
receptor78 and 70-fold less potent at releasing calcium.89 The receptor binding potency 
is comparable with that of D-2,3,6-trideoxy-Ins(l,4,5)P3 (48), which was found to be 
about 600-fold weaker than Ins(l,4,5)P3 75 Comparing the relative potencies of (48) and 
(36) (above) indicates that loss of binding and calcium releasing potencies of (48) is 






It has been suggested that the 6-hydroxyl group may donate a hydrogen bond to an 
amino acid residue in the receptor,75 or that intramolecular hydrogen bonding to the 1- 










o p o ;
25
The receptor probably cannot tolerate steric bulk at position 6. DL-6-O-Methyl- 
Ins(l,4,5)P3 (49) is 120-fold less potent than Ins(l,4,5)P3 (ref.54) and Ins(l,4,5,6)P4 (50) 
is inactive.80
Although Ley and co-workers have prepared DL-6-deoxy-6-fluoro-Ins(l,4,5)P3 (51) and 
DL-6-deoxy-6-methyl-Ins(l,4,5)P3 (52) from benzene,91,92 biological data on these 
compounds have not been reported.
Multiple modifications: Ins(l,3,4,6)P4 (53) is formed naturally and was first identified 
in adrenal glomerulosa cells exposed to angiotensin II93,94 It is approximately ten times 
less potent than Ins(l,4,5)P3 at mobilising intracellular calcium,95,96 and has been 
unambiguously demonstrated to compete for the same receptor site and to release 
calcium from the same store as Ins(l,4,5)P3.95 Ins(l,3,4,6)P4 only releases 80-90% of 
the Ca2+ mobilised by Ins(l,4,5)P3 in SH-SY5Y neuroblastoma cells,95*97 i.e. it is a 





It is interesting that (53) should have any calcium-releasing capacity at all, since the 
molecule lacks a 4,5-bisphosphate arrangement. However, two binding orientations can 
be envisaged for (53) such that a pseudo d-4 ,  d -5 -  (or, more precisely, d-threo-) 
bisphosphate moiety is presented to the receptor, and these are illustrated in fig. 1.8.
In arrangement (a; fig. 1.8), position 5 of Ins(l,3,4,6)P4 mimics position 6 of 
Ins(l,4,5)P3 with retention of equatorial displacement of the hydroxyl group; in 
orientation b), position 2 of Ins(l,3,4,6)P4 becomes pseudo-position 6 and the hydroxyl 
group is inverted. As stated above, position 6 of Ins(l,4,5)P3 is sensitive to change. 
Therefore, conformation a) is intuitively more likely to be that responsible for Ca2+
26
mobilisation. Two related enantiomeric pairs of trisphosphates have been prepared and 
tested, namely d - (54a) and L-Ins(l,4 ,6)P3 (54b), and d -  (55a) and L-Ins(l,3,4)P3 (55b).
Fig. 1.8 Possible binding orientations of Ins( 1,3,4,6)P4
In permeabilised rabbit platelets, (54a) and (55b) were full agonists for Ca2+-release 
[EC5o 1.56 and 8.05}Xm respectively; cf Ins(l,4 ,5)P3 0.69}Im], while (54b) and (55a) 
only mobilised Ca2+ at concentrations above 100 |1m .98 Compounds (54a) and (55b) 
were also full agonists in rat basophilic leukaemic cells." In Limulus photoreceptors, 
which tend to show an “all-or-nothing” response to agonists, (55b) produced a rapid 
burst of depolarisation similar to Ins(l,4 ,5)P3, while (55a) did not.100
Therefore, eutomers in both cases were the enantiomers which contained a D-threo 
bisphosphate arrangement. Similarly to (53), two binding orientations can be proposed 
for each of these eutomers, such that the bisphosphate mimics that of Ins(l,4 ,5)P3, and 
these are presented in fig. 1.9.
jcy//oIns(l,2,4 ,5)P4 (56), in which the position 2 hydroxyl of Ins(l,4 ,5)P3 is inverted 
and phosphorylated, released Ca2+ with equal potency to Ins(l,4 ,5)P3.72 This is 
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Fig. 1.9 Possible binding orientations of D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3
The most potent agonists described to date are the naturally occurring adenophostins, 
which are discussed in chapter five.
In conclusion, a reassessment of requirements for agonism and definition of the 
pharmacophore would suggest a D-threo bisphosphate (or phosphorothioate) 
arrangement to be an essential feature, while a third suitably orientated phosphate and a 
pseudo-position 6 hydroxyl group increase potency.
1.3.3 Partial Agonists
As discussed above, Ins(l,3,4,6)P4 was the first partial agonist to be described, releasing 
80-90% of the Ca2+ mobilised by Ins(l,4,5)P3 in SH-SY5Y cells. Jcy//o-Ins(l,2,4,5)PS4
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Only a few other partial agonists have been identified. L-c/z/ro-Ins(2,3,5)PS3 (58) and d-
6-deoxy-Ins(l,4,5)PS3 (59) both competed fully with Ins(l,4,5)P3 for [3H]Ins(l,4,5)P3 
binding sites on adrenal cortical membranes, but, respectively, released 34% and 42% of 
the calcium released by Ins(l,4,5)P3.97 DL-Ins(l,3,4)PS3 (60) and DL-Ins(l,4,6)PS3 (61) 
were also found to be partial agonists, releasing ca. 30% and 20% respectively of the 
Ca2+ store mobilised by Ins(l,4,5)P3.101 The partial agonism of these 







D-3-Amino-3-deoxy-Ins(l,4,5)P3 (62) has been characterised as a pH-dependent partial 
agonist.103 Thus, at pH 7.2 and 7.6 (62) was a full agonist [EC50 values 1.07 and 1.49pM 
respectively; cf. Ins(l,4,5)P3 0.05 and 0.1 lpM respectively], while at pH 6.8 it was a 
partial agonist, releasing ca. 80% of the Ca2+ store mobilised by Ins(l,4,5)P3.103 This
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was surprising as the amino function would be expected to be in its conjugate acid form
i niat all three pH values. It has been suggested that the lower pH might cause 
conformational changes in amino acid residues around the binding site.
Too few partial agonists have been prepared to allow generalisations to be made as to 
structural requirements for partial agonism. This is a challenge of the next few years.
1.3.4 Antagonists
The most well characterised antagonism of Ins(l,4,5)P3-induced Ca2+ release is 
produced by heparin (63). The competitive and reversible inhibitory action of heparin 
has been demonstrated to be mediated through its interaction with the Ins(l,4,5)P3 
receptor in several cell types,104-108 and it has been shown that both N- and 0-linked 
sulphate groups are important.109 Ghosh et a l.105 calculated a K\ value of 2.1mA for 4 - 








The basic structure of heparin (63)
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Heparin is of little use in structure-activity studies as it is a large molecule and relatively 
non-selective, for example it also inhibits the ability of Ins(l,3,4,5)P4 to bind to 
cerebellar membranes.110 However, the molecule has proved useful in other 
experiments. Showing that the activity of novel agonists is heparin-sensitive 
demonstrates that they compete for the same receptor site as Ins(l,4,5)P3. And, when 
isolating the Ins(l,4,5)P3 receptor from rat brain, Supattapone et al.24 used a heparin- 
agarose column to purify the receptor.
Another antagonist is the polyoxoanion decavanadate, which inhibited Ins(l,4,5)P3- 
induced calcium release in permeabilised rat insulinoma and PC 12 cells,111 but the agent 
was subsequently found to possess low specificity, binding to all known recognition 
sites for both Ins(l,4,5)P3 and Ins(l,3,4,5)P4.112 Strupish et al.112 suggested that oxygen 
atoms become placed in areas usually occupied by the 4,5-bisphosphate moiety of 
Ins(l,4,5)P3.
There have been two reports of small-molecule antagonists of calcium release by 
Ins(l,4,5)P3. The first was the 5-phosphonate analogue (45) of Ins(l,4,5)P3,88 the 
biological data for which have only appeared in preliminary form and have yet to be 
confirmed. The second was benzene-1,2,4-trisphosphate (64),113 which only grossly 
resembles Ins(l,4,5)P3 insomuch as having vicinal phosphates on one side of the 
molecule and a third phosphate on the other side. Compound (64) was reported to 




A model of the binding site of the Ins(l,4,5)P3 receptor may be tentatively proposed 
from the biological results of the compounds discussed in section 1.3. The model is 
schematically represented in fig. 1.10.
1 .4  S y n th e s is  o f  I n o s i t o l  P h o sp h a te s  fr o m  u i j o - I n o s i t o l
1.4.1 General Considerations
The study of structure-activity relationships at the Ins(l,4,5)P3 receptor (and other 
binding proteins) requires syntheses of analogues. The most common starting material 
is myo-inositol (although many other imaginative compounds have been used11) and a 
number of problems must be overcome:
i) Selective protection of some of the hydroxyl groups must be achieved to provide the 
phosphorylation precursor.
ii) Selective protection of the meso-starting material usually leads to racemic mixtures 
of subsequent compounds. Occasionally, one enantiomer may have an unpredicted or 
unwanted activity {e.g. 14b inhibited the phosphorylation and dephosphorylation of its 
enantiomer 14a). Therefore, ideally intermediates should be resolved to provide 
optically pure target compounds.
iii) A phosphorylation procedure must be employed such that cyclic phosphates do not 
form.
iv) The protected, phosphorylated intermediate must be deprotected without phosphate 
migration and the final polyphosphate must be efficiently purified.
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Cationic residues to which 
D-threo bisphosphate 
binds - essential for channel 
opening and Ca2+ mobilisation
Position 3 hydroxyl positioned 
with sufficient space for inversion 
but not bulky substitution
Hydrogen bond-donating 
residue with which hydroxyl 
at position 2 interacts
Area of space into which 
bulky substituents on 
position 1 phosphate and 
position 2 hydroxyl can 
protrude
Cationic residue to which 
phosphate at position 1 binds, 
but accessible to phosphates 
at position 2
6-hydroxyl buried in 
pocket such that bulky 
substitution is not 
tolerated. Weak binding 
of 6-deoxy-Ins(l,4,5)P3 
suggests hydrogen-bonding 
occurs at this position.
Fig. 1.10 Schematic representation of the proposed shape of the Ins(l,4,5)P3 binding site.
The discovery of the second messenger function of Ins(l,4,5)P3 in 198318 led to 
considerable chemical investigation of the synthesis of inositol phosphates. During the 
late 1980s, as chemists attempted to solve the problems outlined above, the inositol 
phosphates they synthesised seemed almost chosen at random. More recently, choices 
of target compound have become more rational, in an effort to probe stracture-activity 
relationships, as described in section 1.3.
Detailed reviews of inositol phosphate chemistry and the preparation of inositol 
phosphates have appeared.11,114-116 Additionally, two excellent complementary texts on
117 1 1Aprotecting group chemistry have been published. ’ Here, the subject will be covered 
by reviewing a single typical example. The synthesis of d- (55a) and L-wyo-inositol- 
1,3,4-trisphosphate (55b) by Riley et a/.100 illustrates many of the difficulties described 
above.
1.4.2 Synthesis of d- and L-myo-inositol-l,3,4-trisphosphate
D-Ins(l,3,4)P3 is produced in vivo by the action of 5-phosphatase on Ins(l,3,4,5)p4 and 
occupies a central position in inositol phosphate metabolism (reviewed52,100). There had 
been conflicting reports in the literature with respect to a) the absolute configuration of 
synthetic enantiomers of Ins(l,3,4)P3 and b) its biological properties, particularly with 
respect to Ca2+ mobilisation via the Ins(l,4,5)P3 receptor. Consequently, Riley et a/.100 
designed a novel route to these enantiomers.
The triols required for phosphorylation were d- (65b; fig. 1.11) and L-2,4,5-tri-0-benzyl- 
myo-inositol (65a), and so a route to place benzyl ethers in these three positions was 
required. Treatment of myo-inositol with 2,2-dimethoxypropane and PTSA followed by 
benzoyl chloride allowed the isolation of the poorly soluble DL-3,6-di-0-benzoyl- 
l,2:4,5-di-0-isopropylidene-myo-inositol (66).119 Cleavage of benzoates under basic 
conditions followed by allylation with sodium hydride and allyl bromide provided dl-
3,6-di-O-allyl-1,2:4,5-di-0-isopropylidene-myo-inositol (67). Acidic hydrolysis 
afforded tetrol (68) and stannylene-mediated p-methoxybenzylation gave (69). 
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Fig. 1.11 Synthesis of the enantiomers of Ins(l,3,4)P3.
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di-0-allyl-2,5,6-tri-0-benzyl-3-0-(p-methoxybenzyl)-mjo-inositol (70). Both allyl and 
p-methoxybenzyl ethers may be removed in the presence of benzyl ethers so the six 
steps so far, employing acetals, esters and three varieties of ether had provided 
appropriate regiochemical protection, but intermediate (70) was still racemic. 
Therefore, resolution was required.
Isomerisation of the allyl ethers to prop-l-enyl ethers followed by hydrolysis with mild 
acid, provided racemic diol (71). On esterification with 2 equiv. of the optically pure 
(5)-(-)-co-camphanic chloride, the enantiomers of (71) were converted to 
diastereoisomers. Diastereoisomers usually differ in their physico-chemical properties, 
allowing their separation. In this case (72) and (73) were separated by column 
chromatography. This is not always possible and sometimes separation is achieved by 
first crystallising one diastereoisomer formed with, say, (-)-camphanic chloride, then 
recovering the parent alcohol enriched in the second isomer from mother liquors and 
recrystallising esters formed with (+)-camphanic chloride.
d -  (74b) and L-2,4,5-tri-0-benzyl-l-0-(p-methoxybenzyl)-wyo-inositol (74a) were 
obtained by ester hydrolysis, but it was not known which enantiomer was which. This 
can be determined either by obtaining a crystal structure of the parent diastereoisomer, 
or, if suitable crystals are unavailable, by converting one of the compounds to a known 
chiral intermediate. In this case benzylation and acidic hydrolysis of (74b) provided
1,2,4,5,6-penta-O-benzyl-myo-inositol (75), identified as the lL-(-)-enantiomer by 
comparing its specific rotation to literature values. Therefore, the absolute 
configurations of the resolved enantiomers could be deduced.
Acidic hydrolysis of the enantiomeric diols provided triols (65a) and (65b). Many 
phosphorylation methods are available (reviewed11), but the one used in this example 
employed a P(HI) reagent. Bis(benzyloxy)(diisopropylamino)phosphine was reacted 
with l//-tetrazole to provide a tetrazolide intermediate. One of the chiral triols was then 
added to rapidly provide a trisphosphite. This was oxidised to the fully protected 
trisphosphate (76a or b) with f-butyl hydroperoxide.
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The required enantiomeric trisphosphates (55a) and (55b) were then obtained by use of 
sodium in liquid ammonia, which cleaved the three benzyl ethers and six benzyl esters 
in a single step. The trisphosphates were purified from the basic resultant solution by 
ion-exchange chromatography.
Thus, from myoinositol, thirteen steps were necessary to provide a chiral trisphosphate, 
and a further two were required to establish the absolute stereochemistry of the resolved 
intermediate.
1.5  A im s of the P roject
Results of structure-activity studies at the Ins(l,4,5)P3 receptor outlined in this chapter 
had indicated that important structural features for agonism were a D-threo bisphosphate 
arrangement as an absolute requirement, while a third phosphate and a hydroxyl group 
increased potency. Synthesis of chiral analogues from myoinositol requires resolution 
of intermediates, which can be a difficult, tedious and expensive process.
Positions 4, 3 and 2 of D-glucose possess the same relative stereochemistry as positions 
4, 5 and 6 respectively (and positions 4, 5 and 3 respectively) of D-myoinositol 
derivatives. Therefore, use of D-glucose as starting material ought to eliminate the 
necessity of resolution. It was intended to examine regioselective protection of 
carbohydrate precursors and to utilise various carbohydrate rearrangement methodology 
to furnish selectively protected, chiral cyclohexane or cyclopentane derivatives, which 
could be further elaborated to target tris- or tetrakisphosphates. A fundamental 
objective was to ascertain whether compounds quite diverse from Ins(l,4,5)P3, but 
retaining the pharmacophore, would exhibit agonism.
The first target was D-2-deoxy-myo-inositol-1,3,4,5-tetrakisphosphate, an analogue of 
the naturally occurring Ins(l,3,4,5)P4, about which there was some controversy in the 
literature regarding its Ca2+-mobilising ability and biological function (reviewed in 
chapter two). 2-Deoxy-Ins(l,3,4,5)P4 could potentially be prepared by converting a 
selectively protected carbohydrate precursor to a 2-deoxyinosose using the Ferrier 
rearrangement (reviewed in chapter two).
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A modification of the Ferrier rearrangement could be explored to attempt to prepare a 
versatile, selectively protected, chiral inositol intermediate suitable for the synthesis of 
several Ins(l,4,5)P3 analogues.
The second target group of compounds were ring-contracted analogues of Ins(l,4,5)P3. 
No cyclopentane-based compounds had previously been described, and these were 
potentially available using recently described ring-contraction techniques.
The discovery of the naturally occurring adenophostins, the most potent full agonists yet 
described (reviewed in chapter five), prompted investigations to prepare the third class 
of target compounds, based on glucose. The structure of the adenophostins was 
dissected to provide the most likely minimum active structure, and a route to this 
structure was designed, in addition to a versatile intermediate for synthesis of 
adenophostin analogues. Finally, a fluorescently labelled analogue of the above 
minimum structure was designed.
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CHAPTER TWO
SYNTHESIS OF d-2-DEOXY-w^o-INOSITOL-I,3,4,5- 
TETRAKISPHOSPHATE
2 .1  I n tr o d u c tio n
2.1.1 Metabolism of Ins(l,3,4,5)P4
As outlined in chapter one, Ins(l,4,5)P3 is metabolised by two pathways: hydrolysis of 
the phosphate at position 5 by a 5-phosphatase giving Ins(l,4)P2 (12); or 
phosphorylation at position 3 by a 3-kinase giving Ins(l,3,4,5)P4 (13). It is with the 
latter compound that this chapter is concerned.
Ins(l,3,4,5)P4 was discovered in 1985,120 and the kinase was subsequently 
characterised.121,122 The metabolism of Ins(l,3,4,5)P4 has been studied and is 
summarised in fig. 2.1. The main route for the production of Ins(l,3,4,5)P4 is 
phosphorylation of Ins(l,4,5)P3 by the 3-kinase enzyme. Ins(l,3,4,5)P4 has also been 
isolated in vitro as a product of Ins(l,3,4)P3 5/6-kinase action on Ins(l,3,4)P3,123 but 
this route is not believed to be physiologically significant.123 The main route of 
Ins(l,3,4,5)P4 catabolism is dephosphorylation by 5-phosphatase giving Ins(l,3,4)P3 
(ref. 52); it is also dephosphorylated by a 3-phosphatase, regenerating Ins( 1,4,5)P3.124-126 
It has been noted52 that Ins(l,3,4,5)P4 is probably not the physiological substrate of 3- 
phosphatase as the enzyme is inhibited by physiological concentrations of 
Ins(l,3,4,5,6)P5 and InsP6.124 However, the activity of the phosphatase may be 
significant in experimental situations which involve broken and permeabilised cells 
{vide infra).
In 1992, when this project commenced, there were two controversies surrounding 
Ins(l,3,4,5)P4. First, whether it possessed any physiological role (and what that role 
might be) and second, whether it could directly mobilise intracellular Ca2+ via the 
Ins(l,4,5)P3 receptor. These two problems will be considered in turn.
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2.1.2 Potential Roles of Ins(l,3,4,5)P4 and Putative Ins(l,3,4,5)P4 receptors
The first suggestion that Ins(l,3,4,5)p4 might possess an important physiological 
function followed the observation that a combination of Ins(l,4,5)P3 and Ins(l,3,4,5)P4 
mimicked the effect of fertilisation in Xenopus oocytes, whereas no mimicry occurred 


















Fig. 2.1 Metabolism of Ins( 1,3,4,5)P4.
Subsequently, Hill et al.m  presented evidence that Ins(l,3,4,5)P4 induced Ca2+ 
sequestration into storage pools in rat liver cells. No other inositol phosphates tested 
were found to cause any sequestration.
It has also been suggested that Ins(l,3,4,5)P4 is involved in Ca2+ homeostasis at the 
plasma membrane, helping to control entry of extracellular Ca2+ into the cell.21’129
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Evidence against this hypothesis has been provided by Bird et a l ,130 who examined Ca2+ 
entry using Ins(2,4,5)P3, an Ins(l,4,5)P3 mimic which is not phosphorylated to the 
corresponding tetrakisphosphate. The trisphosphate alone was found to be necessary 
and sufficient for entry of Ca2+ across the plasma membrane.130 In another study, the 
level of the 3-kinase enzyme present in NIH 3T3 fibroblasts and CCL39 cells was 
increased by transfection techniques, thereby generating high concentrations of 
Ins(l,3,4,5)P4 at the expense of Ins(l,4,5)P3.131 There was no evidence that high 
Ins(l,3,4,5)P4 levels promoted Ca2+ mobilisation, Ca2+ entry or Ca2+ sequestration, and 
it was concluded that Ins(l,4,5)P3 was the major determinant in each case.
However, subsequently in support of the Ca2+-entry hypothesis, Smith132 found that 
Ins(l,3,4,5)P4 could stimulate Ins(l,4,5)P3-insensitive Ca2+ influx in mouse lacrimal 
cells. Additionally, an Ins(l,3,4,5)P4-sensitive Ca2+-permeable channel has been 
characterised from endothelial cells;133 Ins(l,4,5)P3 failed to induce an increase in this 
channel’s activity.
One way to support the proposal of a physiological role for a ligand is to isolate its 
receptor. Intracellular sites that specifically bind Ins(l,3,4,5)P4 in high affinity [and 
with high selectivity over Ins(l,4,5)P3] have been noted in HL60 cells,134 bovine adrenal 
cortex,135 bovine parathyroid,136 rat137 and pig138 cerebellum and human platelets.139 
Ins(l,3,4,5)P4-binding proteins have been purified from pig140 and rat141’142 cerebellum 
and porcine platelets.143 The last example has received particular recent interest: this 
protein has been tentatively proposed to be an Ins(l,3,4,5)P4 receptor143-145 and has 
demonstrated a high specificity for Ins(l,3,4,5)P4 over all other inositol tetrakis-144 and 
various other polyphosphates.143 In vitro Ins(l,3,4,5)P4-stimulated GAP activity against 
the oncogene ras has been demonstrated.145 The Ins(l,3,4,5)P4 binding region of this 
protein has been identified.145 Evidence for the physiological significance of this 
protein together with the role of Ins( 1,3,4,5)P4 is awaited with interest.
Consistent with their proposed Ca2+-entry function, Ins(l,3,4,5)P4-binding proteins are 
located on the inner leaflet of the plasma membrane. However, it has yet to be 
unambiguously demonstrated that these proteins are not in fact receptors for
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phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3, 5] another putative second 
messenger located in the plasma membrane,8*15 of which Ins(l,3,4,5)P4 represents the 
polar headgroup.
2.1.3 Ca2+-mobilising capacity of Ins(l,3,4,5)P4
Early studies investigating whether or not Ins(l,3,4,5)P4 mobilised intracellular Ca2+ 
directly via the Ins(l,4,5)P3 receptor produced conflicting results. Thus, it was reported 
that Ins(l,3,4,5)P4 did not mobilise intracellular Ca2+ in Swiss 3T3 cells,146 
permeabilised Jurkat T-lymphocytes147 or from aortic sarcoplasmic reticulum 
vesicles.148 However, other studies reported direct Ca2+ release in cerebellar149 and 
adrenal150 microsomes, Xenopus oocytes151 and permeabilised SH-SY5Y neuroblastoma 
cells.95
Based on the structure-activity relationships discussed in chapter one, Ins(l,3,4,5)P4 
should be an agonist at the Ins(l,4,5)P3 receptor since it possesses the essential 
recognition elements, i.e. the D-threo bisphosphate arrangement at positions 4 and 5, a 
third phosphate at position 1 and a hydroxyl group at position 6. Indeed, given that the 
charged 3-O-methylenecarboxylate derivative (40) was found to mobilise intracellular 
Ca2+ in permeabilised SH-SY5Y neuroblastoma cells with an E C 5 0  value of 3.50jxm,82 it 
would be surprising if the presence of a phosphate group at position 3 entirely abolished 
activity.
As the potency of Ins(l,3,4,5)P4 was 10-100 fold lower than that of Ins(l,4,5)P3 in the 
“positive” experiments, three potential reasons for false positive results could be 
identified:
i) Were the Ins( 1,3,4,5)P4 preparations free from contamination by Ins( 1,4,5)P3?
ii) Was Ins( 1,3,4,5)P4 competing with Ins( 1,4,5)P3 for 5-phosphatase and thereby 
protecting Ins(l,4,5)P3 from 5-phosphatase-catalysed deactivation?
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iii) Was endogenous 3-phosphatase converting Ins( 1,3,4,5)P4 back to Ins( 1,4,5)P3?
It was planned to clarify the situation by two approaches. First, to use pure, synthetic 
Ins(l,3,4,5)P4 to eliminate any contamination problem. Second, to design and 
synthesise potential inhibitors of 3-phosphatase based on Ins(l,3,4,5)P4. These would 
hopefully possess similar characteristics at the Ins(l,4,5)P3 receptor, and would [in the 
absence of Ins(l,4,5)P3] eliminate all three of the above problems.
Two potential 3-phosphatase inhibitors were designed. As replacement of the relevant 
phosphate group by a phosphorothioate had previously produced phosphatase inhibitors 
(e.g. Ins(l,4,5)P3-5S inhibited 5-phosphatase86), Ins(l,3,4,5)P4-3S (77) was an obvious 
target. Alternatively, deletion of hydroxyl groups adjacent to phosphomonoesters had 
also engendered inhibitory activity against phosphatases [e.g. 6-deoxy-Ins(l)P 
competitively inhibited inositol monophosphatase152 and 6-deoxy-Ins(l,4,5)P3 inhibited 
Ins(l,4,5)P3 5-phosphatase89], so D-2-deoxy-Ins(l,3,4,5)P4 (78) was another target.
Compound (78) was also potentially useful to determine the importance of the hydroxyl 
at position 2 of Ins(l,3,4,5)P4 with respect to binding to its putative receptor, similarly 
to the study of 2-deoxy-Ins(l,4,5)P3 at the Ins(l,4,5)P3 receptor.67
A route to (78) was explored and is described in this chapter.
A common route to chiral deoxyinositols is via Ferrier rearrangement of carbohydrate 
precursors. The Ferrier rearrangement is included in an extensive review of the 
conversion of carbohydrates to cyclopentane and cyclohexane derivatives.153 As it
OH
Ins(l,3,4,5)P4-3S (77) D-2-deoxy-Ins(l,3,4,5)P4 (78)
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forms an important part of the work in two chapters of this thesis it will be briefly 
reviewed here, with an emphasis on relevance to this project, and to the field of inositol 
phosphate chemistry.
2 .2  T he F errier R earrangement
2.2.1 Background
During the late 1970s, R. J. Ferrier was investigating potential routes to chiral 
cyclopentane derivatives from carbohydrates. He reasoned that a 6-deoxy-5-hexosulose 
derivative with a good leaving group at position 2 {e.g. 79; fig. 2.2) might be induced to 
undergo a displacement reaction giving a cyclopentanone {e.g. 80).
CH(OCH3)2
(80)
Fig. 2.2 Ferrier's proposed route to cyclopentanes from 5-hexosuloses.
Unexpectedly, treatment of enol ether (81) with methanolic HC1 did not furnish (79), 
but (82).i54










It was known that hydroxymercuration of carbohydrate derivatives such as D-glucal 
triacetate (83) leads to binding of the mercury (II) cation to the double bond, followed 
by ring opening (fig. 2.3).155-156 Thus, Ferrier reasoned that hydroxymercuration of (81) 
would similarly generate a hemi-acetal at C-5 (fig. 2.4), with subsequent ring opening to 
give intermediate (84). In such a case C-6 would be expected to yield a potent 
carbanion, being stabilised both by a mercury ion and a carbonyl group. This anion 
might attack C-2 with elimination of tosylate as above to give the cyclopentanone (80a).
— OAc — OAc
(83)


























Fig. 2.4 Ferrier’s potential route to cyclopentanes by hydroxymercuration of 6-deoxy- 
hex-5-enopyranosides.
Thus, (81) was heated under reflux in aqueous acetone (1:2) in the presence of an excess 
of mercury (II) chloride.154 However, instead of the expected cyclopentanone, the 
substituted cyclohexanone (85) crystallised from the reaction mixture on cooling. The 
structure of (85) was unambiguously established by !H NMR spectroscopy, which 
indicated coupling constants consistent with a six-membered ring and not a five- 
membered ring; by 13C NMR spectroscopy which indicated the presence of a carbonyl 
group; and by conversion via enone (86) to substituted benzene (87). This report also 
suggested stereospecificity of the rearrangement, thereby placing the C-5-OH cis to C-4- 










Subsequent studies demonstrated that the initial hydroxymercuration occurred as 
predicted,157*158 but the dicarbonyl intermediate (84) underwent an aldol-like closure, the 
nucleophilic centre at C-6 reacting with C-l rather than C-2. Ferrier and Haines159 have 
argued that the nucleophilic centre in the ring closure process can be assumed to possess 
enolate character as, when the C-6—Hg bond lengthens, the C-6—C-5 bond will 
shorten, transferring electron density to the carbonyl oxygen. In such a case, Ferrier’s 
predicted closure [5-(enol endo)-exo-tet] is disfavoured according to Baldwin’s 
rules,160,161 whereas the observed closure [6-(enol endo)-exo-trig] is favoured.161 It has 
been demonstrated that analogous cyclopentanones are not obtained from fiiranoside 
derivatives such as (88), which would have to undergo the disfavoured 5-(enol endo)- 





The observed Ferrier ring closure resembles the reaction catalysed by the NAD+- 
dependent enzyme L-myo-inositol synthase, which converts glucose-6-phosphate (89) 
into L-myo-inositol-1 -phosphate (90) via ring opening, a stereospecific intramolecular 
aldol ring closure and inosose reduction. This pathway has been reviewed162 and is 
summarised in fig. 2.5. The ring closure also possesses similarities to the biosynthesis 
of shikimic acid (91) from D-glucose (summarised in fig. 2.6), in which a methylene 
enolate carbanion (92) is involved in an aldol-type ring closure to yield a cyclohexanone 
(93).153
2.2.2 Modifications of Original Conditions.
It soon became apparent that the rearrangement was not stereospecific as initially 
reported.154*163 For example, an epimeric mixture of alcohols (94; major product) and 
(95) is obtained from (96),164 and this is a general observation.
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Fig. 2.5 Mechanism of conversion of D-glucose-6-phosphate to L-myo-inositol-l- 





















In addition, some compounds gave erratic results with mercury (II) chloride,158*165 or 
were difficult to isolate.166 Chretien and Chapleur166 improved their yields by using 
mercury (II) trifluoroacetate at room temperature over a longer period. Concurrently, 
Ferrier’s group established a greater efficiency (under refluxing conditions) with 
mercury (II) acetate.158 It has been suggested158 that the acetic acid produced in this 
case, being weaker than hydrochloric acid produced using mercury (II) chloride, is less 
likely both to reverse the original hydroxymercuration and to hydrolyse the mercurial 
adducts such as (84). Using this salt, (97) was prepared in 93% yield from (98), which 
was a considerable improvement on the mercury (II) chloride method.158 However, 
although the hydroxymercuration step is rapid with mercury (II) acetates, the ring 
closure is sometimes more readily effected by addition of excess chloride ions.158-167
Cleophax et a/.168 reported that methyl 2-0-benzyl-3,4-0-cyclohexylidene-6-deoxy-p-L- 
araZ?mo-hex-5-enopyranoside (99) did not cyclise to (100) and (101) until addition of an 
excess of thiourea to the reaction mixture.
Lukacs and co-workers165 demonstrated that the rearrangement also occurs smoothly 
under catalytic conditions. This group carried out the reaction at 60-80°C in 1,4- 





which had previously been used as an alternative to refluxing aqueous acetone for 
hydroxymercuration of D-glucal.156 It has since been demonstrated that, in the absence 
of acid, the reaction may be catalysed by various mercury (II) salts, of which the 








Adam170 and Barton et al.m  independently carried out both stoichiometric and (acidic) 
catalytic Ferrier rearrangements in the presence of palladium (II) salts. It is of particular 
interest that different ratios of epimeric products were obtained when some compounds 
were treated with palladium (II) chloride compared with mercury (II) sulphate, e.g. (102) 














a) Cat. HgSC>4, 5 h im  H2SO4, aq. 
dioxane, 2 h, 80°C, 78%
85 15
b) Cat. PdCh , 5mM H2SO4, aq. 
dioxane, 2 h, 80°C, 70%
60 40
Table 2.1 Ratios of major and minor cyclohexanone products of (104) 
obtained with mercury (II) sulphate and palladium (II) chloride.
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2.2.3 Mechanism
Initial studies on the mechanism of the rearrangement were undertaken by Ferrier’s 
group,154’157-159’172’173 who established that isolable dicarbonylmercurial adducts such as
(84) were formed. Machado et al.m  recognised that the stereochemistry at position 5 of 
the cyclohexanone products was generally related to the conformation of the hex-5- 
enopyranoside precursors rather than their anomeric configuration. That is, 
carbohydrates adopting a 4Ci conformation give predominantly the a-hydroxy epimer at 
position 5 (of the cyclohexanone product; see Appendix for nomenclature and 







Fig. 2.7 Relationships between conformation of carbohydrate precursor 
and configuration at position 5 of cyclohexanone product.
Laszlo et a /.175 noted that the 5-hydroxyl and 3-substituent of cyclohexanone products 
tend to be trans. They suggested a mechanism in which the mercury atom of the 
dicarbonylmercurial intermediate co-ordinates to a lone pair-bearing substituent at 
position 3 (e.g. 105, fig. 2.8). This directs the nucleophilic C-6 towards C-l from the 
same side as C-3, giving a double boat conformation transition state (106).
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An example to support this hypothesis, methyl 4-0-benzoyl-2,3,6-trideoxy-a-D-g/ycero- 
hex-5-enopyranoside (107), lacks a 3-substituent and gives a 3:4 mixture of Ferrier 
products.175 Additional support comes from compound (108), from which the 
corresponding 5 p-hydroxy cyclohexanone was the exclusive product.176 In this molecule 
the mercury atom could co-ordinate to a lone pair on an oxygen atom of the 3-acetate, 
directing the p-product, but not to the methyl group which would produce the a- 
product.
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Fig. 2.9 Mechanism of the Ferrier rearrangement proposed by Machado et al. 177
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An alternative mechanism has been suggested by Machado et al.}11 who propose one 
transition state involving two six-membered chairs formed by connection of carbonyl 
oxygen atoms to the mercury cation (109, fig. 2.9) which gives rise to the major product, 
and a disfavoured eight-membered twist conformation (110) which yields the minor 
product. They account for the trans C-3-C-5 relationship by proposing that the 1,3- 
diaxial interaction produced by a cis arrangement would destabilise intermediate (109), 
thus shifting the equilibrium towards the minor product.
A third possible mechanism has been proposed by Yamauchi et a /.,178 who prepared the 
selectively deuterated hex-5-enopyranoside (111) and exposed it to the original 
conditions using mercury (II) chloride. Loss of stereochemical integrity of the 
methylene group occurred in the overall reaction. On the basis of isolated intermediates, 
the stereochemistry was suggested to be lost partly during the hydroxymercuration step 
(although note that the isolated intermediates were methoxymercurated) and partly as a 
result of homolytic cleavage of the Hg—C-6 bond of the dicarbonyl adduct (112) (fig. 
2 .10; enolisation was excluded as deuterium was retained), an energetically feasible 
suggestion based on the model compound (l-chloromercurio)acetone. These workers 




Fig. 2.10 Mechanism of Ferrier rearrangement proposed by 
Yamauchi et al.m
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2.2.4 Applications to Inositol Phosphate Chemistry
The Ferrier rearrangement has found, and continues to find, many imaginative 
applications, notably allowing efficient access to modified aminocyclitol components of 
aminoglycoside antibiotics,164*179-183 and to pseudo-sugars.163*174*184-188 A thorough 
account of these areas is beyond the scope of this review, however, and only 
applications to the synthesis of inositol phosphates will be considered.
Sato et al.m  unambiguously prepared l-  1,2,4-tri-O-benzyl-myo-inositol (114; fig. 2.11), 
a phosphorylation precursor to Ins(l,4,5)P3, from D-glucose. Methyl 2-0-benzyl-6-
deoxy-3,4-di-0-(methoxymethyl)-a-D-xy/o-hex-5-enopyranoside (115) was prepared 
from D-glucose in six steps. Ferrier rearrangement of (115) followed by p-elimination 
gave enone (116), which was reduced to the equatorial alcohol with complete 
stereoselectivity using NaBH4-CeCl3. After benzylation, treatment with osmium
tetraoxide furnished cw-diol (117). Stannylene-mediated methoxymethylation








(118) R ^ H ; R2=MOM
Fig. 2.11 Route to l -  1,2,4-tri-O-benzyl-myo-inositol (114) from D-glucose 
by Sato et alA89
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Several 6-deoxy-myo-inositol polyphosphates have been prepared from methyl p-D- 
galactopyranoside, by way of olefin (99).168 A 2:1 mixture of the axial and equatorial 
products (100; fig. 2.12) and (101) respectively were obtained on modified Ferrier 
rearrangement (vide ultra). The equatorial product was reduced stereoselectively with 
lithium borohydride to give L-6-O-benzyl-1,2-0-cyclohexylidene-4-deoxy-myo-inositol
(119), a versatile intermediate which was further elaborated to provide 6-deoxy-Ins(l)P
(120), 6-deoxy-Ins(l,5)P2 (121), 6-deoxy-Ins(l,4,5)P3 (47), 6-deoxy-Ins(l,3,4,5)P4 (122) 
and 6-deoxy-Ins(l,2-cyclic-4,5)P3 (123). The biological properties of (47) were 

















(121) Rj=R2=H; R3=P03 
(47) R,=H; R2=R3=P03
(122) R1=R2=R3=P03
Fig. 2.12 Route to D-6-deoxy-myo-inositol polyphosphates from D-galactose 
by Cleophax et a/.168
D-Glucose was used as starting material in a preparation of 3-deoxy-Ins(l,4,5)P3 (18) 
and D-3-deoxy-mMCo-Ins( 1,4,5)P3 (17),61 a synthesis noteworthy for incorporating allyl 
ethers in this mercury(II)-catalysed rearrangement. The anomeric mixture (124; fig. 
2.13) gave (125) and (126) in a ratio of 6:1. Trisphosphate (18) was prepared by 
protecting the hydroxyl group of (126) as a tetrahydropyranyl ether. The ketone was
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reduced to the axial alcohol, which was then benzylated followed by standard 
allyl/tetrahydropyranyl deprotection, then phosphorylation and complete deblocking. 
The muco analogue (17) was prepared from the major Ferrier product (125) similarly, 
except that the ketone was reduced exclusively to the axial alcohol in this case.























(18) r—  R,=A11; R2=THP 
h f -  Rj=Prop; R2=THP 
L*- Rj=R2=H
Rj=R2=P(0 )(0 Bn)2
Fig. 2.13 Synthesis of 3-deoxy-mwco- and myo-Ins(l,4 ,5)P3 by Poirot et al.61
Bender and Budhu167 devised an elegant biomimetic route to optically active myo­
inositol derivatives. Various partially protected glucose intermediates (127; fig. 2.14; 
e.g. Rn=Bn) were oxidised to aldehydes (128), which were trapped as enolates by acetic 
anhydride to give a mixture of enol acetates (129ab). These underwent Ferrier 
rearrangement with high stereoselectivity for the D-rayo-inos-6-oses (130), which could
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be reduced stereospecifically with sodium triacetoxyborohydride to give myo-inositol 
derivatives (131).
Of related interest is the recent report by Park and Danishefsky190 in which the 
substituted enol ether (132) was subjected to classical Ferrier conditions to give (133). 
The axial or equatorial displacement of the aromatic group was not described.
Bender and Budhu’s modification of the Ferrier rearrangement has been applied by 
Estevez and Prestwich191 to prepare a chiral, P-l-tethered Ins(l,3,4,5)P4 affinity label. 
The enol acetate (129; R„=PMB) was converted to (130; R^PMBjand thence to (131; 
R,=PMB). Protection of the hydroxyl groups as benzyloxymethyl ethers gave fully 
protected (134), which was saponified to (135). A protected (3-aminopropyl)phosphate 
was then introduced at position 1, and standard deprotection-phosphorylation chemistry 
supplied the P-l aminopropyl tethered Ins(l,3,4,5)P4 analogue (136). Coupling of (136) 
to a 125I-labelled aminosalicylic acid derivative provided the target affinity label (137), 
which has been used to purify Ins(l,3,4,5)P4 binding sites.141*142 Intermediate (135) has 
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Prestwich and co-workers193 have used similar chemistry to prepare a P-5-tethered 
photoaffinity label of Ins(l,2,5,6)P4 [Ins(l,2,6)P3 inhibits inflammation and oedema in
0 - (p - m e th o x y b e n z y l ) - a - D - g lu c o p y r a n o s id e .
2 .3  R e t r o s y n t h e t ic  A n a ly s is
It is clear from the above review that the Ferrier rearrangement may be useful to prepare 
enantiomerically pure 2-deoxy-Ins(l,3,4,5)P4 from a suitably protected carbohydrate 
precursor.
D-2-Deoxy-Ins(l,3,4,5)P4 (78; fig. 2.15) may be synthesised by phosphorylation of d-1- 
0-benzyl-3-deoxy-^cy//o-inositol (138) followed by deprotection. All substituents in 
(138) are equatorial. This arrangement may be obtained by reduction of the ketone of a 
cyclohexanone Ferrier product in which all substituents are equatorial (i.e. 139) to give 
the corresponding equatorial alcohol (140). Removal of protecting groups R, which 
must be orthogonal to benzyl ethers, would provide (138).
Cyclohexanones of type (139) are obtained as the minor products of the mercury(II) 
reaction on D-xy/o-hex-5-enopyranosides (141), ultimately derived from D-glucose. To 
prepare (78), a methyl a-D-xy/o-hex-5-enopyranoside derivative is required with a 
benzyl ether at position 2 and an alternative protecting group at positions 3 and 4.
skin burn by acting as a neuropeptide Y antagonist]193 from methyl 2,3-di-0-benzyl-4-
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Benzoate esters are easily introduced in high yield, orthogonal with respect to benzyl 
ethers, compatible with the conditions of the Ferrier rearrangement and often facilitate 
interpretation of !H NMR spectra. Benzoate esters were therefore chosen for this route.
HO. V^OBn







Fig. 2.15 Retrosynthetic analysis showing a potential route to (78) via Ferrier rearrangement.
The potential route envisaged to prepare d-(78) from methyl a-D-glucopyranoside (142) 
is outlined in fig. 2.16. This route involved benzylation of the 4,6-O-benzylidene 
derivative of (142), selection of the 2-O-benzyl product (143) and conversion via 
monobenzoate (144) to methyl 3,4-di-0-benzoyl-2-0-benzyl-6-bromo-6-deoxy-a-D- 
glucopyranoside (145) using standard carbohydrate chemistry. Elimination of HBr from 
(145) ought to provide the olefin (146), which on Ferrier rearrangement should give a 
mixture of C-5 epimeric cyclohexanones, (147) and (148). Inversion of stereochemistry 
at position 5 of the expected major product (148) and acylation would provide an 
intermediate (149). The stereochemistry at positions 2, 3,4 and 5 of (149) is identical to
OH









































©  = protected phosphate
(78)
Fig. 2.16 Proposed route to D-2-deoxy-Ins( 1,3,4,5)P4.
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that at positions 4, 5, 6 and 1 respectively of Ins(l,4 ,5)P3. Additionally, the 
regiochemical protection would allow incorporation of phosphate groups into the 
appropriate positions. Intermediate (149) could therefore potentially furnish several 
useful polyphosphorylated compounds. In particular, stereoselective reduction of the 
ketone to the equatorial alcohol followed by ester hydrolysis, phosphorylation and 
deprotection should give (78).
2 .4  D iscussion  of S ynthetic W ork
2.4.1 An Improved Preparation of Methyl 4,6-O-benzylidene-a-D-glucopyranoside 
and Methyl 4,6-0-benzyIidene-oc-D-mannopyranoside
The benzylidene acetal is a commonly used protecting group for the 4,6-diol of 
hexopyranosides.194 Many methods have been described for the preparation of methyl 
4,6-O-benzylidene-a-D-glucopyranoside (150), including the reaction of methyl a-D - 
glucopyranoside (142) with zinc chloride-benzaldehyde195*196 (and note an important 
modification197); with benzaldehyde dimethyl acetal in DMF in the presence of p- 
toluenesulphonic acid (PTSA)198*200 or pyridinium p-toluenesulphonate200 or 
tetrafluoroboric acid;201 with benzaldehyde dimethyl acetal in 10% methanolic 
H2SO4;202 and with benzaldehyde diethyl acetal in DMF in the presence of HC1,203 or in 
dioxane in the presence of a strong cation exchange resin,204 or in chloroform in the 
presence of camphorsulphonic acid.205 Although excellent yields are reported for most 
of these techniques, their suitability to large-scale preparation {i.e. 0.5 mole or more) is 
rarely discussed.
In a synthesis of methyl 2,3:4,6-di-0-benzylidene-a-D-mannopyranoside (151), Horton 
and Weckerie206 modified the method of Evans,198*199 and stirred a mixture of methyl a- 
D-mannopyranoside, benzaldehyde dimethyl acetal, PTSA and DMF at 70°C with 
continuous removal of the liberated methanol via an air condenser attached to a water 
pump. This author applied their method206 to methyl a-D-glucopyranoside, using 1.05 
equiv. of benzaldehyde dimethyl acetal on a 0.5mole scale. The reaction was 
conveniently followed, being complete when methanol ceased condensing on the air
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condenser. After evaporation of the solvent, the product was obtained in 90% yield as 
fine white needles by crystallisation from 2%w/v aqueous sodium hydrogen carbonate 
























As this methodology was likely to be generally useful to carbohydrate chemists, the 
procedure was extended to the other two commonly used methyl hexopyranosides, 
methyl a-D-galactopyranoside (152) and methyl a-D-mannopyranoside (153). The 
galactoside gave a major product and a slightly less polar minor product (identified by 
Patroni et al.200 as a diastereomeric mixture of the 3,4-0 -benzylidene isomers) by TLC. 
The required 4 ,6-0 -benzylidene derivative (154) did not crystallise from 2%w/v aqueous 
sodium hydrogen carbonate solution, and could only be isolated pure after several 
crystallisations from ethanol. The yield was poorly reproducible, suggesting that other 
methods, notably benzaldehyde-zinc chloride,207 may be superior.
Methyl 4,6-O-benzylidene-a-D-mannopyranoside (155), however, was easily isolable by 
this method on a 0.5mole scale. When the reaction was completed, TLC indicated a 
major product corresponding to (155), a less polar minor product corresponding to the
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dibenzylidene derivative (151)206 and unreacted starting material. After evaporation of 
the solvent the residue was shaken with 2%w/v aqueous sodium hydrogen carbonate 
solution and petrol, on the assumption that (151) would dissolve in the organic layer, 
while (153) would dissolve in the aqueous layer and (155) would precipitate. A 
precipitate was obtained, but contained a mixture of (151) and (155); pure (155) was 
obtained as fluffy white crystals by recrystallisation from chloroform-toluene. The yield 
(48%) was comparable to a 50mmol scale preparation by an adaptation of Evans’ 
method,208 and represents an improvement on a previous large-scale preparation using 
benzaldehyde-formic acid.209
2.4.2 Benzylation of Methyl 4,6-0-benzylidene-a-D-gIucopyranoside and Related 
Reactions
With (150) in hand, attention turned to prepare the 2-0-benzyl derivative (143). 
Treatment of a solution of (150) in DMF with 1 equiv. of sodium hydride and 1.05 
equiv. of benzyl bromide at room temperature gave 39% of (143), together with its 3- 
substituted isomer (156) (8%) and a relatively large proportion of the disubstituted 
derivative (157) (22%). As the yield of (143) was poor, a better benzylation method 
was sought. The monobenzyl ethers (143) and (156) have been prepared with little or 
no disubstitution using 1.1 equivalents of sodium hydride in neat benzyl chloride,210 via 
phase transfer catalysis,211 copper and mercuric chelates,212 stannyl ethers213 and 
stannylene acetals.213 Of these, the last gave the highest reported yield of (143)* and 
was selected for further investigation. The selective manipulation of hydroxyl groups 
using organotin derivatives has been reviewed.215 The dibutylstannylene intermediate 
(158; fig. 2.17; p.68) was formed by boiling a mixture of (150) and dibutyltin oxide in 
toluene for 2-3 h with azeotropic removal of water. The residue from this process was 
then heated with benzyl bromide in dry DMF to give (143) (46%) and (156) (19%) 
(table 2.2). No disubstitution occurred under these conditions. Slightly improved 
selectivity (and yield of 143) was observed when the reaction was carried out in 
refluxing acetonitrile in the presence of quaternary ammonium salts, a procedure 
employed by Corrie216 to o-nitrobenzylate (158).
* After completion of this work, Dasgupta and Garegg (ref. 214) reported a refinement of the stannyl ether 



















A claim by Boons et al.2X1~ that benzylation of (158) (obtained from 150 and dibutyltin 
dimethoxide) in toluene at 50°C gave exclusively the 3-substituted product (156) could 
not be reproduced in this author’s hands. Instead, an approximate ratio of 2.7:1, with 
(156) as the minor product, was obtained (table 2.2). In addition, treatment of the 
cooled solution of (158) with benzoyl chloride or tosyl chloride was found to give 
exclusively the 2-substituted product (159 and 160 respectively) in both cases, in 
contrast to the above report.217 The author’s esterification results are consistent with 
those of a previous report,218 which employed dioxane as solvent.
However, treating the stannylene (158) with benzyl bromide in dry DMF at room 
temperature in the presence of caesium fluoride,219 did reverse benzylation selectivity. 








Allyl bromide b 42 14
e 19 40
p-Methoxybenzyl chloride c 48 18
e 17 25
Table 2.2 Yields of 2- and 3-O-alkylated methyl 4,6-O-benzylidene-a-D- 
glucopyranoside. (See experimental section for conditions. Yields are 
based upon isolated products).
The corrigendum for ref. 217 was issued after communication of the results herein to the authors.
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result as it is well established that, in the absence of steric effects, the 2-hydroxyl group 
is more reactive than the 3-hydroxyl in methyl a-D-glucopyranoside derivatives.215’220’221
Nagashima and Ohno219 have suggested that caesium fluoride exerts its effect in two 
ways. First, that the caesium cation interacts with the bromine atom of benzyl bromide 
such that the electrophilicity of the benzyl methylene group is increased. Second, that 
the Sn—O bonds are activated by formation of a pentacoordinate complex involving 
two fluorine atoms. Applied to stannylene (158; fig. 2.17), it was reasoned that the 
bulky trigonal bipyramidal complex might be better accommodated at position 2 where 
steric interaction with the equatorial benzylidene acetal would be considerably reduced. 
Such an arrangement would yield the 3-O-benzyl product (156).
Such a mechanism would be expected to have little dependence on the alkyl halide used; 
the study was therefore extended to two other commonly used alkyl halides, allyl 
bromide (giving 161 and 162) and p-methoxybenzyl chloride (giving 163 and 164), and 
the caesium fluoride method reversed selectivity to some extent in both cases (table 
2.2).
The argument above may be an oversimplification given the low solubility of caesium 
fluoride in DMF (0.3%w/w at 80°C).222
Some generalisations observed by the author for the properties of 2- and 3-0-substituted 
derivatives of (150): 2-substituted derivatives tend to be less polar by TLC, possess 
lower melting points, exhibit sharper OH stretching bands in their IR spectra and have 
smaller 7H Oh values than their 3-substituted isomers.
Attempts to isolate (143) from the purified reaction mixture by crystallisation met with 
limited success, since there was little consistency between successive experiments. 
However, after benzoylation of the purified mixture, the corresponding 3-benzoate ester 
(144) could be selectively obtained by fractional crystallisation from ethanol in 30-35% 
yield, a result reproducible on a 0.5mole scale. Compound (144) was identified from its
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!H NMR spectrum, which displayed a deshielded triplet at 5.85 ppm corresponding to 






Fig. 2.17 Possible mechanism for benzylation of stannylene (158) using CsF.
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2.4.3 Preparation of Methyl 3,4-di-0-benzoyl-2-0-benzyl-6-deoxy-a-D-jc<y/o-hex-5- 
enopyranoside (146)
The conversion of 4,6-0-benzylidene hexopyranosides to 4-0-benzoyl-6-bromo-6- 
deoxy hexopyranosides by A-bromosuccinimide (NBS) in carbon tetrachloride 
containing excess barium carbonate (the “Hanessian-Hullar” reaction) was first 
described by Hanessian,223 and a modified procedure subsequently by Hullar and co- 
workers.224 This transformation has been widely used in carbohydrate chemistry and is 
applicable to large-scale procedures.225
A mixture of (144), NBS (1.2 equiv.) and barium carbonate (1.5 equiv.) was heated 
under reflux in dry carbon tetrachloride. The system changed in appearance from a 
white solid in a colourless solution to a pale yellow solid in a colourless solution 
followed by a white suspension in an intensely orange solution and then back to its 
original appearance within about 35 min, a characteristic sequence.226 On purification, 
only 28% of the required bromo-dibenzoate (145) was obtained; the known methyl 3,4- 
di-0-benzoyl-6-bromo-6-deoxy-a-D-glucopyranoside227 (165; 16%) and methyl 3-0- 
benzoyl-4,6-0-benzylidene-a-D-glucopyranoside228 (166; 10%), representing O-
debenzylated product and starting material respectively, were also obtained, together 




The structure of (145) was established chiefly by NMR spectroscopy and mass 
spectrometry. The presence of two benzoate esters was apparent by the four deshielded 
aromatic protons, corresponding to the ortho protons of the benzoyl group; the position 
of these esters at C-3 and C-4 of the pyranoside ring was confirmed by the two 
deshielded triplets (fig 2.18) at 5.28 and 5.94ppm; the presence of bromine in the
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molecule was confirmed by the characteristic bromine isotope pattern in the mass 
spectrum.
The unwanted O-debenzylation side reaction was not entirely unexpected as the 
irradiation of mixtures of NBS, calcium carbonate and solutions of carbohydrates in 
aqueous carbon tetrachloride with a 375-W incandescent lamp has been used to 
selectively deprotect benzyl ethers. 2 2 9  In the hope that benzyiidene cleavage occurred 
more rapidly than debenzylation, a fine suspension of NBS in carbon tetrachloride was 
added dropwise to a refluxing mixture of the other components. This failed to increase 
the yield of (145), as did more rigorous purification of reagents, 2 3 0  or using exactly one 
equivalent of NBS.
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Fig. 2.18 Part of the 400MHz ‘H NMR spectrum of (145) in CDCI3 .
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A more efficient route from (144) to (145) required acidic hydrolysis of the benzylidene 
acetal to give methyl 3-<9-benzoyl-2-0-benzyl-a-D-glucopyranoside (167), followed by 





Elimination of HBr from (145) to provide the Ferrier precursor (146) was initially 
attempted using silver (I) fluoride in dry pyridine.232 However, for complete reaction at 
least six equivalents of the expensive silver salt were required, and a poor yield was 
obtained (31% after crystallisation). Interhalogen exchange with sodium iodide in 
acetone followed by treatment with DBU in refluxing toluene failed to effect complete 
conversion, but interhalogen exchange at 100°C in DMSO containing molecular sieves, 
followed by addition of DBU233 worked efficiently, giving (146) in 63% yield after 
crystallisation. Olefin (146) crystallised readily from ethanol and was perfectly stable at 
room temperature in its crystalline form.
The structure of (146) was assigned as follows. The TLC chromatogram stained brown 
with potassium permanganate solution. The IR spectrum displayed the characteristic163 
hex-5-enopyranoside C=C enol ether stretching at 1670cm-1. The !H NMR spectrum 
(fig. 2.19) displayed two one-proton triplets (7 2.0Hz for each proton) at 4.62ppm and 
4.79ppm corresponding to the position 6 methylene, in which the geminal olefinic 
coupling was equal to four bond couplings to the position 4 methine; this methine 
presented as a doublet of triplets, with an axial-axial coupling to position 3, together 
with the long range coupling described above. In the 13C NMR spectrum the methylene 
C-6 resonated at 97.34ppm and the quaternary C-5 at 150.30ppm.
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Fig. 2.19 Part of the 400MHz ‘H NMR spectrum of (146) in CDCI3 .
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2.4.4 Ferrier Rearrangement of (146)
When a stoichiometric amount of mercury (II) trifluoroacetate was added to a solution 
of (146) in aqueous acetone containing 1% acetic acid, the starting material was rapidly 
consumed, as observed by TLC. However, no clearly defined product was apparent 
until the addition of sodium chloride. On purification, the expected C-5 epimeric 
cyclohexanones (147) and (148) were isolated, in yields of 5% and 50% respectively. 
The structures were assigned mainly on the basis of lU NMR and 13C NMR 
spectroscopy. The isomers were easily distinguishable by comparing the coupling 
constants of the newly generated axial methylene proton at position 6 (fig. 2.20). In 
(147) this proton experiences a geminal (AB) coupling of 14.5Hz and a vicinal axial- 
axial coupling of 11.2Hz with the position 5 methine; in (148) the geminal coupling 
(12Hz) is accompanied by the much smaller (vicinal) axial-equatorial coupling of 
3.7Hz. In both cases the less shielded position 6 equatorial proton experiences a 
geminal coupling together with a smaller (equatorial-axial in 147; equatorial-equatorial 
in 148) vicinal coupling, giving essentially the same splitting pattern.
The proportion of minor product (147) in this case is much lower than in those reported 
for the corresponding 2,3,4-tri-Obenzyl (3:1) and 2,4-di-0 -allyl-3-Obenzyl (6:1) d -  
xylo- precursors and the 2-0-benzyl-3,4-0-cyclohexylidene-L-arfl&i>zo precursor (2:1) 
(section 2.2.4). It is noteworthy that lower proportions of minor product (if any) have 
been isolated in all previous examples in which esters, rather than ethers, have been 
employed at positions 3 and 4. This may indicate a subtle influence of protecting groups 
on the stereochemical outcome of the mercury (H)-catalysed rearrangement.
A catalytic Ferrier rearrangement of (146) using mercury (II) trifluoroacetate increased 
the overall yield obtained, but did not alter the product ratio. Neither did the palladium 
(II) chloride reaction,170*171 which had significantly increased the proportion of the 
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Fig. 2.20 High field regions of the 270MHz NMR spectra of (148) and (147) in 
CDCI3 showing coupling of the position 6 methylene protons.
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2.4.5 Attempted Inversion of Stereochemistry at position 5 of (148)
Attention now turned to inversion of stereochemistry at position 5 of (148); a literature 
search found no previous attempt at inverting the hydroxyl group at this position of 
Ferrier products.
Ferrier products readily undergo p-elimination to give P-enones.154-173’180-189 In order to 
minimise this side reaction it was decided to protect (148) as ethylene acetal (168). 
Ferrier and Haines173 examined several methods for introducing an ethylene acetal to the 
related cyclohexanone (85) and optimised their yield by reacting (85) with ethylene 
glycol in dioxane-benzene containing a catalytic quantity of H2S04. In the case of (148) 
this method (substituting toluene for benzene) provided 54% of (168), but also 33% of 
the eliminated product (169).
Ri
(168) Rj=OH; R2=H (169)
(170) R,=H; R2=OCOCH3
Mitsunobu conditions234 [DEAD-Ph3P or l,r-(azodicarbonyl)-dipiperidine-Bu3P] failed 
to give any reaction, in keeping with previous inositol examples.235-237
Attempted SN2 inversions of the 5-0-triflate with caesium acetate in DMF,71 or of the 5- 
O-mesylate with caesium acetate in refluxing toluene in the presence of crown ethers238 
provided only 12-18% of the required acetate (170), together with 50-55% of (169). 
The structure of (170) was assigned on the basis of its NMR spectrum (fig. 2.21). 
The axial position 6 methylene proton presented as a triplet with an axial-axial vicinal 
coupling equal to the geminal coupling; the methyl group of the acetate presented as a
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singlet at 2.01 ppm; and the deshielded position 5 methine was observed as a ddd 
exhibiting two axial-axial couplings and one axial-equatorial coupling.
OAcOBn
PhCHo 0(170)
H - 3 H - 2
—i > i i------------ 1------------ 1-------------1-------------1-------------.------------ 1------------- 1-------------1-------------1-------------1-------------1-------------r









Fig. 2.21 Part of the 400MHz lH NMR spectrum of (170) in CDC13.
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The tendency of (168) to eliminate, despite protection of the ketone of (148), may be 
explained by the antiperiplanar arrangement of the axial H-6 proton and the leaving 
group at C-5.
As the yield of inverted products using the above methodology was unsatisfactory, 
attention turned to an oxidation-reduction procedure which should avoid the elimination 
problem. Oxidation of (168) using oxalyl chloride and DMSO in dichloromethane 
(“Swem” oxidation)239 gave a highly crystalline, strongly dextrorotatory product in high 
yield which was not, however, the required product (171), but enone (172), i.e. 
elimination of the benzoate at position 3 of (168) had also occurred. The driving force 
for this elimination is the resultant conjugation, but the mechanism is less obvious. An 
antiperiplanar arrangement of the axial H-4 proton and the cw-C-3-benzoate cannot 
occur and triethylamine is therefore unlikely to abstract H-4 in the classical E2 
mechanism. An alternative possibility is an entirely intramolecular mechanism (fig. 
2.22) involving anchimeric assistance from the C-3-O-benzoate to give a six-membered 
ring transition state.
The I3C NMR spectrum of (172) was particularly useful in assigning its structure: all six 
ring carbons exhibited predictable chemical shift values (given in fig. 2.22) and signals 







The required ketone (171) was eventually obtained by oxidation of (168) with 
pyridinium chlorochromate.240 Compound (171) was obtained in 53% yield by 
crystallisation from ethanol and further quantities (total 62%) were available by flash 
















Fig. 2.22 Possible mechanism for elimination of benzoate during formation of (172) 
and l3C NMR chemical shift values for the cyclohexenone ring of (172).
Reduction of (171) with sodium borohydride in dioxane or with sodium borohydride­
cerium trichloride in methanol gave exclusively the axial alcohol (168). Jaramillo and 
Martm-Lomas237’241 experienced similar difficulty attempting to reduce the 
cyclohexanone (173) to the myoinositol derivative (174). The only reagents which gave 
(174) in appreciable yield (rather than 175) were (R)- and (5)-Alpine hydride. 











On building a Dreiding model of (171) it became clear that an equatorial approach of the 
reducing agent (leading to 168) is much less hindered than an axial approach.
At this stage, inversion attempts were not pursued further, and the minor Ferrier 
rearrangement product (147) was used to prepare the target tetrakisphosphate (78).
2.4.6 Preparation of 2-deoxy-Ins(1^3,4,5)P4
Conversion of (147) to the target tetrakisphosphate required reduction of the ketone to 
the equatorial alcohol, benzoate hydrolysis to provide tetrol (138), followed by 








In an earlier study,164 the 2,3,4-tri-O-benzyl Ferrier products (94) and (95) were reduced 
with sodium borohydride in dioxane. While (94) gave exclusively the axial product, 
(95) was found to give an approximately 1:1 mixture of the axial and equatorial 
products. Treatment of (147) in this way gave d -  1,6-di-0-benzoyl-5-0-benzyl-3-deoxy- 
myo-inositol (176) and d -  1 ,2-di-0 -benzoyl-3-0 -benzyl-5-deoxy-5cy//o-inositol (177), in 
a ratio of ca. 1:3.3 respectively. The structures of (176) and (177) were established by 
considering the coupling constants of the deshielded methine proton vicinal to the newly 
created hydroxyl group. In (176), this signal (H-l) presented as a doublet of doublets
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having an axial-axial coupling (to H-6) and an axial-equatorial coupling (to H-2); in 
(177) it experiences two axial-axial couplings and presented as a triplet.
The benzoate esters of (177) were smoothly cleaved with methanolic sodium hydroxide 
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Fig. 2.23 Route to (78) from (147).
Phosphitylation of (138) was carried out at room temperature using the P(III) reagent 
bis(p-chlorobenzyloxy)(diisopropylamino)phosphine242 with 2 equiv. of phosphitylating 
reagent per hydroxyl group and 3 equiv. of tetrazole, in a small volume of dry
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dichloromethane. After the mixture of phosphitylating reagent and tetrazole had been 
stirred for 15min, the 3IP NMR spectrum indicated a peak at 126.26ppm, corresponding 
to phosphitylating agent-tetrazolide intermediate. Thirty minutes after addition of the 
tetrol, the 31P NMR spectrum indicated a complex overlapping pattern of phosphite 
signals at 139.7-140.0 and 141.5-142. lppm. The complexity of the spectrum arises 
from multiple VPP coupling.243 After oxidation with MCPBA and work-up, the 31P 
NMR spectrum of (178) revealed four phosphate signals at -1.59, -1.63, -1.68 and -  
2.15ppm.
Deblocking of the nine benzyl/p-chlorobenzyl protecting groups was achieved using 
sodium in liquid ammonia.100 The product was purified using ion-exchange 
chromatography and phosphate-containing fractions were detected and then combined 
and the amount of (178) quantified using a modification of the Briggs phosphate 
assay.244
The structure of the product was identified as the required tetrakisphosphate (78) on the 
basis of its ^-coupled 31P NMR spectrum which showed four doublets, and its !H 
NMR spectrum in D20  which showed the distinct methylene protons and a triplet 
corresponding to the ring methine geminal to the sole unphosphorylated alcohol at 
position 6 (myo-inositol numbering). The accurate negative FAB mass spectrum 
showed a mass consistent with that predicted for [M-H]\
Preliminary biological evaluation of (78) at the Ins(l,4 ,5)P3 receptor in SH-SY5Y 
neuroblastoma cells has been performed by Dr R. A. Wilcox at the University of 
Leicester. Compound (78) was a full agonist with respect to Ca2+-mobilisation, 
possessing an EC50 value of ca. 20jim, a value about four-fold higher than that of pure, 
synthetic D-Ins(l,3,4,5)P4.
2 .5  S ubsequent  D evelopments
While this work was in progress, the synthesis of racemic245 and chiral246 Ins( 1,3,4,5)P4- 
3S (77) were described. Biological studies246*247 clearly demonstrated that the d-
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enantiomer was a full agonist at the Ins(l,4,5)P3 receptor, with a potency ca. 50-fold 
lower than Ins(l,4,5)P3, strongly suggesting that Ins(l,3,4,5)P4 can mobilise 
intracellular Ca2+.
With the current interest in recently purified Ins(l,3,4,5)P4-binding proteins, it is hoped 
that (78) will prove a useful ligand in determining the relative importance of the 
hydroxyl at position 2 of Ins(l,3,4,5)P4 in ligand-protein binding. These studies, and 
investigations into the interaction of (78) with the enzymes 3-phosphatase, 5- 
phosphatase and 3-kinase are presently being pursued.
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CHAPTER THREE
SYNTHESIS OF A RING-CONTRACTED ANALOGUE OF
Ins(l,4,5)P3
3 .1  I n t r o d u c t io n
All reported approaches to structural modification of Ins(l,4,5)P3 which produced 
agonists (see chapter 1) at the start of this work had focused upon modifications at 
phosphorus or hydroxyl group deletion, reorientation, alkylation or replacement with 
isosteres and other groups in the six-membered ring. Despite numerous single and 
multiple modifications, the fundamental requirement of a six-membered ring had not 
been addressed. Even in the adenophostins (discussed in chapter five), which differ in 
many respects from Ins(l,4,5)P3, the important 3,4-bisphosphate / 2-hydroxyl triad, 
analogous to the 4,5-bisphosphate / 6-hydroxyl arrangement of Ins(l,4,5)P3, is contained 
within the six-membered pyranoside ring.
Since many studies demonstrated that positions 2 and 3 of Ins(l,4,5)P3 are tolerant to 
extensive modification, it was reasoned that a contracted structure such as (179), 
obtained essentially by deletion of the 2-position carbon of Ins(l,4,5)P3 with its 
associated hydroxyl group, should also fulfil the recognition requirements of the 
Ins(l,4,5)P3 receptor.
Many methods for converting carbohydrates into cyclopentane derivatives have been 
described,153 but the disclosure by Ito et al,248 that treatment of methyl 2,3,4-tri-O- 
benzyl-6,7-dideoxy-a-D-g/wc0-hex-6-enopyranoside(l,5) (180) with zirconocene
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(“Cp2Zr”) followed by boron trifluoride etherate produced vinylcyclopentane (181) (see 
ref. 249 for a review) was of particular interest, as positions 1,2,3 and 4 of (181) possess 
the same relative stereochemistry as the equivalent positions in (179), and therefore as 
positions 4,5,6 and 1 respectively in Ins(l,4,5)P3. It was decided to apply this 
methodology in an attempt to prepare (1R, 2R, 35, 4/?, 55)-3-hydroxy-1,2,4-trisphospho-
5-vinylcyclopentane (182; fig. 3.1), an analogue of (179) which would allow the 




















Fig. 3.1 Retrosynthetic analysis showing a potential route to a 
cyclopentane-based Ins(l,4,5)P3 analogue.
Trisphosphate (182) would require a ring-contracted intermediate in which the 
protecting groups at positions 1 and 2 are orthogonal to that at position 3, to allow 
selective removal to provide the appropriate triol for phosphorylation. It was decided to 
employ p-methoxybenzyl ethers at positions 1 and 2, and a benzyl ether at position 3 
(i.e. giving intermediate 183), as this combination was as close as possible to the 
tribenzyl arrangement used by Ito et al.2A% The carbohydrate precursor to (183) is 
heptoside (184). The 5-vinyl moiety of (184) would be introduced by successive Swem 
oxidation and Wittig methylenation250 of methyl 2-O-benzyl-3,4-di-0-(p-
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methoxybenzyl)-a-D-glucopyranoside (185). As part of a collaborative effort to produce 
trisphosphate (182), the author examined methods to prepare primary alcohol (185).
3 .2  P reparation o f  M ethyl 2 - 0 - benzyl-3 ,4 -di- 0 - ( p -m ethoxybenzyl) - oc- 
D-GLUCOPYRANOSIDE (185 )
p-Methoxybenzylidene acetals have the property that either of the acetal C—O bonds 
may be selectively cleaved to furnish a p-methoxybenzyl ether.251 The direction of 
cleavage depends upon steric and electronic factors as well as upon the choice of 
cleavage reagent.251 Various methods252*253 have been used to cleave the acetal of 2,3- 
disubstituted derivatives of methyl 4,6-0-(p-methoxybenzylidene)-ot-D-glucopyranoside 
(186) resulting in selective formation of 4-0 -(p-methoxybenzyl) ethers. It was therefore 
decided to attempt to benzylate (186) selectively at position 2 using similar 
methodology to that developed for the benzylidene derivative (150) in chapter 2. After 
p-methoxybenzylation of the hydroxyl group at position 3, reductive cleavage of the 







p-Methoxybenzaldehyde dimethyl acetal (187) was prepared by a slight modification of 
the method of Johansson and Samuelsson.252 Thus, a mixture of p- 
methoxybenzaldehyde, trimethyl orthoformate and PTSA was stirred at room 





formate (b.p. 31.5°C at 760mmHg254) more efficiently, thereby driving the reaction to 
completion. Compound (187) was purified by distillation in vacuo and was greater than 
99% pure by *H NMR spectroscopy.
The known252 (186) was prepared in an analogous procedure to (150), i.e. by reaction of 
methyl a-D-glucopyranoside with (187) at 70°C in DMF containing a catalytic quantity 
of PT3A, with continuous removal of methanol. Compound (186) required about six to 
eight times more boiling 2 % w/v aqueous sodium hydrogen carbonate solution to dissolve 
it during recrystallisation than (150).
Benzylation of (186) with dibutyltin oxide and benzyl bromide in acetonitrile in the 
presence of tetrabutylammonium iodide and 4A molecular sieves gave a major and a 
minor product by TLC. These were easily separated by column chromatography and 
were identified as the 2-benzyl ether (188) (48%) and the 3-benzyl isomer (189) (11%). 
The structure of (188) was established from its *H NMR spectrum in CDC13: coupling 
of the methine at position 3 to the hydroxyl proton was observed, which disappeared on 
D20  exchange. The OH stretching observed in the IR spectra of (188) and (189) 
conformed to the generalisations described in chapter 2; in addition, the hydroxyl proton 
of (189) exhibited the characteristically large coupling constant (7 7.3Hz) in the *H 
NMR spectrum in CDC13.
The major product (188) was smoothly p-methoxybenzylated using sodium hydride and 
p-methoxybenzyl chloride in DMF at room temperature, to furnish (190). During the 
work-up it was necessary to use chloroform as extracting solvent because (190) was not 
sufficiently soluble in other solvents.
With (190) in hand, attention turned to cleavage of the acetal. Samuelsson and 
Johansson252 treated methyl 2,3-di-Obenzyl-4,6-0(p-methoxybenzylidene)-a-D- 
glucopyranoside (191) with sodium cyanoborohydride and trimethylsilyl chloride in 
acetonitrile, and obtained the 4-0-substituted p-methoxybenzyl ether (192) in 76% 









(192) R1=:Bn; R2=PMB; R3=H (198)




When (190) was treated with these reagents, the chromatographically separable methyl 
2-0-benzyl-3,6-di-0-(p-methoxybenzyl)-(X-D-glucopyranoside (194) and the required 4- 
substituted isomer (185) were obtained in a ratio of ca. 1:1.7 . The structures of (194) 
and (185) were established by comparison of chemical shifts of their position 6 carbon 
atoms (identifiable by 135DEPT experiments), as observed in their 13C NMR spectra in 
CDC13. The C-6 of (194) resonates at lower field (69.18ppm) than that of (185) 
(61.84ppm) due to the a-effect of alkylation.255 These assigned structures were 
confirmed by preparation of benzoate esters (195) and (196). The !H NMR spectrum of 
(195) displayed a deshielded triplet at 5.28ppm, corresponding to the position 4 
methine; the position 6 methylene protons of (196) were deshielded to 4.46-4.97ppm.
As selectivity of cleavage using the above method was disappointing, alternative 
conditions were explored. Joniak et al.253 used LiAlH4-AlCl3 to convert methyl 4,6-0- 
(p-methoxybenzylidene)-2,3-di-0-methyl-oc-D-glucopyranoside (197) exclusively to the 
4-0-(p-methoxybenzyl) ether (198). Reaction of (190) with LiAlH4-AlCl3 in refluxing 
THF gave exclusively the required product (185) in 73% yield. This result supports the 
suggestion253 that a substituent at position 3 of the glucopyranoside ring hinders access 
of the reagent to the oxygen lone pair at position 4, thereby directing exclusive 
coordination to the oxygen at position 6 (fig. 3.2). Cleavage of the acetal C—0-6 bond 
then results in exclusive formation of the 4-substituted ether. Similar effects have been 
reported for the cleavage of related 4 ,6-O-benzylidene acetals in 3-substituted glucose 
derivatives.257 Why the electrophile in the Me3SiCl-NaCNBH3 experiment should
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coordinate to the position 4 acetal oxygen more easily than does the LiAlH4-AlCl3 








Fig 3.2 Cleavage of the 4,6- 0-{ p-methoxybenzylidene) acetal of (190) using 
LLAIH4 -AICI3. The active species is believed to be AIH2CI (ref. 256).
The rest of the synthetic route to (182) (fig. 3.3) was completed by another worker, and 
proceeded smoothly.258 Of particular interest was the ring-contraction step, which gave 
a small amount of (199) in addition to the required (183). An equivalent minor product 
from the tribenzyl gluco precusor (180) had not been reported by Ito et al.24* The 
relative stereochemistry of (199) and (183) was determined by 2D NOESY and NOE 
difference spectroscopy.
Biological data: Trisphosphate (182) was examined for heparin-sensitive Ca2+
mobilising activity at the platelet Ins(l,4,5)P3 receptor using fluorescence techniques, 
and also using saponin-permeabilised platelets loaded with 45Ca2+. It was found to be a 
full agonist [EC50 23|Xm; cf Ins(l,4,5)P3 0.2|iM], confirming its functional recognition by 
this receptor. These results demonstrate that Ins(l,4,5)P3 receptor mediated Ca2+ 
mobilisation does not necessarily require a cyclohexyl (or equivalent) structural motif. 
A smaller ring phosphate which retains crucial recognition elements of Ins(l,4,5)P3 , i.e.
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Fig. 3.3 Synthesis of (182) from (185).
3 .3  P r e p a r a t io n  of (1/?, 2R, 3 5 ,4 R, 5 5 )-3 -H y d r o x y -5 -h y d r o x y m e th y l-  
1 ,2 ,4 -tr is p h o sp h o c y c lo p e n ta n e  (200 ).
Noting that DL-3-0-methyl-Ins( 1,4,5)P3 and DL-3-0-ethyl-Ins( 1,4,5)P3 both have EC50 
values of greater than IOOjim  in SH-SY5Y neuroblastoma cells [cf Ins(l,4,5)P3 0.18p 
m],259 it seemed reasonable that replacement of the hydrophobic vinyl group of (182) 
with a hydroxyl-containing side chain should markedly increase its potency. An 
obvious target was (200), in which the vinyl substituent is replaced by hydroxymethyl. 
Initially it was intended to prepare (200) by p-methoxybenzylation of (183) followed by 
treatment with 0 s04-NaI04 and reduction of the intermediate aldehyde to give (201). 
Benzylation of the primary alcohol followed by removal of p-methoxybenzyl ethers
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However, a recent report by Chenede et al.260 offered the possibility of a simpler route. 
These workers treated aldehyde (203; fig. 3.4) with samarium (II) iodide in the presence 
of f-butanol and HMPA, and obtained cyclopentane (204). The structure of (204) was 
established by conversion to known compounds, and a mechanism for the ring 
contraction has been proposed.260 It was decided to attempt this rearrangement on 
aldehyde (205), which should give (206). Benzylation of the primary hydroxyl group 
and acidic hydrolysis would furnish triol (202), which could be elaborated to (200).
Aldehyde (205) was prepared by Swem oxidation of (185). After column 
chromatography, some O-H stretching was apparent in the IR spectrum of the product 
in addition to the expected C=0 stretching. As azeotropic drying abolished this O-H 
stretching, it was assumed to arise from hydration of the aldehyde rather than from 
contamination by starting material. Although sufficiently stable to allow full 
characterisation (which had not been carried out previously), (205) gradually rehydrated 
after standing in air for several days, and was therefore best prepared freshly.
Treatment of (205) with samarium (II) iodide in THF in the presence of f-butanol and 
HMPA with rigorous exclusion of air and moisture gave two products after 1 h, as 
judged by TLC. These were identified as alcohol (185; 19%), arising from reduction of 

























Fig. 3.4 Route to cyclopentane-based trisphosphate (200).
The structure of (206) was assigned as follows: the negative FAB mass spectrum 
showed a peak at m!z 493, corresponding to (M-l)-. Characteristic carbohydrate signals 
were absent from both !H and 13C NMR spectra. The 13C NMR spectrum contained 
inter alia a methine signal at 46.68ppm, assigned as C-5 and a methylene signal at 
60.93ppm, assigned as the hydroxymethyl carbon. The *H NMR spectrum exhibited a 
high-field one-proton signal at 2.24ppm corresponding to the methine at position 5 in 
addition to other expected signals. Part of the !H 2D COSY spectrum of (206) is given 
in fig 3.5. Admittedly, the stereochemistry of (206) cannot be unambiguously assigned 















Fig. 3.5 Part of the 'H 2D COSY NMR spectrum of (206) in CDC13.
one isomer and the absence of an NOE effect does not exclude a particular 
stereochemical arrangement. However, the !H NMR spectrum of (206; fig. 3.6b) was 
compared with those of the two isomers (183; fig. 3.6a) and (199; fig. 3.6c) obtained 
from the zirconium-mediated contraction. 2 5 8  The similar relative chemical shift values 
(and splitting patterns) of H-4, H-l and H-2 of (206) and (183) is apparent, as is the 
dissimilarity between these positions of (206) and (199). The structure of (206) was
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therefore assigned as shown, consistent with the results of Chenede et al.260 It is 
intended eventually to confirm this assignment by benzylation of (183) and conversion 
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Fig. 3.6 Part of the ‘H NMR spectra of a) (183), b) (206) and c) (199) in CDCI3 .
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Benzylation of (206) at 0°C with 1 equiv. sodium hydride and 1.1 equiv. benzyl bromide 
in dry DMF gave a mixture of (207) and (208) in a ratio of 3:2 respectively, together 
with unreacted starting material. The structures of (207) and (208) were distinguished 
between by comparison of chemical shifts of the methylene carbon atoms of the C-5 
side chain in the 13C NMR spectra: the a-effect of alkylation causes this signal in the 
spectrum of (208) (67.98ppm) to be deshielded relative to that of (207) (60.95ppm).
Acidic hydrolysis of (208) with 2:1 ethanol-1 m  aqueous HC1 provided triol (202) in 
72% yield. Phosphitylation of (202) with tetrazole-activated
bis(benzyloxy)(diisopropyl-amino)phosphine in dichloromethane provided a 
trisphosphite intermediate, the 31P NMR spectrum of which exhibited a singlet at 
140.3ppm and an AB system at 140.2 and 139.9ppm with a characteristically258 large 
5 / p p  coupling constant of 7.0Hz. Oxidation of this intermediate with MCPBA provided 
the fully protected intermediate (209). Compound (209) contained some impurities 
which could not be entirely removed by column chromatography with various eluents. 
As the impurities did not contain phosphorus, as judged by 31P NMR spectroscopy, the 
crude material was deprotected using sodium in liquid ammonia. The target 
trisphosphate (200) was obtained pure as its triethylammonium salt after ion-exchange 
chromatography and was quantified by Briggs phosphate assay.
The ‘H-coupled 31P NMR spectrum of (200) (fig. 3.7) comprised three doublets, 
confirming the presence of three ring phosphates. The *H NMR spectrum of (200) in 
D2O (fig. 3.8) contained a high-field quintet at 2.29ppm corresponding to the methine at 
position 5; an ABX system at 3.65 and 3.71 ppm corresponding to the methylene 
protons; a triplet at 3.94ppm corresponding to the methine at position 3; and a 








Fig. 3.7 162MHZ 'H-coupled >  NMR spectrum of the triethylammonium sal, of 
(200) in D20 , pH ca. 4.
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Fig. 3.8 Part of (he 400MHz 3IP -coup,ed 'HNM R
salt of (200) in D20 , pH ca. 4.
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The biological properties of (200) are being evaluated.
In conclusion, two recently reported carbohydrate ring-contraction methods have been 
successfully applied to prepare chiral cyclopentane-based Ins(l,4 ,5)P3 analogues.
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CHAPTER FOUR
ATTEMPTED PREPARATION OF A VERSATILE 
CHIRAL INTERMEDIATE FOR SYNTHESIS OF 
ANALOGUES OF Ins(l,4,5)P3
4 .1  I n tr o d u c tio n
There are several problems inherent to the synthesis of inositol polyphosphates starting 
from myo-inositol. First, selective protection of the hydroxyl groups is necessary. 
Second, as myo-inositol possesses a plane of symmetry through C-2 and C-5 (fig. 4.1), 
its protection often leads to racemic mixtures of compounds; as only one inositol 
polyphosphate enantiomer is usually active, racemic precursors need to be resolved by 
conversion to a pair of diastereoisomers which may be separable by crystallisation or 
column chromatography. Third, efficient phosphorylation of the appropriate polyol is 
required. Fourth, efficient deprotection without phosphate migration must be achieved 
and fifth, the final target polyphosphate must be purified.
The last three problems have generally been adequately addressed during the last ten 
years.11 However, the efficient preparation of a versatile, chiral inositol intermediate
Fig. 4.1 The plane of symmetry in myo-inositol oftens leads to 
racemic mixtures of subsequently protected compounds.
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which would allow many target polyphosphates to be prepared has been less 
satisfactorily achieved, and an attempt to prepare such an intermediate is described in 
this chapter.
Conversion of a selectively protected carbohydrate to an assymmetrically protected 
inositol would obviate the need for resolution. In particular, Bender and Budhu’s 
modification of the Ferrier rearrangement167 (section 2.2.4), in which enol acetates 
(129ab; fig. 4.2) are transformed into D-myo-inos-6-oses (130), is particularly elegant, as 
the Ferrier step directly introduces a selectively protected hydroxyl group (as an acetate 
ester) at position 1. The ketone of compounds (130) can be stereoselectively reduced to 
give myo-inositol derivatives in over 90% yield using sodium triacetoxyborohydride,167 
and the resulting two hydroxyl groups have been benzyloxymethylated in the presence 







Fig. 4.2 Direct synthesis of D-myo-inos-6-oses from D-xy/o-hex-5-enopyranosides.
Positions 2, 3 and 4 of methyl a-D-glucopyranoside (142) possess identical relative 
stereochemistry to positions 3, 4 and 5 respectively of D-myo-inositol derivatives. 
Therefore, if R\ in (129ab) was orthogonal with respect to all other groups used, the 
scheme outlined in fig. 4.2 potentially allows the preparation of a chiral D-myo-inositol 
intermediate in which positions 1, 3 and the 4 ,5-diol are all independently accessible.
Choice of protecting groups is important. Allyl ethers were felt to be inappropriate in 
this case as the Ferrier step involves binding of mercury (II) ions to a double bond/ 
However, p-methoxybenzyl ethers may be removed in the presence of, inter alia,
* A recent report (ref. 61) has shown that allyl ethers are unaffected by catalytic Ferrier conditions; 
whether they are stable to prolonged exposure to the stoichiometric quantities of mercury (II) ions used in 
the modified route remains to be established.
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benzyloxymethyl ethers, ketones, acetate esters and isopropylidene ketals.261 
Introduction of a PMB group to position 2 of (142) is therefore logical.
Positions 4 and 5 of myo-inositol intermediates are frequently protected with an 
isopropylidene ketal;11 formation of a 3,4-0 -isopropylidene in this case would give 
(210; fig. 4.3). The product of a Ferrier rearrangement on the corresponding enol 
acetate would be D-l-(9-acetyl-4,5-0-isopropylidene-3-(9-(p-methoxybenzyl)-myo-inos-
6-ose (211). Reduction of (211) would give the corresponding myo-inositol derivative
(212). In addition, protection of the hydroxyl group of (211) and elaboration of the 
ketone potentially allows chiral analogues of both Ins(l,4 ,5)P3 and Ins(l,3,4 ,5)P4 







Fig. 43 Potential route to (212).
Thus, compound (211) was regarded as a desirable target and a potential synthetic route 
to it was investigated.
4 .2  D isc u ssio n  of S ynthetic  W o rk
4.2.1 Preparation of (U,Z)-Methyl 6-0-acetyI-3,4-0-isopropylidene-2-0-(p- 
methoxybenzyl)-a-D-Jty/0-hex-5-enopyranoside (216ab).
When methyl a-D-glucopyranoside (142) is reacted with one equivalent of dibutyltin 
oxide, the 2,3-O-dibutylstannylene (213) is preferentially formed.218’262 Haque et al.262 
found that benzylation, allylation, methylation and methoxymethylation of (213) in 
either acetonitrile or dioxane gave 2-substituted ethers as major products in each case.
This author found that stannylation of (142) in methanol followed by p-methoxy- 
benzylation in acetonitrile gave a mixture of at least six products by TLC. The required 
product (214) was isolated from the reaction mixture by a combination of column 
chromatography and fractional crystallisation. All attempts at obtaining pure (214) by 
crystallisation alone failed in the author’s hands. Compound (214) was alternatively 
prepared by the hydrolysis of methyl 4,6-0-benzylidene-2-0-(p-methoxybenzyl)-a-D- 
glucopyranoside (163) (see chapter two) with aqueous acetic acid, thereby confirming 
its structure as the 2-substituted ether.
(213)
The use of isopropylidene ketals in carbohydrates is an important protection method
which has been reviewed.263*264 Where more than one monoketal product is possible in
a molecule, cis-1,2-diols tend to be protected over 1,3-diols, which in turn tend to be
favoured over trans- 1,2-diols,263*265 and these generalisations were confirmed in the
present case. Thus, acid-catalysed reaction of (214) with 2-methoxypropene gave 
exclusively the 4,6-O-isopropylidene derivative (215). The required 3,4-0- 
isopropylidene isomer (210) was obtained in excellent yield by the sequential treatment
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of (214) with f-butyldiphenylsilyl chloride,266 2-methoxypropene and 
tetrabutylammonium fluoride. The structures of (210) and (215) were distinguished 
between chiefly on the basis of their 13C NMR spectra, which showed characteristic267 
chemical shift values for isopropylidene carbons in the proposed 1,3-dioxane (215) and 














Fig. 4.4 13C NMR chemical shift values for isopropylidene carbons in (210) and (215).
Enol acetate precursors to the modified Ferrier rearrangement are prepared by a two step 
process.167 The primary alcohol is first oxidised to the corresponding aldehyde which is 
subsequently trapped in its enolate form by refluxing in a mixture of dry acetonitrile and 
acetic anhydride in the presence of potassium carbonate.
When (210) was subjected to the Swem oxidation followed by trapping of the crude 
product as above, only 26% of the required enol acetates (216ab) were isolated. The 
major product was the geminal diacetate (217) (43%), presumably formed by acetylation 
of the hydrated intermediate aldehyde. Estevez and Prestwich191 reported that the 
intermediate aldehyde (218) was more than 90% hydrated. Partial purification of the 
aldehyde intermediate followed by azeotropic drying and trapping increased the yield of 
(216ab) to 70% with no concomitant production of (217). !H NMR spectroscopy 
indicated that (216ab) was formed as a mixture of geometrical isomers, in an 
approximate ratio of 4:1 by the integral ratio of the anomeric methyl signals. As the
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stereochemical outcome of the Ferrier rearrangement is independent of the geometrical 
arrangement of the precursor enol acetate,167 no attempt was made to separate these 











The modified Ferrier rearrangement involves treatment of a solution of the enol acetate 
in aqueous acetone with one equivalent of mercury (II) trifluoroacetate167 or acetate191 to 
open the carbohydrate ring, followed by sodium chloride to effect cyclohexanone ring 
closure.
When (216ab) was treated with mercury (II) acetate (chosen over the trifluoroacetate 
because of the acid lability of the isopropylidene ketal) as above, TLC indicated swift 
consumption of starting material to give a baseline product. Overnight stirring with 
enough sodium chloride to saturate the system caused consumption of the baseline 
product to give a less polar product. This was not the expected cyclohexanone (211), 
however, but 6-0-acetyl-3,4-0-isopropylidene-2-0-(p-methoxybenzyl)-D-xy/o-5- 
hexosulose (219). The structure of (219) was assigned on the basis of its and 13C 
NMR spectra. Part of the !H NMR spectrum of (219) and pertinent 13C chemical shift 
values are shown in fig. 4.5.
Compound (219) corresponds to a hydroxymercurated ring-opened Ferrier intermediate 
(220; fig. 4.6) which, instead of ring closing, has lost mercury. Although Bender and 
Budhu167 reported a resistance of the equivalent 2,3,4-tri-O-triethylsilyl analogue to ring 
closure, it was the organomercurial intermediate (221) which they isolated. In their 
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Fig. 4.5 Part of the 270MHz 'H NMR spectrum of (219) in CDCI3 and some 13C NMR 
chemical shift values.
of which tin (IV) chloride was the best. The 6-deoxy-5-hexosulose product (222) was 
isolated by Blattner et al.l5S from a classical Ferrier rearrangement, and was rationalised 
as the result of acid-catalysed hydrolysis of the intermediate (223). When the product 
from (216ab) was worked up immediately after addition of sodium chloride, ‘H NMR 
analysis indicated the presence of a 1 : 1  diastereomeric mixture of organomercurial 
intermediates (220; duplicate H - 6  singlets at 5.39 and 5.60ppm) in addition to (219).
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The relative proportions of (220) (as mixture) and (219) was approximately 2:1 
respectively, from the integral ratio of the H-6 singlets of (220) and the position 6 
methylene AB quartet of (219). Addition of this mixture to a solution of tin (IV) 
chloride at -78°C gave an intractable mixture of at least four products by TLC, none of 

















It is believed that the resistance of (220) to normal ring closure is due to the presence of 
the 3,4-0-isopropylidene protecting group, which is required to adopt a relatively 
strained trans formation for ring closure to occur. Although positions 3 and 4 of 
carbohydrate precursors have been incorporated into ring systems in other studies,153*168 
none has been a trans-fused five-membered ring.
4.2.3 Preparation of D-l-0 -AcetyI-3-O-benzyl-4,5-di-0 -(p-inethoxybenzyI)-#?iy0 - 
inos-6-ose (225)
The failure of (216ab) to furnish the expected cyclohexanone coincided with the 
successful preparation of methyl 2-0-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D- 
glucopyranoside (185), as described in chapter three. It was decided to continue the 
route with this compound for two reasons. First, because successful conversion of 
(224ab) to (225) would provide supporting evidence that the resistance of (216ab) to 
ring closure was attributable to the isopropylidene acetal and second, because although 
(225) was not as versatile an intermediate as (211), it did offer the prospect of furnishing 
some chiral analogues of Ins(l,4 ,5)P3 modified at position 6.
Conversion of (185) to enol acetates (224ab) was achieved in 86% yield using the 
methodology described above. Treatment of a solution of (224ab) in aqueous acetone 
with mercury (II) trifluoroacetate followed by sodium chloride gave (225), obtained in 
36% yield by a combination of column chromatography and crystallisation.
The structure of (225) was assigned on the basis of its and 13C NMR spectra. Part of 
the !H 2D COSY spectrum of (225) is shown in fig. 4.7. All five ring methines have 
been assigned. In addition, the 13C NMR spectrum exhibited signals from five inosose
OAc
PMBO.
P M B O ^ ~ o p m b
o c h 3
(224ab) (225)
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ring methines and a quaternary carbon at 198ppm corresponding to C-6. Characteristic 
carbohydrate signals were absent.
With (225) in hand, attention turned to protection of the hydroxyl group at position 2. 
Attempted benzyloxymethylation with benzyloxymethyl chloride in dry acetonitrile 
containing proton sponge and quaternary ammonium salts,191 or benzylation with benzyl 
bromide and silver (I) oxide in DMF gave mixtures of several p-methoxybenzyl- 
containing compounds by TLC, which presumably arose by p-elimination and 
subsequent aromatisation.
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Fig. 4.7 Part of the 400MHz 2D 'H COSY NMR spectrum of (225) in CDC13.
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4 .3  S u g g estio n s  fo r  F u r t h e r  W o rk
Ley and co-workers268 have developed the “dispiroketal” protecting group for selective
protection of trans vicinal diols. The use of this group is attractive in the above route 
for two reasons. First, because reaction of (214) with 3,3'4,4'-tetrahydro-6,6'-bi-2-//- 
pyran (226) would be expected to furnish the 3,4-Oacetal (227) directly, thus avoiding 
the need for protection and subsequent deprotection of the primary hydroxyl group. 
Second, the 3,4-diol of the enol acetates (228ab) would be contained within a six- 
membered ring, which, experiencing less strain than the isopropylidene, might be 
expected to allow the ring closure to cyclohexanone (229). Reduction of (229) should 












SYNTHESIS OF INTERMEDIATES AND ANALOGUES OF 
Ins(l,4,5)P3 BASED ON ADENOPHOSTIN A
5 .1  In tr o d u c tio n
5.1.1 General Introduction
Although most of the active inositol polyphosphates and related compounds tested for 
Ca2+ release at the Ins(l,4,5)P3 receptor during 1987-93 had been full agonists, most 
exhibited potency comparable to or less than that of the natural ligand (reviewed in 
chapter one). However, in late 1993 a Japanese group reported the isolation of two 
potently agonistic trisphosphates from a culture broth of Penicillium brevicompactum.269 
These were named adenophostins A and B, and identified as 3'-0-(a-D-glucopyranosyl)- 
adenosine-2',3",4"-trisphosphate (231) and its 6"-0 -acetyl derivative (232) 












The adenophostins have been demonstrated to be heparin-sensitive full agonists in rat 
cerebellar microsomes, with potencies 100-fold higher than Ins(l,4,5)P3 [EC50 values
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1.4nM (231) and 1.5nM (232); cf 170nM Ins(l,4,5)P3];272 these relative potencies are 
consistent with binding data.272 In another study involving the purified Ins(l,4,5)P3 type
1 receptor, (232) was found to be 10-fold more potent than Ins(l,4,5)P3 [EC50 values 
llnM (232); cf. lOOnM Ins(l,4,5)P3].273 In this study, (232) demonstrated a positive 
cooperativity in binding to the Ins(l,4,5)P3 receptor not exhibited by Ins(l,4,5)P3. Both 
(231) and (232) are resistant to the metabolic enzymes 5-phosphatase and 3-kinase and, 
as expected, produce a sustained Ca2+ release.272
5.1.2 Structure-Activity Considerations
The high potency of the adenophostins is intriguing, as they bear little apparent 
resemblance to Ins(l,4,5)P3. However, the structures of (231) and (232) show 
consistencies with many of the generalisations discussed in chapter one.
The glucose 3,4-bisphosphate moiety possesses D-threo stereochemistry and the position
2 hydroxyl group may be regarded as analogous to position 6 . Indeed, molecular 
modelling studies272-274 demonstrate similarity of positions 4, 3 and 2 of (231) with 
positions 4, 5 and 6 respectively of Ins(l,4,5)P3. In addition, the adenophostins possess 
a third phosphate, which, similarly to Ins(l,4,5)P3, is essential for high potency: 3'-0-(a- 
D-glucopyranosyl)-adenosine-3",4"-bisphosphate (233), in which this third phosphate is 
removed, possessed a 1000-fold lower binding affinity than (231).272
Although the broad basis for the activity of (231) and (232) is clear, a full structural 
rationalisation for their exceptional potency is lacking. An interesting combination of 
compounds to compare, for example, would be (231), methyl 3-0-(a-D-glucopyranosyl)- 
p-D-ribofuranoside-2,3',4'-trisphosphate (234) and (2-hydroxyethyl) a - D -  
glucopyranoside 2',3,4-trisphosphate (235). Such a study would establish the relative 
importance of the adenine and adenosine components of (231). The work described in 
this chapter represents initial attempts at preparing selectively protected glucose-based 




The preparation of adenophostin A would require deprotection of a fully protected, 
phosphorylated intermediate such as (236; fig. 5.1), derived from triol (237). Triol 
(237) could be obtained from a derivative in which positions 2', 3" and 4" are protected 
with a group removable in the presence of benzyl ethers, benzamides and glycosidic 
linkages. The p-methoxybenzyl ether fulfils this requirement. 6-//-Benzoyl-2'-0-(p- 
methoxybenzyl)-adenosine (238) is known,275 and benzylation of the primary 5'- 
hydroxyl in favour of the secondary 3-hydroxyl to give (239) ought to be 
straightforward. Selective coupling of (239) to position 1 of 2,6-di-0-benzyl-3,4-di-O- 
(p-methoxybenzyl)-D-glucopyranose (240) to provide the a-anomeric derivative (241) 
should be possible using trichloroacetimidate methodology commonly employed in 
oligosaccharide synthesis.276
The p-trichloroacetimidate derivative of (240) could also act as a glycosyl donor to 
other alcohols, such as 2-(p-methoxybenzyloxy)-ethanol, giving a precursor to (235), or 
methyl 5-0-benzyl-2-0-(p-methoxybenzyl)-p-D-ribofuranoside, giving a precursor to
(234). Clearly, compound (240) is an important intermediate and, as part of a 










Fig. 5.1 Retrosynthetic analysis showing a potential route to (231).
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5 .2  P r e p a r a t io n  o f  2 ,6 -d i-0 -b e n z y l-3 ,4 -d i-0 -(p -m e th o x y b e n z y l) -d -  
GLUCOPYRANOSE (240)
5.2.1 Attempted Preparation from the Methyl Glycoside
Two methods are commonly used to cleave methyl glycosides, namely acidic hydrolysis 
and acetolysis. Although 2,3,4,6-tetra-O-benzyl-D-glucopyranose (242) has been 
prepared by refluxing a solution of the corresponding a-methyl glycoside (243) in ca. 
2:1 acetic acid-1m  sulphuric acid for 24 hours,277 the acid-lability of p-methoxybenzyl 

















It is known that treatment of (243) with acetic anhydride containing 1% sulphuric acid 
rapidly produces l,6-di-0-acetyl-2,3,4-tri-Obenzyl-D-glucopyranose (244),278 i.e. 
cleavage of both the primary benzyl ether and the glycoside occurs. Leaving the 
reaction for longer (ca. 2 h) results in additional cleavage of the benzyl ethers at 
positions 2 and 3.278 However, more recently, the milder catalyst boron trifluoride 
etherate has been used to acetolyse methyl 2-0-benzyl-3-deoxy-2-C-methyl-a-D- 
arafcmo-hexopyranoside (245)279 and methyl 3,4,6-tri-0-acetyl-2-0-(o-nitrobenzyl)-a-D- 
glucopyranoside (246).216 These reactions required treatment at 0°C for 4 h. Although
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neither of these examples contained primary benzyl ethers, it was hoped that anomeric 








Methyl 2,6-di-O-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D-glucopyranoside (247) could 
easily be obtained by benzylation of (185), prepared in chapter three. Instead, an 
alternative route was explored. The synthesis of methyl 3-Obenzoyl-2-O-benzyl-4 ,6-0 - 
benzylidene-a-D-glucopyranoside (144; fig. 5.2), isolated without recourse to column 
chromatography on a 75g scale, was described in chapter two. Regioselective cleavage 
of the benzylidene acetal to give the primary benzyl ether (248), followed by 
saponification and p-methoxybenzylation would allow large amounts of (247) to be 
produced.
The required direction of benzylidene cleavage has been reported using sodium 
cyanoborohydride-hydrogen chloride,280'281 aluminium chloride-triethylamine-borane 
complex282 and trifluoroacetic acid-triethylsilane.283 The first of these has been 
successfully applied to both methyl 2,3-di-O-benzyl- and 2,3-di-0-benzoyl-4,6-O 
benzylidene-a-D-glucopyranosides,280'281 and seemed ideally suited to (144).
Addition of dry hydrogen chloride in ether to a solution of (144) and sodium 
cyanoborohydride in THF at room temperature caused conversion of starting material to 
a single product. This was not characterised, but benzoylated, to provide methyl 3,4-di- 
0-benzoyl-2,6-di-0-benzyl-a-D-glucopyranoside (249), identifiable by deshielded 
triplets at 5.49 and 5.92ppm in its *H NMR spectrum, corresponding to H-3 and H-4 
respectively, and thereby confirming the direction of benzylidene cleavage. Compound 


















Fig. 5.2 Potential route to (247) from (144).
Treatment of (249) with acetic anhydride and boron trifluoride etherate* at 0°C resulted 
in swift conversion of starting material to methyl 6-O-acetyl-3,4-di-O-benzoyl-2-0- 
benzyl-a-D-glucopyranoside (250; fig. 5.3; 64%) and l,6-di-0-acetyl-3,4-di-0-benzoyl- 
2-O-benzyl-D-glucopyranose (251; 7%). In the !H NMR spectra of both (250) and 
(251), the deshielded two-proton signals demonstrated that the primary benzyl ether, and 
not the secondary, had been replaced by an acetate ester. Thus, primary ether cleavage 
is more rapid than deglycosylation. Presumably a small amount of methoxide loss 
occurs via the oxonium ion (252; fig. 5.3) initially. Methoxide then reacts with acetic 
anhydride to form methyl acetate and acetate anion, the nucleophile, which either 
recombines with the oxonium ion (route A) or cleaves the primary benzyl ether of 
another molecule of (249) (route B). This latter route generates benzyl acetate and 
alkoxide and a self-perpetuating pathway Attack of acetate at the benzyl ether 
methylene carbon is more likely than at C-6 because acetolysis of secondary benzyl
* Failure to dry this reagent freshly resulted in complete absence of reaction.
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ethers proceeds with retention of configuration.278 To the best of the author’s 
knowledge, this is the first example of a selective benzyl ether acetolysis in the presence 
of a glycoside.
AcOAc









Fig. 5.3 Possible mechanism of formation of (250) and (251) from (249).
In conclusion, a route to (240) from the methyl glycoside was not convenient, and an 
alternative method was sought.
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5.2.2 Preparation from the Allyl Glycoside
An alternative preparation of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (242) from the 
corresponding allyl glycosides has been described by Gigg and Gigg.284 Allyl ethers 
have been widely used as protecting groups in carbohydrate and inositol chemistry 
because, while relatively stable themselves, they can be induced to isomerise to prop-1- 
enyi ethers by a variety of reagents.285*286 These enol ethers are hydrolysed by mildly 
acidic (and other285*286) conditions.
Thus Gigg and Gigg prepared an anomeric mixture of allyl 2,3,4,6-tetra-O-benzyl-D- 
glucopyranosides (253), isomerised the allyl groups using potassium f-butoxide in dry 
DMSO at 100°C for 15 min and obtained (242) by refluxing a solution of the products 
in 9:1 acetone-0. 1m aqueous HC1 for 30 min.284 Using essentially this methodology, 
allyl ethers have been removed in the presence of p-methoxybenzyl ethers,100*287 making 
this an ideal route for the preparation of (240).
Selective protection of positions 2 and 6 of the allyl glycoside(s) is required in this 
route. As position 2 bears the most reactive secondary hydroxyl group in a-alkyl
A4 g  AAA AA4
glycosides, whereas position 3 bears the most reactive in the P-isomers, * ’ the 
preparation of allyl a-D-glucopyranoside (254a) was required. In addition, use of the a- 
allyl glycoside potentially allowed preparation of (2-hydroxyethyl) a-D-glucopyranoside 
2',3,4-trisphosphate (235) directly: Ferrier and Stutz185 had prepared (255) from (256) by 
reaction of the latter with osmium tetraoxide-sodium metaperiodate followed by 
reduction of the intermediate aldehyde with sodium borohydride. It followed that an 
allyl glycoside ought to be similarly convertible to a (2-hydroxyethyl) glycoside.




Glycoside (254a) was first obtained pure by reaction of D-glucose with dry allyl alcohol 
containing dissolved hydrogen chloride gas (i.e. a classical Fischer glycosylation), 
followed by dry acetone extraction and fractional crystallisation,288 although a recent 
report289 found this general method unsatisfactory. A more commonly used method is a 
modified Fischer glycosylation in which a mixture of D-glucose, allyl alcohol and a 
strong ion-exchange resin are heated under reflux.289-291 When this author applied the 
latter procedure, an orange syrup was obtained after cooling, filtration and evaporation. 
In agreement with Lee and Lee,290 no crystallisation could be induced at this stage. 
Column chromatography of.this syrup gave a white solid (254ab). *H NMR 
spectroscopy of (254ab) in D20  revealed a ca. 7:3 a:P anomeric mixture of allyl 
glycosides, estimated from the integral ratio of the anomeric protons, resonating at 
4.92ppm (7 3.1Uz) and 4.46ppm (7 7.9Hz) respectively. A single crystallisation from 
ethyl acetate-ethanol typically gave a 9:1 a:p mixture. Fractional crystallisation gave 




(254ab) 7:3 oc:P 
(254a) a-anomer
Attention now turned to selective protection of positions 2 and 6. In principle, allyl 2,6- 
di-Obenzyl-3,4-di-<9-(p-methoxybenzyl)-a-D-glucopyranoside (257) could be prepared 
from the 4,6-0-(p-methoxybenzylidene) acetal using similar methodology to that 
described in chapter three, or from the 4 ,6-O-benzylidene acetal, as described for the 
methyl glycoside above. However, a more challenging and potentially more convenient 
approach would be to protect positions 2 and 6 simultaneously.
Methyl 2,6-di-Obenzyl-a-D-glucopyranoside (258) was produced in 30% yield when 
methyl a-D-glucopyranoside was treated with 1.5 equiv. of bis(tributyltin) oxide, 
followed by neat benzyl bromide,255 presumably by formation of the 2,6-
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bis(tributylstannyl) diether. A possible method of disubstitution of (254a) would 
therefore be to react it with 2 equiv. of bis(tributyltin) oxide and to benzylate it as 
above. An alternative possibility was to extend the use of stannylene acetals.
Reaction of methyl a-D-glucopyranoside with 1 equiv. of dibutyltin oxide results in 
formation of the 2,3-0-dibutylstannylene derivative, with selective esterification218 or 
alkylation262 occurring at position 2. In addition, benzyl 2,3-di-O-benzyl-a-D- 
glucopyranoside (259) has been regioselectively methoxymethylated at position 6 via its 
4,6-0-dibutylstannylene derivative.292 Therefore, it seemed reasonable that reacting an 
alkyl glucopyranoside with more than 2 equiv. of dibutyltin oxide ought to result first in 
the formation of the 2,3-0-dibutylstannylene, followed by the 2,3:4,6-di-0- 
dibutylstannylene. The latter derivative of an a-anomer (260) would be expected to 



















As the a-anomer (254a) had been more difficult than expected to isolate from the 
glycosylation reaction, an ideal situation would be the isolation of a 2,6-disubstituted a- 
anomeric derivative directly from (254ab). Such methodology would be potentially of
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general use to carbohydrate chemists and consequently, it was decided to attempt both 
esterification and alkylation using a bis stannylene approach.
When (254ab) was reacted with 2.5 equiv. of dibutyltin oxide in toluene and the 
reaction mixture cooled, a precipitate formed which could not be redissolved in toluene 
or dioxane. Hoping that gradual dissolution and reaction would occur, this suspension 
(in toluene) was stirred for several days with 2.1 equiv. of benzoyl chloride, but no 
reaction occurred. After completion of these studies, Qin and Grindley293 noted the 
poor solubility of methyl 2,3:4,6-di-0-dibutylstannylene-a-D-glucopyranoside in 
chloroform and suggested oligomerisation.
The stannylation product of (254ab) with 1.05-1.2 equiv. of dibutyltin oxide did not 
precipitate on cooling. Treatment of the cooled solution with 2.1 equiv. of benzoyl 
chloride gave a mixture of products by TLC, from which the known291 allyl 2,6-di-O- 
benzoyl-a-D-glucopyranoside (261; fig. 5.4) was isolated in 34% yield by a combination 
of column chromatography and crystallisation. Presumably the 2,3-0-dibutylstannylene 
derivative of the a-anomer formed, was soluble in cold toluene and directed substitution 
at position 2, while the primary hydroxyl was selectively benzoylated over the 
remaining free secondary hydroxyl at position 4 as expected. This two-step preparation















Fig. 5.4 Route to (264) from D-glucose via dibenzoate (261).
Reaction of (261) with 2-methoxypropene gave fully protected (262; fig. 5.4). It is 
noteworthy that best yields of 3,4-CMsopropylidene derivatives were obtained with a 
short reaction time. To the best of the author’s knowledge, the publication of this 
procedure294 represented the first literature example of the use of an isopropylidene 
acetal to protect positions 3 and 4 of a glucose derivative. Recently, a variation of this 
method has been described on the enantiomer of (261) using THF as solvent over a 
longer period.295 The benzoate esters of (262) were easily replaced with benzyl ethers in 
two-steps: basic methanolysis provided diol (263) which was benzylated with sodium 
hydride and benzyl bromide in DMF to provide allyl 2,6-di-0-benzyl-3,4-0- 
isopropylidene-a-D-glucopyranoside (264).
Attention now turned to potential direct benzylation. Alkylation is carried out at higher 
temperatures than esterification, at which the bis stannylene intermediate (260) might be 
soluble. As benzylation tends to be less selective than benzoylation, the pure a-anomer 
(254a) was used initially to test the viability of this method.
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Treatment of the stannylated product with benzyl bromide in refluxing toluene or 
acetonitrile (both containing quaternary ammonium salts) resulted in sluggish reactions 
providing many products by TLC, none of which dominated and which were not 
completely separable by column chromatography. However, when stirred with neat 
benzyl bromide at 100-110°C, the stannylated product dissolved within one hour and 
after two days a major product and several minor products (of similar Rf value) were 
obtained. After work up and column chromatography to remove excess benzyl bromide, 
attempts were made to crystallise the major product. Although no crystallisation could 
be induced with most common solvents (methanol, ethanol, isopropanol, diethyl ether, 
ethyl acetate-hexane), diisopropyl ether yielded a single dibenzyl derivative in 44% 
yield (two crops). This was identified as the required allyl 2,6-di-Obenzyl-a-D- 
glucopyranoside (265) by preparation of its 3,4-dibenzoate (266), the *H NMR spectrum 
of which displayed deshielded triplets at 5.52 and 5.98ppm corresponding to H-4 and H- 

















In the hope that further quantities of (265) could be obtained via the less polar (264), the 
mother liquor of the benzylation mixture was reacted with 2-methoxypropene. A single 
new product was formed, which was easily isolated by flash chromatography. This
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compound was not (264), however, but a dibenzyl derivative possessing an 
isopropylidene acetal in a 1,3-dioxane chair conformation, as apparent from the 
characteristic267 chemical shifts of the isopropylidene axial methyl (19.18ppm), 
equatorial methyl (29.22ppm) and quaternary (99.34ppm) carbons in the 13C NMR 
spectrum in CDC13. Its structure was therefore assigned as allyl 2,3-di-0-benzyl-4,6-0- 
isopropylidene-a-D-glucopyranoside (267), thereby demonstrating that all of (265) had 
been isolated by crystallisation.
With appropriate benzylation methodology and a convenient isolation procedure 
established, the technique was attempted on (254ab) on a 35g scale. In this case (265) 
could still be crystallised from the (more complicated) product mixture, but only in poor 
yield {ca. 15%). Reaction of the mother liquor with 2-methoxypropene in this case gave 
a mixture of several acetal-containing species which could not be separated further. 
Although the yield of crystalline (265) from the anomeric mixture was rather 
disappointing, this method has been found to be the most convenient overall to produce 
it in multigram quantities.
While this work was in progress, Qin and Grindley293 reported similar benzylation 
selectivity on methyl a-D-glucopyranoside, confirming the general applicability of this 
method. In their studies, conducted on a lmmol scale, only the 2,6-dibenzyl derivative 
was obtained, and an improved yield was reported when using only 1.5 equiv. of 
dibutyltin oxide. This has not been attempted on (254a). Another interesting result was 
the product mixture obtained from methyl p-D-glucopyranoside: the 2,6-di-O-benzyl 
derivative was the major product (56%) and not the 3,6-di-O-benzyl derivative (16%). 
This selectivity is the reverse of that observed with the 4,6-0-benzylidene derivative 
(268) which gave a ca. 1:2 ratio of the 2- and 3-O-benzyl ethers,296 although it is 
consistent with the ratio of monoalkylated products from use of 1 equiv. of dibutyltin 
oxide with methyl P-D-glucopyranoside.262
The conversion of (265) to target (240) was achieved in three steps. p- 
Methoxybenzylation of (265) with sodium hydride and p-methoxybenzyl chloride gave 
fully protected (257), which was isomerised to the corresponding prop-l-enyl glycosides 
(269ab) using potassium f-butoxide in dry DMSO. Finally, hydrolysis with refluxing
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10:1 acetone-1m aqueous HC1 for 20 min gave (240) in 77% yield after crystallisation. 
Compound (240) was identified by positive Fehling’s test and by its !H NMR spectrum, 
which indicated its solution in CDCI3 to be a ca. 1:1 anomeric mixture.
Use of (240) in trichloroacetimidate coupling methodology is currently being 
investigated in these laboratories.
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5 .3  P reparation o f  (2-H ydroxyethyl) oc-d -glucopyranoside  2*,3,4  
TRISPHOSPHATE (235)
Attention now turned to direct preparation of (235), which represents the derivative of 
adenophostin A in which most of the adenosine moiety has been deleted.
As both benzyl ethers185 and isopropylidene acetals297 should be stable to osmium 
tetraoxide, (264) was chosen as an appropriate selectively protected intermediate for the 
synthesis of (235). Reaction of (264) with 0.3 equiv. of osmium tetraoxide and excess 
sodium metaperiodate for 5 h produced a polar product which was not isolated but was 
reduced with sodium borohydride to furnish (2-hydroxyethyl) 2,6-di-O-benzyl-a-D- 
glucopyranoside (270) in 56% overall yield from (264). The structure of (270) was 
assigned chiefly on the basis of its 13C NMR spectrum (fig. 5.5) which showed loss of 
isopropylidene and allyl signals and the presence of methylene carbons at 61.47 and 
70.28ppm, typical298 of the 2' and 1' positions respectively of an a-(2-hydroxyethyl) 
glucoside.
Loss of the isopropylidene acetal in this reaction was unexpected. It could not have 
occurred in the presence of sodium metaperiodate, as the resulting diol would have been
solvents compared to water,299 it presumably partitioned into the organic layer during 
purification of the intermediate aldehyde and was subsequently reduced to osmic acid 
(H20 s0 4), an acid sufficiently strong to remove the labile trans ketal. Nevertheless, the 
loss of the acetal was advantageous, as it directly provided the triol required for 
phosphorylation.
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Fig. 5.5 100M Hz l3C NM R spectrum o f  (270) in CDC13.
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Phosphitylation of (270) with tetrazole-activated bis(benzyloxy)(diisopropylamino)- 
phosphine gave a trisphosphite triester, in which the vicinal bisphosphite presented as an 
AB quartet and the primary phosphite as a singlet in the 31P NMR spectrum (fig. 5.6). 
After oxidation with MCPBA and purification, the ^-coupled 31P NMR spectrum of 
the product (271; fig. 5.7) exhibited a septet corresponding to the phosphorylated 
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Fig. 5.7 162MHz ^-coupled 3IP NMR spectrum of (271) in CDCI3.
Deprotection of (271) with sodium in liquid ammonia, followed by purification by ion- 
exchange chromatography, provided the required trisphosphate (235), isolated as the 
triethylammonium salt and quantified by Briggs phosphate assay.
Trisphosphate (235) has also been prepared by Gigg and co-workers from d -  
galactose;300 to date only its biological evaluation has been published.274
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5 .4  B iological D ata for (2-H ydroxyethyl) oc-d -glucopyranoside 
2 !,3 ,4 -trisphosphate
Trisphosphate (235) was examined for Ca2+-mobilising activity at the platelet 
Ins(l,4 ,5)P3 receptor. It was found to be a full agonist with a potency ca. 10-fold lower 
than that of Ins(l,4 ,5)P3 [EC50 0.6|Hm; cf. Ins(l,4 ,5)P3 0.05pM, fig. 5.8], a result 











Two related studies are of interest to this discussion. First, DL-3-deoxy-3- 
hydroxymethyl-^cy/Zo-inositol-1,2,5-trisphosphate (272) demonstrated a Ca -mobilising 
potency approximately equal to that of Ins(l,4 ,5)P3 at the platelet Ins(l,4 ,5)P3 receptor 
[ E C 5 0  0.1 jim; cf. Ins(l,4 ,5)P3 0.1 Ijim].301 Assuming the L-enantiomer is inactive, and 
noting that D-scyllo-lns( 1,2,4)P3 has approximately equal Ca2+-mobilising potency to
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Ins(l,4 ,5)P3, this implies that the CH2OH component is at least tolerated by the 
Ins(l,4 ,5)P3 receptor, and may even give rise to a modest increase in potency. The 
observation that (235) is less active than either (272) or Ins(l,4 ,5)P3 suggests that the 
conformationally rather mobile 2-phosphate group of (235) is not a good mimic of the 
2'-phosphate in adenophostin A, nor of the 1-phosphate of Ins(l,4 ,5)P3. Thus, all or part 
of the adenosine moiety in adenophostin A may be necessary to orientate the 2'- 
phosphate group in a particularly favourable way at the receptor binding site. The 
biological data above clearly demonstrate that at least part of the adenosine component 
of the adenophostins is essential for the extreme potency exhibited by these 
glyconucleotides. Furthermore, (235) represents the first carbohydrate-based 
trisphosphate to exhibit any significant agonistic activity at the Ins(l,4 ,5)P3 receptor. It 
therefore complements and consolidates the other work in this thesis, showing that 
structurally diverse polyphosphates which retain the pharmacophore defined in chapter 
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Fig. 5.9 Displacement of specific [3H]-Ins(l,4,5)P3 binding in rat cerebellar membranes by Ins (1,4,5)P3 and by (235). 
Non-specific binding was defined as binding not displaced by 10pM  Ins(l,4,5)P3 (n=3).
Fig. 5.10 EC50 values for Ca2+ mobilisation in permeabilised hepatocytes (taken from 
Moitessier et a/.302)
The second finding of interest is the relative Ca2+-mobilising potencies of a series of 
both a- and p-anomeric (2-hydroxyethyl) and (3-hydroxypropyl) xylopyranoside 
trisphosphates.302 Their structures and EC50 values for Ca2+-release in permeabilised 
hepatocytes are given in fig. 5.10. It is noteworthy that (273), which represents the 
derivative of (235) in which the hydroxymethyl group has been deleted, and which of 
the four xylopyranosides most closely resembles the adenophostins, is the most potent. 
Increasing the aglycon chain length by one carbon atom approximately halved potency, 
while inversion of configuration at the anomeric centre reduced it approximately four­
fold. Given that the hydroxymethyl group of (235) may engender a favourable ligand- 
receptor interaction {vide ultra), it would be interesting to compare (235) and (273) in 
the same system.
The sample of (235) prepared by Gigg et al was found to be resistant to catabolism by 
both 5-phosphatase and 3-kinase, being neither a substrate nor an inhibitor of either of
, 274these enzymes.
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5 .5  P r e p a r a t io n  of a F lu o r e s c e n t  L a b e l B a sed  U pon (2 -H y d ro x y -  
ETHYL) (X-D-GLUCOPYRANOSIDE 2',3,4-TRISPHOSPHATE
The metabolic resistance of (235) made it an ideal compound onto which to attach a 
fluorescent label. Of particular interest was the possibility of preparing a probe to carry 
out fluorescence resonance energy transfer (FRET) experiments to study the purified 
Ins(l,4 ,5)P3 receptor. This technique is based on the concept that the fluorescence 
emission of one molecule may excite the fluorescence of another, provided the two 
molecules are sufficiently close. The maximum distance (4-10nm) can only arise 
through specific binding; non-specifically bound molecules and non-bound molecules 
are too distant to allow the occurrence of FRET.
Fluorescently labelled compounds have been prepared previously by reaction of 
phosphorothioates with an iodinated derivative of the required label, for example dl-  







It was reasoned that, as the 3,4-bisphosphate/2-hydroxy triad of (235) is essential for 
binding, the primary phosphate would be the ideal place onto which to append the label. 
Collaborators had previously used the BODIPY FL label,303 and consequently it was
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decided to react iodoacetamide (275; fig. 5.11) with (2-hydroxyethyl) a - D -  
glucopyranoside 3,4-bisphosphate-2'-phosphorothioate (276) in order to prepare the 
required (277). A route to (276) was designed.
Allyl 2,6-di-O-benzyl-a-D-glucopyranoside (265) was phosphitylated with tetrazole- 
activated bis(p-chlorobenzyloxy)(diisopropylamino)phosphine, then oxidised with 
MCPBA to give fully protected (278). The p-chlorobenzyl phosphate diester was 
chosen because of its increased acid stabilty compared to the benzyl diester.242 This was 
considered important as the following step had produced acid strong enough to remove 
an isopropylidene acetal (vide ultra).
Intermediate (278) was converted to the corresponding (2-hydroxyethyl) glycoside (279) 
using osmium tetraoxide-sodium metaperiodate followed by sodium borohydride as 
described above. In this case a much longer reaction time was required and the 
intermediate aldehyde was purified by flash chromatography in an attempt to remove 
osmium tetraoxide. The structure of (279) was assigned largely on account of its 13C 
NMR spectrum, which showed loss of allyl signals and presence of C-21 at 61.54ppm.
Thiophosphorylation of (279) was achieved using the method of Mills et al.m  Thus,
(279) was phosphitylated with tetrazole-activated bis(p-chlorobenzyloxy)- 
(diisopropylamino)phosphine in the usual way. The solvents were then evaporated and 
the monophosphite bisphosphate ester was treated with elemental sulphur in DMF- 
pyridine (2:1) to give (280), the sulphoxidation being complete within 30 min. The 1H- 
coupled 31P NMR spectrum of (280) in CDCI3 (fig 5.12) exhibited the two protected 
ring phosphates as sextets at -2.33 and -1.89ppm, and the protected phosphorothioate as 
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Fig. 5.12 162MHz 'H-coupled 31P NMR spectrum of (280) in CDCI3 . Different 
degrees of expansion have been used.
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Deprotection of (280) with sodium in liquid ammonia provided (276), which was 
purified by ion-exchange chromatography and isolated as its triethylammonium salt. 
The ‘H-coupled 31P NMR spectrum of (276) (fig 5.13) showed a triplet at 45.5ppm, 
corresponding to the primary phosphorothioate and two doublets at 1.43 and 0.94ppm, 
corresponding to the ring phosphates.
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Fig. 5.13 162MHz 3IP NMR and (inset) ‘H-coupled 31P NMR spectra of (276) in D2 0 , 
pH ca. 4.
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Phosphorothioate (276) was stirred with 1.2 equiv. of (275) in ethanol at room 
temperature. After two hours 31P NMR spectroscopy indicated that the orange 
suspension contained a coupled product, judging by signals at 8 P 16.5, 1.3 and 0.9ppm. 
After ion-exchange chromatography, the 'H-coupled 31P NMR spectrum of (277; fig.
5.14) demonstrated the presence of the two ring phosphates, presenting as doublets, and 
the coupled phosphorothioate, presenting as a quintet. In addition, the 19F NMR 
spectrum showed a peak at 5f - 1 2 2 .6 ppm and fluorescence spectra were obtained (fig.
5.15). However, the 31P NMR spectrum clearly exhibits an impurity and the extremely 
poor yield of this reaction (ca. 10%) is cause for concern. Lack of time prevented 
optimisation of this strategy, but this will be investigated if encouraging results emerge 
from the preliminary FRET experiments.
OH
OH
0(CH2 )2OPS CH2CNH(CH2)2 NHC(CH2 )2
o
(277)
19.1 19 0 10.9 10.1 10.7 18.6 10.5 0.9
PPK
Fig. 5.14 162MHz ‘H-coupled 31P NMR spectrum of (277) in D20 , pH ca. 5.
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6 .1  G en er a l  I n fo r m a tio n
Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC 
aluminium sheets silica 60 F254, Art no. 5554): the compounds were detected by 
spraying with phosphomolybdic acid in methanol followed by heating, unless otherwise 
stated. Flash chromatography refers to the procedure developed by Still et a /.,304 and 
was carried out using Sorbsil C60 silica gel.
*H and 13C NMR spectra were recorded on either JEOL GX270 or 400 spectrometers. 
Unless otherwise stated, chemical shifts were measured in parts per million (ppm) 
relative to internal tetramethylsilane. 31P NMR spectra were recorded on JEOL FX-90Q 
or GX-400 NMR spectrometers and 31P NMR chemical shifts were measured in ppm 
relative to external 85% H3PO4. J  values are given in Hz and the following 
abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet, br, broad; 
exch., exchanged with. Proton assignments were established with 2D COSY 
experiments and the number of protons attached to carbon atoms was established by 
DEPT experiments. Where second order spectra do not deviate substantially from first 
order, the first order approximation has been used.
Infrared spectra were recorded on a Perkin-Elmer 782 spectrophotometer and were 
obtained on liquid films on NaCl plates or as KBr discs.
Melting points were determined using a Reichert-Jung Thermo Galen Kofler block and 
are uncorrected.
Microanalysis was carried out at the University of Bath Microanalysis Service.
Low resolution mass spectra were recorded at the University of Bath Mass Spectrometry 
Service using +ve and -ve fast atom bombardment (FAB) with m-nitrobenzyl alcohol 
(NBA) as the matrix. High resolution accurate mass spectra were recorded at the 
University of Bath Mass Spectrometry Service and at the EPSRC Mass Spectrometry 
Service, Swansea.
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Optical rotations were measured at ambient temperature using an Optical Activity Ltd. 
AA-10 polarimeter in a cell volume of 1cm3 and specific rotations are given in 10"1 deg
-icm g .
Ion-exchange chromatography was performed on an LKB-Pharmacia Medium Pressure 
Ion-Exchange Chromatograph using Sepharose Q fast flow resin and gradients of 
triethylammonium bicarbonate (TEAB) as eluent.
Synthetic phosphates were assayed by adaptations of the Briggs phosphate test244 as 
follows. For the qualitative test, 200mm3 aliquots of the ion-exchange column fractions 
were pipetted into a test tube and the solutions were evaporated to dryness at 200°C. 
Four drops of concentrated sulphuric acid were added to each tube, which was then 
heated in an oven at 200°C for 90 min. The tubes were cooled to room temperature and 
water (200mm3) was added with shaking to dissolve the residue. To each tube were 
added 400mm3 of a solution of ammonium molybdate (2.5g) in water (20cm3) and 
concentrated sulphuric acid (8cm3), followed by 200mm3 of a solution of quinol 
(lOOmg) in water (20cm3) and one drop of concentrated sulphuric acid, then finally 
200mm3 of a solution of sodium sulphite (4g) in water (20cm3). Each tube was heated 
at the boiling point of the mixture for 10 s. A blue colour indicated the presence of 
inorganic phosphate.
For the quantitative assay the mixtures treated as above were transferred to volumetric 
flasks and made up to 10cm3 with water. The UV absorbances at 340nm were recorded 
using 3cm3 quartz cells. Concentration was calculated from a standard curve compiled 
from UV absorbance values of known concentrations of KH2PO4 treated as above and 
measured at 340nm.
Compounds containing phosphorothioates were assayed qualitatively by a modification 
of the Ellman test305 for sulphydryl groups as follows. To 250mm3 aliquots of the ion- 
exchange column fractions was added 1cm of a buffered solution of Ellman’s reagent 
[0.04% w/v 5,5'-dithio-bis(o-nitrobenzoic acid) in 10mM Tris buffer, pH 8]. The 
fractions containing phosphorothioates were identified by their deep yellow colour.
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Chemicals were purchased from the Aldrich and Sigma chemical companies.
Dioxane refers to 1,4-dioxane; ether refers to diethyl ether; hexane refers to w-hexane; 
light petroleum refers to the boiling range of 60-80°C. Evaporation refers to removal of 
solvent under reduced pressure.
Acetonitrile, boron trifluoride etherate, f-butanol, dichloromethane and toluene were 
dried over calcium hydride, distilled and stored over 4A sieves. N>N- 
dimethylformamide (DMF) was dried over barium oxide, distilled under reduced 
pressure and stored over 4A sieves. Dimethyl sulphoxide (DMSO) and triethylamine 
were purchased in anhydrous form. Methanol was dried by the method of Lund and 
Bjerrum.306 Pyridine was dried over potassium hydroxide pellets, distilled and then 
stored over potassium hydroxide pellets. Tetrahydrofuran (THF) was dried by passing 
through activated alumina to expel peroxide radicals followed by distillation from 
sodium in the presence of benzophenone ketyl.
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6 .2  S y n th esis o f  d -2 -D eo xy-i7^0-In o sito l-1 ,3 ,4 ,5 -T et r a k isph o sph a t e
6.2.1 Methyl 4,6-0-benzylidene-a-D-glucopyranoside (150)
A 1 litre flask containing methyl a-D-glucopyranoside (142) (112g, 0.58mol), PTSA 
(2g), benzaldehyde dimethyl acetal (91cm3, 0.61 mol) and DMF (500cm3) was fitted 
with an air condenser, attached to a water pump via a three-way tap and evacuated. The 
system was stirred at 70°C until methanol ceased to condense (4 h). The solution was 
cooled and concentrated to give a waxy white residue. Crystallisation from 2 % w/v  
aqueous NaHC03 solution (1200cm3) gave the title compound as fine white needles 
(147g, 90%); m.p. 167-168°C [lit.198 167.5-168.5°C]; [a]D +92.0 (c 5.0, CHC13) [lit.198 
+105].
6.2.2 Methyl 4,6-0-benzylidene-a-D-mannopyranoside (155)
A 1 litre flask containing methyl a-D-mannopyranoside (153) (105g, 0.54mol), PTSA 
(2g), benzaldehyde dimethyl acetal (85cm3, 0.57mol) and DMF (500cm3) was fitted 
with an air condenser, attached to a water pump via a three-way tap and evacuated. The 
system was stirred at 70°C until methanol ceased to condense (3.5 h). TLC (ethyl 
acetate : methanol 4:1) indicated a major product (Rf  0.58), a minor product (Rf  0.71) 
and unreacted starting material (Rf  0.25). The solution was cooled and concentrated. To 
the clear residue was added light petroleum (500cm3) and 2 % w/v aqueous NaHC03 
solution (1000cm3). The mixture was vigorously shaken for 5 min, then stood at 0°C 
for 3 h. The white precipitate thus obtained was filtered and washed well with light 
petroleum. Recrystallisation from chloroform-toluene 1:9 (1000cm3) gave the title 
compound as fluffy white crystals (73g, 48%); m.p. 145-146°C [lit.208 146-147°C]; 
[oc]D +35.1 (c 2.5, DMF) [lit.208 +52].
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6.2.3 Methyl 2,3-di-0-benzyl-4,6-0-benzylidene-a-D-glucopyranoside (157), methyl 
2-0-benzyl-4,6-0-benzylidene-a-D-glucopyranoside (143) and methyl 3-0-benzyl- 
4,6-0-benzyIidene-a-D-gIucopyranoside (156)
a) A solution of (150) (5.5g, 19.5mmol) in dry DMF (40cm3) was stirred with sodium 
hydride (813mg of a 60%w/w dispersion in mineral oil, 19.5mmol) and benzyl bromide 
(2.4cm3, 20.5mmol) for 2 h. Methanol (10cm3) was added and stirring was continued 
for a further 15 min. The solvents were evaporated and the residue was extracted with 
ether (250cm3). The organic extract was washed with water (100cm3) and saturated 
aqueous NaCl solution (100cm3), dried (MgS04), filtered and concentrated. The 
residual oil was subjected to flash chromatography (eluent hexane : ethyl acetate 7:3) to 
give (157) (1.9g, 21%); R{ 0.62 in hexane : ethyl acetate 3:2; m.p. 93-94°C (from 
ethanol) [lit.307 93°C]; [a]D -29.6 (c 4.6, CHC13) [lit.307 -32].
Further elution gave (143) (2.8g, 39%); R{ 0.50 in hexane : ethyl acetate 2:3; m.p. 128- 
130°C (ethyl acetate-hexane) [lit.210 129.5°C]; [oc]D +35.4 (c 5.0, CHC13) [lit.210 +35].
Further elution gave (156) (1.3g, 19%); Rf 0.31 (hexane : ethyl acetate 2:3); m.p. 184- 
187°C (ethanol) [lit.210 185°C]; [a]D +77.8 (c 5.0, CHCI3) [lit.210 +84].
b) A mixture of (150) (10.4g, 37.0mmol) and dibutyltin oxide (10. lg, 40.7mmol) in 
toluene (300cm3) was heated under reflux for 3 h with continuous azeotropic removal of 
water (Dean-Stark trap). The solution was cooled and concentrated. To the white 
residue thus obtained was added dry DMF (30cm3) and benzyl bromide (6.4cm3, 
53.8mmol). This mixture was stirred at 100°C for 3 h, then cooled. The solvent was 
evaporated and the residue was stirred with ether (500cm3) and saturated aqueous 
NaHCC>3 solution (200cm3) for 1 h. The resulting suspension was filtered through 
Celite, the organic layer was collected, dried (MgS04), filtered and concentrated. The 
orange oil thus obtained was subjected to flash chromatography (eluent hexane : ethyl 
acetate 7:3) to give (143) (6.3g, 46%) and (156) (2.7g, 19%).
c) The method employed is a modification of that described by Corrie.216 A mixture of 
(150) (9.7g, 34.2mmol), dibutyltin oxide (9.1g, 36mmol), tetrabutylammonium iodide
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(12.7g, 34.2mmol), benzyl bromide (4.5cm3, 37.7mmol) and acetonitrile (400cm3) was 
heated under reflux for 16 h via a Soxhlet thimble containing 4A molecular sieves. The 
solution was cooled and concentrated. Purification and flash chromatography as above 
gave (143) (6.2g, 49%) and (156) (1.6g, 13%).
d) The method employed is a modification of that described by Boons et al.2n A 
mixture of (150) (4.9g, 17.4mmol) and dibutyltin dimethoxide (4.1mi, 19.5mmol) was 
heated under reflux in dry toluene (300cm3) for 1 h under Dean-Stark conditions. The 
solution was cooled to room temperature. Tetrabutylammonium iodide (9.7g, 
26.1mmol) and benzyl bromide (2.3cm3, 19.1mmol) were added and the mixture was 
stirred at 50°C under an atmosphere of nitrogen for 48 h. The solution was cooled and 
concentrated. Purification and flash chromatography as above gave (143) (2.6g, 41%) 
and (156) (l.Og, 15%).
e) The method employed is a modification of that described by Lampe et al.M 
Compound (150) (11.3g, 39.9mmol) was stannylated as in method b). To the 
concentrated residue were added caesium fluoride (15.2g, 99.8mmol, dried in vacuo 
over P20 5 at 60°C for 24 h), dry DMF (40cm3) and benzyl bromide (5.2cm3,43.9mmol). 
This suspension was stirred at room temperature under an atmosphere of nitrogen for 16 
h. Purification and flash chromatography as above gave (143) (3.7g, 25%) and (156) 
(7.7g, 52%).
6.2.4 Methyl 2-0-allyl-4,6-0-benzyIidene-a-D-gIucopyranoside (161) and methyl 3- 
O-allyI-4,6-0-benzylidene-a-D-glucopyranoside (162)
Analogous treatments of the stannylene (158) with allyl bromide gave (161), Rf  0.63 
(ethyl acetate); m.p. 118.5-120°C (ethyl acetate-hexane) [lit.308 115-116°C]; [a]o +70.0 
(c 1.5, CHClj) [lit.308 +75.8]; and (162), R f 0.53 (ethyl acetate); m.p. 155°C [lit.308 154- 
155°C]; [a]D +100.7 (c 1.5, CHCI3) [lit.308 +104],
144
6.2.5 Methyl 4,6-0-benzyIidene-2-0-(p-methoxybenzyl)-a-D-glucopyranoside (163) 
and methyl 4,6-0-benzylidene-3-0-(p-methoxybenzyl)-a-D-gIucopyranoside (164)
Analogous treatments of the stannylene (158) with p-methoxybenzyl chloride gave 
(163), Rf 0.44 (hexane : ethyl acetate 2:3); m.p. 102°C (ethanol); [a]o +38.6 (c 1.4, 
acetone); (Found: C, 65.8; H, 6.56. Calc, for C22H260?: C, 65.64; H, 6.52%); 5h (CDCI3; 
270MHz) 2.75 (1 H, d, J  2.2, exch. D20, OH), 3.35 (3 H, s, OCH3), 3.40-3.50 (2 H, m,
2-H, 4-H), 3.64-3.84 (5 H, m, 5-H, 6-Hax, ArOCH3), 4.12 (1 H, td, J  2.2, 9.3, simplifies 
to t on D20  exch., 3-H), 4.25 (1 H, dd, J 4.4, 9.7, 6-Heq), 4.55 (1 H, d, J  3.5, 1-H), 4.62, 
4.69 (2 H, AB, Jab 11.9, ArCtf20), 5.50 (1 H, s, 7-H), 6.88 (2 H, d, J  8.6, 3-H and 5-H 
of p-methoxybenzyl ring), 7.24-7.50 (7 H, m, aromatic CH); 8h (CDCI3, 67.8MHz)
55.14, 55.22 (2 x OCH3), 61.90 (CH), 68.84 (6-C), 69.91 (CH), 72.82 (ArCH20), 79.06, 
81.14 (2 x CH), 98.57 (1-C), 101.81 (7-C), 113.83 (3-C and 5-C of p-methoxybenzyl 
ring), 126.83, 128.83, 129.03, 129.64 (aromatic CH), 129.87 (1-C of p-methoxybenzyl 
ring), 137.02 (1-C of benzyl ring), 159.39 (4-C of p-methoxybenzyl ring); m/z: (FAB+) 
403 [(M+l)+, 5%];
and (164), Rf 0.25 (hexane : ethyl acetate 2:3); m.p. 174-175.5°C (ethanol); [a]D +45.8 
(c 1.2, acetone); (Found: C, 65.6; H, 6.53. Calc, for C22H260?: C, 65.64; H, 6.52%); 8h 
(CDCI3, 400MHz) 2.42 (1 H, d, J  7.3, exch. D20, OH), 3.43 (3 H, s, OCH3), 3.59-3.94 
(8 H, m, 2-H, 3-H, 4-H, 5-H, 6-Hax, ArOCH3), 4.28 (1 H, dd, J  4.4, 9.9, 6-Hcq), 4.71 (1 
H, d, 7ab 11.0, ArCtfHO), 4.77 (1 H, d, J  4.0, 1-H), 4.87 (1 H, d, JAB 11-0, ArCHtfO), 
5.56 (1 H, s, 7-H), 6.84 (2 H, d, J  8.5, 3-H and 5-H of p-methoxybenzyl ring), 7.24-7.51 
(7 H, m, aromatic CH); 8h (CDCI3, 100MHz) 55.23, 55.36 (2 x OCH3), 62.58 (CH), 
69.00 (6-C), 72.31 (CH), 74.47 (ArCH20), 78.38, 81.95 (2 x CH), 99.89 (1-C), 101.26 
(7-C), 113.79 (3-C and 3-C of p-methoxybenzyl ring), 126.02, 128.24, 128.95, 129.70 
(aromatic CH), 130.54 (1-C of p-methoxybenzyl ring), 137.38 (1-C of benzyl ring),
159.25 (4-C of p-methoxybenzyl ring); mlz: (FAB+) 403 [(M+l)+, 5%].
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6.2.6 Methyl 2-0-benzoyl-4,6-0-benzylidene-a-D-glucopyranoside (159)
A mixture of (150) (5.0g, 17.7mmol) and dibutyltin dimethoxide (4.1cm3, 19.5mmol) 
was heated under reflux in dry toluene (300cm3) for 1 h under Dean-Stark conditions. 
The solution was cooled to 0°C under an atmosphere of nitrogen and triethylamine 
(0.1cm3, 0.9mmol) was added. Benzoyl chloride (2.3cm3, 19.5mmol) was added 
dropwise and the solution was stirred at room temperature for 1 h, when TLC (ethyi 
acetate : hexane 3:2) indicated a single product (Rf  0.74). The solution was stirred with 
methanol (5cm3) for 5 min and the solvents were evaporated. The residue was dissolved 
in ether (300cm3) and the solution was stirred with saturated aqueous NaHC03 solution 
(100cm3) for 30 min. The resulting suspension was filtered through Celite and the 
organic layer was dried (MgS04), filtered and concentrated. The resulting oil was 
purified by flash chromatography (eluent hexane : ethyl acetate 7:3) to give exclusively 
the title compound (4.9g, 72%); m.p. 170-172°C (ethanol) [lit.309 169-170°C]; [ oc] d  
+108.5 (c 1.2, CHC13) [lit.309 +108].
6.2.7 Methyl 4,6-0-benzylidene-2-0-tosyI-a-D-glucopyranoside (160)
Compound (150) (500mg, 1.8mmol) was stannylated as above and cooled to 0°C. 
Triethylamine (0.01cm3, O.lmmol) and tosyl chloride (355mg, 1.8mmol) were added 
and the solution was stirred at room temperature for 16 h. The solvent was evaporated 
and the residue was subjected to flash chromatography (eluent hexane : ethyl acetate 
7:3) to give exclusively the title compound (533mg, 69%); Rf  0.63 in hexane : ethyl 




A mixture of (150) (129g, 0.46mol) and dibutyltin oxide (125g, 0.50mol) was heated 
under reflux in toluene (1500cm3) for 3 h with continuous azeotropic removal of water 
(Dean-Stark trap). The solution was cooled and concentrated to give a white solid to 
which were added acetonitrile (1200cm3), tetrabutylammonium bromide (lOOg,
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0.31mol) and benzyl bromide (60cm3, 0.50mol). This mixture was heated under reflux 
for 2 days via a Soxhlet thimble containing 4A molecular sieves. The solution was 
cooled, triethylamine (100cm3) was added and stirring was continued for 3 h. The 
solvents were evaporated and to the residue ether (2000cm3) and saturated aqueous 
NaHCC>3 solution (700cm3) were added. The mixture was vigorously stirred for 1 h and 
the resultant suspension was filtered through Celite. The residue was well washed with 
ether (250cm3) and the combined organic fraction was dried (MgSCU), filtered and 
evaporated. This crude mixture of monobenzyl ethers was dissolved in pyridine 
(500cm3) containing DMAP (lg). Benzoyl chloride (100cm3, 0.86mol) was added 
dropwise at 0°C and the system was stirred at room temperature for 3 h. Methanol 
(200cm3) was added and stirring was continued for a further 30 min. The solvents were 
evaporated and co-evaporated with toluene (3 x 500cm3). The orange residue thus 
obtained was triturated with ether (3 x 500cm3) and the combined organic extracts were 
washed with 5 m  aqueous HC1 (2 x 250cm3) and water (4 x 250cm3), dried (MgS04), 
filtered and concentrated to give a pale yellow syrup. The title compound was obtained 
by fractional crystallisation from ethanol (74g, 34%); Rf 0.57 (hexane : ethyl acetate 
3:2); m.p. 136-137°C (ethanol); [a]D -6.3 (c 4.4, CHC13); (Found: C, 70.3; H, 5.82. 
Calc, for C28H280 7: C, 70.56; H 5.93%); ^  (CDC13; 270 MHz) 3.43 (3 H, s, OCH3), 
3.66—3.79 (3 H, m, 2-H, 4-H, 6-Hjm), 3.97 (1 H, td, 75_H>6_Hax = / s - h ,  4 -h  = 9* / 5 -H, 6 -Heq 4*5, 
5-H), 4.30 (1 H, dd, J  4.5, 10.5, 6-H^), 4.61,4.61 (2 H, AB, / AB 12.7, PhCtf20), 4.75 (1 
H, d, J  3.8, 1-H), 5.46 (1 H, s, 7-H), 5.85 (1 H, t, J  9, 3-H), 7.16-7.61 (13 H, m, 
aromatic CH), 8.02-8.07 (2 H, m, 2-H; 8C (CDC13; 67.8 MHz) 55.45 (OCH3), 62.44 
(CH), 69.01 (6-C), 71.23 (CH), 72.90 (PhCH20), 79.69 (2-C), 98.81 (1-C), 101.44 (7- 
C), 126.14, 127.91, 127.96, 128.10, 128.28, 128.40, 128.88, 129.81 (aromatic CH),
130.26 (1-C of benzoyl ring), 132.87 (4-C of benzoyl ring), 137.04, 137.64 (2 x 1-C of 
phenyl rings), 165.37 (PhC02); m/z (Cl) 477 [(M+l)+, 10%]; vmax 1730cm-1.
6.2.9 Methyl 3-0-benzoyl-2-0-benzyI-a-D-glucopyranoside (167)
A solution of (144) (12.9g, 27.2mmol) in 80%v/v acetic acid in water (100cm3) was 
heated under reflux for 1.75 h. The solution was cooled, the solvents evaporated and 
co-evaporated with toluene (3 x 60cm3). The white residue thus obtained was extracted
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with ethyl acetate (3 x 100cm3). The combined extracts were washed with water 
(50cm3), dried (MgS04), filtered and concentrated to give the title compound as a white 
solid of sufficient purity to be used for the next step (10.4g, 98%). A sample was 
crystallised twice from isopropanol to provide an analytically pure sample; Rf 0.17 
(hexane : ethyl acetate 2:3); m.p. 114—115°C; [a]D +97.7 (c 1.1, CHC13); (Found: C, 
64.6; H, 6.22. Calc, for C21H240 7: C, 64.92; H, 6.23%);8H (CDC13; 270MHz) 2.60 (1 H, 
t, /  5.6, exch. D20, 6-OH), 3.39 (3 H, s, OCH3), 3.54 (1 H, d, J  4.6, exch. D20 , 4-OH), 
3.61 (1 H, dd, /  3.7, 9.6, 2-H), 3.69-3.75 (2 H, m, 4-H, 5-H), 3.83 (2 H, br s, 6-H, 6-H’), 
4.60, 4.60 (2 H, AB, / AB 12.2, PhC//20), 4.72 (1 H, d, J  3.7, 1-H), 5.50 (1 H, br t, J  9.3,
3-H), 7.23-7.62 (8 H, m, aromatic CH), 7.98-8.01 (2 H, m, 2-H and 6-H of benzoyl 
ring); 5C (CDC13; 67.8MHz) 55.25 (OCH3), 61.71 (6-C), 69.67, 71.22 (CH), 
72.77(PhCH20), 75.75, 76.66 (CH), 97.73 (1-C), 127.86, 128.33 (aromatic CH), 129.69 
(1-C of benzoyl ring), 129.82 (aromatic CH), 133.21 (4-C of benzoyl ring), 137.57 (1-C 
of benzyl ring), 167.35 (PhC02); nUz (FAB') 387 [(M-l)\ 30%].
6.2.10 Methyl 3,4-di-0-benzoyl-2-0-benzyl-6-bromo-6-deoxy-a-D-glucopyranoside
(145), methyl 3,4-di-0-benzoyI-6-bromo-6-deoxy-a-D-glucopyranoside (165) and 
methyl 3-0-benzoyl-4,6-0-benzylidene-a-D-glucopyranoside (166)
a) From (144) by Hanessian-Hullar reaction. The method employed is a modification 
of that described by Hanessian.311 Carbon tetrachloride (50cm3) was passed through 
activated alumina and collected in a dry 100cm3 round bottomed flask containing a 
mixture of (144) (2.0g, 4.2mmol), barium carbonate (1.2g, 6.3mmol, dried in vacuo over 
P2Os at 75°C for 16 h) and N-bromosuccinimide (897mg, 5.0mmol, dried as for barium 
carbonate). This mixture was heated under reflux under an atmosphere of nitrogen for 1 
h, when TLC indicated three major products and unreacted starting material. The 
suspension was cooled, filtered and the residue well washed with dichloromethane 
(100cm3). The combined filtrates were washed with 5%w/v aqueous Na2S2C>3 solution 
(100cm3) and water (100cm3), dried (MgS04), filtered and concentrated to give a 
colourless oil which was subjected to flash chromatography (eluent hexane : ethyl 
acetate 7:3) to give (145) (653mg, 28%); R{ 0.69 (hexane : ethyl acetate 2:3); m.p. 
l i r e  (ethanol); [a]D -26.0 (c 2.5, CHC13); (Found: C, 60.7; H 4.80. Calc, for
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C28H270 7Br: C, 60.64; H, 4.91%); 8H (CDC13; 400 MHz) 3.43 (1 H, ABX, 2J ^  11.3,37
7.6, 6-H), 3.51 (3 H, s, OCH3), 3.51 (1 H, ABX, 2J ^  11.3,372.7, 6-H'), 3.76 (1 H, dd, 7
3.7, 10.0, 2-H), 4.18 (1 H, ddd, 7 2.4, 7.3, 9.8, 5-H), 4.59, 4.63 (2 H, AB, 7^  12.5, 
PhC//20), 4.81 (1 H, d, 7 3.7, 1-H), 5.28 (1 H, t, 7 9.8, 4-H), 5.94 (1 H, t, 7 9.8, 3-H), 
7.20-7.61 (11 H, m, aromatic CH), 7.89-7.93 (4 H, m, 2-H and 6-H of benzoyl rings); 
5C (CDC13; 100.4 MHz) 31.71 (6-C), 55.74 (OCH3), 69.04, 71.73, 71.76 (CH), 73.10 
(PhCH20), 76.90 (CH), 97.91 (1-C), 128.00, 128.29, 128.46 (aromatic CH), 128.77 (1- 
C of benzoyl ring), 129.63,129.74 (aromatic CH), 129.90 (1-C of benzoyl ring), 133.03,
133.52 (2 x 4-C of benzoyl rings), 137.42 (1-C of benzyl ring), 165.53 (PhC02); m/z 
(FAB+) 555, 557 [(M+l)+, 35%].
Further elution gave starting material (326mg, 16%).
Further elution gave (165) as a pale yellow oil (310mg, 16%); R{ 0.48 (hexane : ethyl 
acetate 2:3); [cc]D +30.9 (c 1.4, CHC13) [lit.227 +32.8 and +34.4]; ^  (CDC13; 270MHz) 
2.48 (1 H, br s, exch. D20 , 2-OH), 3.43-3.54 (2 H, m, 6-H, 6-H'), 3.57 (3 H, s, OCH3), 
3.91 (1 H, br dd, sharpens D20  exch., 7 3.7, 9.7, 2-H),4.19(1 H ,ddd,73.7, 9.7, 10.6, 5- 
H), 4.95 (1 H, d, 7 3.7, 1-H), 4.96 (1 H, t, 7 9.7, 4-H), 5.36 (1 H, t, 7 9.7, 3-H), 7.26- 
7.95 (10 H, m, aromatic CH); m/z (FAB+) 465,467 [(M+l)+, 5%].
Further elution gave (166) (158mg, 10%); Rf 0.40 (hexane : ethyl acetate 2:3); m.p. 
215-220°C (ethanol) [lit.228 217-218°C]; [oc]D +19.5 (c 1.3, CHC13) [lit.228 +33.5].
b) The method employed is a modification of that described by Smith et al.231 A 
solution of (167) (15.4g, 39.7mmol) in freshly distilled, dry THF (250cm3) at 0°C under 
an atmosphere of nitrogen was sequentially treated with triphenylphosphine (10.9g, 
41.7mmol) and freshly sublimed carbon tetrabromide (15.8g, 47.6mmol). The mixture 
was stirred for 1 h at 0°C and for 16 h at room temperature, when TLC (ethyl acetate) 
indicated consumption of starting material (R{ 0.38) to give a product (Rf 0.73). The 
solvent was evaporated and the residue was subjected to flash chromatography (eluent 
hexane : ethyl acetate 1:1) to remove triphenylphosphine oxide (Rf 0.30 in ethyl acetate). 
The crude product was dissolved in dry pyridine (150cm3) and stirred with DMAP 
(250mg) and benzoyl chloride (5.0cm3,43.1mmol) for 2 h. Methanol (5cm3) was added
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and stirring was continued for 5 min. The solvents were evaporated and co-evaporated 
with toluene (3 x 200cm3). The residue thus obtained was vigorously shaken with ether 
(500cm3) and the resulting suspension was filtered. The filtrate was washed with water 
(200cm3), dried (MgS04), filtered and concentrated to give a pale yellow oil. 
Crystallisation from ethanol gave (145) (13.9g, 63%).
6.2.11 Methyl 3,4-di-0-benzoyl-2-0-benzyl-6-deoxy-a-D-xy/o-hex-5-enopyranoside
(146)
a) Silver fluoride method. The method employed is a modification of that described by 
Cheung et al.232 To a mixture of (145) (2.1g, 3.8mmol) and silver (I) fluoride (5.3g, 
22.7mmol, dried in vacuo over P20 5 at 75°C for 24 h) was added dry pyridine (30cm3) 
under an atmosphere of nitrogen. The suspension was stirred vigorously in the dark for 
48 h. The suspension was concentrated and co-evaporated with toluene (3 x 50cm3) The 
residue was taken up in ether (200cm3). The suspension was filtered through Celite and 
the filtrate was washed with 5%w/v aqueous Na2S2C>3 solution (100cm3) and water 
(100cm3), dried (MgS04), filtered and concentrated. The orange oil thus obtained was 
purified by flash chromatography (eluent hexane : ethyl acetate 4:1) to give a pale 
yellow oil. Crystallisation from ethanol gave the title compound (561mg, 31%); R{ 0.69 
(hexane : ethyl acetate 2:3); m.p. 102-104°C; [a]D -32 (c 1.0, CHC13); (Found: C, 70.8; 
H, 5.45. Calc, for C28H260 7: C, 70.86; H 5.53%); ^  (CDC13; 270MHz) 3.51 (1 H, s, 
OCH3), 3.88 (1 H, dd, J  3.3, 9.9, 2-H), 4.62 (1 H, t, ^  = 2J6.H, ^  =2.0, 6-H), 4.64,
4.66 (2 H, AB, JAB 12.6, PhCtf20), 4.79 (1 H, t, = 2- W h * =2.0, 6-H'), 4.85 (1 
H, d, J  3.3, 1-H), 5.77 (1 H, dt, 3J 9.7, V  2.0, 4-H), 5.96 (1 H, t, J  9.7, 3-H), 7.20-7.54 
(11 H, m, aromatic CH), 7.93-8.03 (4 H, m, 2-H and 6-H of benzoyl rings); 8C (CDC13; 
67.8 MHz) 55.71 (OCH3), 70.21, 71.47 (CH), 73.08 (PhCH20), 76.53 (CH), 97.34 (6- 
C), 98.86 (1-C), 127.94, 127.99, 128.26, 128.41 (aromatic CH), 128.96, 129.66 (2 x 1-C 
of benzoyl rings), 129.71, 129.90 (aromatic CH), 132.96, 133.37 (2 x 4-C of benzoyl 
rings), 137.46 (1-C of benzyl ring), 150.30 (5-C), 165.32, 165.35 (2 x PhC02); m/z 
(FAB+) 475 [(M+l)+, 5%]; vmax 1730, 1670 cm-1.
b) Iodide exchange in DMSO/DBU method. The method is a modification of that 
described by Sato et al.233 A mixture of (145) (20.9g, 37.7mmol), sodium iodide (23.2g,
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154.8mmol, dried in vacuo over P20 5 at 75°C for 2 h), tetrabutylammonium iodide 
(5.8g, 15.7mmol, dried as for sodium iodide) and dry DMSO (90cm3) was stirred at 
100°C under a stream of nitrogen for 2 h in the presence of 4A sieves (about 50 pieces). 
DBU (11.2cm3, 75.3mmol) was added to the orange solution which rapidly turned dark 
brown. Vigorous stirring was continued for 2 h, then the system was cooled. The 
resultant dark brown semi-solid mass was extracted with ether (3 x 500cm3) and the 
combined extracts were washed with 5%w/v aqueous Na2S2C>3 solution (300cm3) and 
saturated aqueous KC1 solution (500cm3), dried (MgS04), filtered and concentrated. The 
concentrate was purified by flash chromatography (hexane : ethyl acetate 4:1) to give 
crude (146) as a pale yellow oil; crystallisation from ethanol gave pure (146) (ll.Og, 
62%).
6.2.12 (25, 3R, 45, 5/?)-2,3-dibenzoyloxy-4-benzyloxy-5-hydroxycyclohexanone
(147) and (25, 3R, 45, 55)-2,3-dibenzoyloxy-4-benzyIoxy-5-hydroxycyclohexanone
(148)
a) By stoichiometric Ferrier rearrangement using mercury (II) trifluoroacetate. To a 
solution of (146) (4.6g, 9.7mmol) in acetone : water (5:2) containing 1% acetic acid 
(200cm3) was added mercury (II) trifluoroacetate (4.3g, 10.2mmol). After 10 min the 
solution had assumed a pale lilac colour and TLC (ethyl acetate : hexane 3:2) indicated 
that all starting material (Rf 0.65) had been consumed to give an ill-defined product (R{ 
0.1-0.5) which stained brown with aqueous potassium permanganate solution. Sodium 
chloride (4.7g, 77.6mmol) was added and the solution was stirred for a further 90min. 
The acetone was then evaporated and the aqueous phase extracted with chloroform (2 x 
150cm3, 1 x 50cm3). The combined extracts, were washed with 5% thiourea solution 
(50cm3) and water (50cm3), dried (MgS04), filtered and concentrated. The pale yellow 
oil thus obtained was subjected to flash chromatography (eluent hexane : ethyl acetate 
7:3) to give (147) as a pale yellow oil (205mg, 5%); Rf 0.47 (ethyl acetate : hexane 3:2); 
[a]D -33 (c 1.4, CHC13); 6h (CDC13; 270MHz) 2.50-3.50 (1 H, br s, exch. D20 , OH), 
2.76 (1 H, ABX, Vab 14.5,V ^-H a* H-2, 6-H J , 2.96 (1 H, ABX, VAB 14.5, % .Ht6.Heq
5.2, 6-Hgq), 3.92-4.10 (2 H, m, 4-H, 5-H), 4.74, 4.85 (2 H, AB, J ^  11.2, PhC//20), 
5.71-5.80 (2 H, m, 2-H, 3-H), 7.21-7.54 (11 H, m, aromatic CH), 7.97-8.03 (4 H, m, 2- 
H and 6-H of benzoyl rings); 8C (CDC13; 67.8 MHz) 43.96 (6-C), 68.16, 71.96 (2 x CH),
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75.33 (PhCH20), 77.58, 83.05 (2 x CH), 128.11, 128.38, 128.44, 128.57, 128.62 
(aromatic CH), 129.10 (1-C of benzoyl ring[s]), 129.75, 130.00 (aromatic CH), 133.52,
133.85 (2 x 4-C of benzoyl rings), 137.27 (1-C of benzyl ring), 165.31, 165.49 (2 x 
PhC02), 196.67 (1-C); m/z (FAB+) 461 [(M+l)+, 5%].
Further elution gave (148) (2.2g, 50%); R{ 0.42 (ethyl acetate : hexane 3:2); m.p. 149- 
150°C (ethanol); [a]D -61.5 (c 4.1, CHC13); (Found: C, 70.2; H, 5.19. Calc, for 
C27H240 7: C, 70.41; H, 5.26%); 8H (CDC13; 270MHz) 2.68 (1 H, ABX, 12, V5.H,6. 
Hax 3.7, 6-H^), 2.86 (1 H, ABX, VAB 12, 3/ 5_H, 6.Heq 3.7, 6-Heq), 3.17 (1 H, br s, exch. 
D20 , OH), 4.09 (1 H, dd, J  2.5, 10, 4-H), 4.45 (1 H, br m, 5-H), 4.60, 4.74 (2 H, AB, 
JAb 12, PhC//20), 5.67 (1 H, d, J  10, 2-H), 6.12 (1 H, t, J  10, 3-H), 7.15-7.58 (11 H, m, 
aromatic CH), 7.95-8.05 (4 H, m, 2-H and 6-H of benzoyl rings); 8C (CDC13; 67.8 
MHz) 42.38 (6-C), 58.27, 65.81, 71.75 (3 x CH), 72.39 (PhCH20), 79.06 (4-C), 127.94, 
128.10, 128.30, 128.35, 128.46 (aromatic CH), 128.75, 129.37 (2 x 1-C of benzoyl 
rings), 129.71, 129.95 (aromatic CH), 133.21, 133.31 (2 x 4-C of benzoyl rings), 136.76 
(1-C of benzyl ring), 165.27 , 165.53 (2 x PhC02), 197.46 (1-C); m/z (FAB+) 461 
[(M+l)+, 20%].
b) By catalytic Ferrier reaction using mercury (II) trifluoroacetate. A solution of (146) 
(14.5g, 30.6mmol) in acetone:water (5:2) containing 1% acetic acid (300cm3) was 
stirred with mercury (II) trifluoroacetate (1.3g, 3.1 mmol) for 30 h. The acetone was 
evaporated and the residual gum was extracted with CHC13 (3 x 200cm3). The 
combined organic extracts were washed with water (200cm3) and saturated aqueous 
NaCl solution (200cm3), dried (MgS04), filtered and concentrated. Flash 
chromatography as above gave (147) (l.lg , 8%) and (148) (lO.Og, 71%).
c) By Ferrier rearrangement using palladium (II) chloride. A solution of (146) (l.Og, 
2.2mmol) in dioxane-5mM aqueous H2S04 (2:1) (30cm3) containing palladium (II) 
chloride (50mg, 0.3mmol) was heated under reflux for 1 h, then cooled. The solvents 
were evaporated. Purification and flash chromatography as in method b) gave (147) 
(61 mg, 6%) and (148) (698mg, 72%).
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6.2.13 (25, 3R, 45)-2,3-Dibenzoyloxy-4-benzyloxycyclohex-5-enone ethylene acetal 
(169) and (25, 3R9 45, 55)-2,3-dibenzoyloxy-4-benzyloxy-5-hydroxycyclohexanone 
ethylene acetal (168)
The method employed is a modification of that described by Ferrier and Haines.173 A 
mixture of (148) (5.2g, 11.3mmol), ethylene glycol (7.5cm3), dioxane (50cm3), toluene 
(75cm3) and conc. H2S04 (0.5cm3) was heated under reflux for 3.5 h with continuous 
azeotropic removal of water (Dean-Stark trap). TLC (ethyl acetate) indicated 
consumption of starting material (R{ 0.62) to give two products (R{ 0.79 and 0.48). 
Pyridine (2cm3) was added, the solution was cooled and the solvents evaporated. The 
dark brown residue thus obtained was extracted with ether (250cm3) and the organic 
solution was washed with 5 m aqueous HC1 (150cm3) and water (2 x 150cm3), dried 
(MgS04), filtered and concentrated to give a pale yellow oil. Flash chromatography 
(eluent hexane : ethyl acetate 1:1) gave (169) (1.8g, 33%); m.p. 125-127°C (ethanol); 
[a]D +14.8 (c 1.6, CHC13); (Found: C, 71.8; H, 5.37. Calc, for C29H260 7: C, 71.58; H, 
5.39%); 5h (CDC13; 400MHz) 3.89-4.12 (4 H, m, 0CH2CH20 ), 4.45 (1 H, dt, J  8.3, 1.5,
4-H), 4.57, 4.69 (2 H, AB, JAB 11.9, PhCtf20), 5.63 (1 H, d, J  11.2, 2-H), 5.75 (1 H, dd, 
4*W -h l 5 ’ 3J5-h,6-h 10-3> 6-H), 5.97-6.01 (2 H, m, 3-H, 5-H), 7.19-7.46 (11 H, m, 
aromatic CH), 7.86-7.96 (4 H, m, 2-H and 6-H of benzoyl rings); 8C (CDC13; 67.8MHz)
66.15, 66.51 (0CH2CH20), 70.84 (PhCH20), 72.75, 72.85, 76.56 (2-C, 3-C, 4-C),
106.02 (1-C), 127.73, 127.89, 128.18, 128.35, 128.98 (5-C, 6-C, aromatic CH), 129.24 
(1-C of benzoyl ring[s]), 129.69, 129.77 (aromatic CH), 132.92, 133.63 (2 x 4-C of 
benzoyl rings), 137.67 (1-C of benzyl ring), 165.60 (PhC02); mlz (FAB+) 487 [(M+l)+, 
5%].
Further elution gave (168) (3.1g, 54%); m.p. 129-131°C (ethanol); [a]D -57.4 (c 0.6, 
CHC13); (Found: C, 68.7; H, 5.78. Calc, for C29H280 8: C, 69.02; H, 5.60%); (CDC13;
270MHz) 1.96 (1 H, ABX, VAB 15, 37 3.3, 6-H J , 2.25 (1 H, ABX, 2JAB 15, V  3.8, 6- 
Hgq), 3.24 (1 H, d, J  6 .6, exch. D20, OH), 3.71 (1 H, dd, J  3.3, 9.5, 4-H), 3.80-3.92 (2 
H, m, OCtf2CH20), 4.06-4.16 (2 H, m, 0CH2CH20 ), 4.21 (1 H, br m, 5-H), 4.60, 4.71 
(2 H, AB, JAB 12, PhCtf20), 5.48 (1 H, d, J  9.5, 2-H), 6.01 (1 H, t, J 9.5, 3-H), 7.16-
7.52 (11 H, m, aromatic CH), 7.88-7.97 (4 H, m, 2-H and 6-H of benzoyl rings); 5C
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(CDC13; 67.8 MHz) 36.63 (6-C), 65.40 (0CH2CH20), 65.55 (CH), 66.72 (0CH2CH20),
70.98 (CH), 71.88 (PhCH20), 73.85, 78.93 (2 x CH), 108.27 (1-C), 127.79 (1-C of 
benzoyl ring), 127.83, 128.18, 128.30, 128.35 (aromatic CH), 129.19 (1-C of benzoyl 
ring[s]), 129.66, 129.72 (aromatic CH), 132.87, 133.16 (2 x 4-C of benzoyl rings),
137.31 (1-C of benzyl ring), 165.42, 165.48 (2 x PhC02); mlz (FAB+) 505 [(M+l)+, 
10%].
6.2.14 Attempted Mitsunobu Reaction on (168)
To a solution of (168) (480mg, l.Ommol) and benzoic acid (174mg, 1.5mmol, dried in 
vacuo over P2O5 at 45 °C for 18 h) in freshly distilled, dry THF (5cm3) at 0°C under an 
atmosphere of nitrogen was added tri-w-butylphosphine (0.35cm3, 1.5mmol). After 2 
min l,r-(azodicarbonyl)-dipiperidine (360mg, 1.5mmol) was added. The system was 
allowed to warm to room temperature and was stirred for 24 h. The system was diluted 
with ether (100cm3) and washed with water (30cm3), dried (MgSC^), filtered and 
concentrated. The residue was subjected to flash chromatography (eluent hexane : ethyl 
acetate 1:1) to give exclusively starting material (422mg, 88%).
6.2.15 (25, 3R, 45, 5R)-5-Acetoxy-2,3-dibenzoyloxy-4-benzyloxycyclohexanone 
ethylene acetal (170)
a) By inversion oftriflate. The method employed is a modification of that described by 
Lampe.66 To a solution of (168) (84mg, 0.2mmol) in dry CH2Cl2-dry pyridine (5:1) 
(3cm3) at -78°C under an atmosphere of nitrogen was added triflic anhydride (0.03cm3) 
dropwise. The solution was allowed to warm to room temperature and was stirred for 
30 min, when TLC (ethyl acetate : hexane 3:2) indicated consumption of starting 
material (/?f 0.16) to give a product (R{ 0.56). The solvents were evaporated. To the 
orange residue were added caesium acetate (200mg, lmmol, dried in vacuo over P20 5 at 
60°C for 24 h), and dry DMF (3cm3). This mixture was stirred at room temperature for 
3 h when TLC (ether) indicated presence of a major product (R{ 0.60) and a minor 
product (Rf 0.53). The solvent was evaporated and the orange residue was extracted 
with ethyl acetate (50cm3). The organic extract was washed with saturated aqueous
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NaCl solution (30cm3) and water (30cm3), dried (MgS04), filtered and concentrated. 
Flash chromatography (eluent hexane : ethyl acetate 7:3) gave (169) (43mg, 53%).
Further elution gave (170) (llmg, 12%); m.p. 217-222°C (ethyl acetate-hexane); [a]D 
-32.2 (c 2.1, CHC13); (Found: C, 68.2; H, 5.44. Calc, for C31H30O9: C, 68.11; H, 5.54%); 
5h (CDC13; 270MHz) 1.84 (1 H, t, 2J = 37 = 12.5, 6-H J , 2.01 (3 H, s, COCH3), 2.30 (1 
H, dd, 2/  12.5,3/  5.1, 6-H^), 3.82-3.92 (3 H, m, 0Ctf2CH20 , 4-H), 4.07^1.12 (2 H, m, 
0CH2C//20), 4.63,4.63 (2 H, AB, JAB 11.6, PhC//20), 5.23 (1 H, ddd, J  12.5, 11.4, 5.1,
5-H), 5.55 (1 H, d, J  10, 2-H), 5.81 (1 H, t, J 10, 3-H), 7.10-7.56 (11 H, m, aromatic 
CH), 7.86-8.04 (4 H, m, 2-H and 6-H of benzoyl rings); 5C (CDC13; 100MHz) 21.03 
(CH3C 02), 37.03 (6-C), 65.84, 66.53 (0CH2CH20), 71.14, 72.62, 74.05 (2-C, 3-C, 5- 
C), 74.56 (PhCH20), 80.82 (4-C), 106.07 (1-C), 127.63, 127.87, 128.22, 128.25, 
128.40, 129.17, 129.55 (aromatic CH), 129.66, 129.77 (2 x 1-C of benzoyl rings), 
132.97, 133.23 (2 x 4-C of benzoyl rings), 137.71 (1-C of benzyl ring), 165.36, 165.58 
(2 x PhC02), 169.84 (CH3C02); mlz (FAB+) 547 [(M+l)+, 15%].
b) By inversion of mesylate. The method employed is a modification of that described 
by Torisawa et a/.238 A solution of (168) (848mg, 1.7mmol) in dry dichloromethane-dry 
pyridine (2:1) (9cm3) was treated with mesyl chloride (0.15cm3, 1.9mmol) at room 
temperature for 5 h, when TLC (ethyl acetate : hexane 3:2) indicated conversion of 
starting material to a product {R( 0.58). The solvents were evaporated and co­
evaporated with toluene (3 x 50cm3). The residue was dissolved in ethyl acetate 
(150cm3) and this solution was washed with water (50cm3) to remove salts, then dried 
(MgS04), filtered and concentrated to give a pale yellow solid. Dry toluene (40cm3), 
caesium acetate (3.2g) and 18-crown-6 (444mg, 1.7mmol) were added and this mixture 
was heated under reflux for 4 days. Purification and flash chromatography as in method 
a) gave (169) (441mg, 54%) and (170) (167mg, 18%).
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6.2.16 (6S)-6-BenzoyIoxy-4-benzyloxycycIohex-4-ene-l,3-dione 1-ethylene acetal 
(172)
Oxalyl chloride (1.7cm3 of a 2 m solution in dichloromethane, 3.4mmol) was added to a 
100cm3 three-necked flask at -50 -  -60°C under an atmosphere of nitrogen. Dry DMSO 
(0.44cm3, 6.2mmol) was added dropwise over 5 min (copious evolution of gas!). After 
5 min, a solution of (168) (1.6g, 3.1mmol) in dry dichloromethane was added dropwise. 
The system was stirred at -50 -  -60°C for 20min, when triethylamine (1.7cm3, 
12.5mmol) was added dropwise. The mixture was allowed to warm to room 
temperature over 20 min, then the solvents were evaporated. The residue was extracted 
with dichloromethane (150cm3) and the organic extract was washed with water 
(150cm3), dried (MgS04), filtered and concentrated. The yellow oil thus obtained was 
purified by flash chromatography (eluent hexane : ethyl acetate 7:3) to give the title 
compound (1.2g, 99%) which crystallised as fine white needles from ethanol; R f 0.59 
(ethyl acetate : hexane 3:2); m.p. 96-97°C; [a]D +125.3 (c 2.2, CHC13); (Found: C, 69.4; 
H, 5.28. Calc, for C22H20O6: C, 69.45; H, 5.30%); SH (CDC13; 400MHz) 2.81 (1 H, 
ABX, VAB 16.1, 47 1.0, 2 -H J, 3.19 (1 H, AB, VAB 16.1, 2-H^), 3.96-4.11 (4 H, m, 
0 C H 2C H 20 \  4.87 (2 H, s, PhO /20), 5.84 (1 H, ABX, 3JAB 5.4,47 1.0, 6-H), 5.90 (1 H, 
AB, 3/ ab 5.4, 5-H), 7.26-7.62 (8 H, m, aromatic CH), 8.01-8.06 (2 H, m, 2-H and 6-H 
of benzoyl ring); 5C (CDC13; 100MHz) 46.05 (2-C), 65.73, 65.82 (0CH2CH20), 69.95 
(6-C), 70.21 (PhCH20), 107.13 (1-C), 110.99 (5-C), 127.63, 128.24, 128.35, 128.55, 
128.62, 128.80 (aromatic CH), 129.55 (1-C of benzoyl ring), 129.70 (aromatic CH), 
133.47 (4-C of benzoyl ring), 135.24 (1-C of benzyl ring), 152.50 (4-C), 165.78 
(PhC02), 189.85 (3-C); mlz (FAB+) 381 [(M+l)+, 10%].
6.2.17 (45, S R , 6/?)-4,5-Dibenzoyloxy-6-benzyloxycyclohexan-l,3-dione 3-ethylene 
acetal (171)
A mixture of (168) (l.Og, 2.0mmol), pyridinium chlorochromate (5.0g, 23.2mmol), 
powdered molecular sieves and dry dichloromethane (15cm3) was stirred at room 
temperature for 6 h, when TLC (ethyl acetate) indicated conversion of starting material 
(Rf  0.42) to a product (Rf  0.67). Ether (250cm3) was added to the dark brown 
suspension and the mixture was filtered through Celite. The filtrate was washed with
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water (200cm3) and saturated aqueous NaCl solution (200cm3), dried (MgS04), filtered 
and concentrated. Crystallisation from ethanol gave the title compound (526mg) and 
further quantities (total 620mg, 62%) were isolated by flash chromatography of the 
mother liquors (eluent hexane : ethyl acetate 1:1); m.p. 185-187°C; [a]o -34.0 (c 1.9, 
CHC13); (Found: C, 69.1; H, 5.22. Calc, for C29H2608: C, 69.30; H, 5.22%); 5H (CDC13; 
400MHz) 2.77, 2.95 (2 H, AB, Jab 14.5, 2-H, 2-H'), 3.84-3.94 (2 H, m, OCtf2CH20), 
4.03-4.12 (2 H, m, 0CH2CH20 ), 4.31 (1 H, m, 6-H), 4.55 (1 H, d, J  12.2, PhCtfHO), 
4.93 (1 H, d, J  12.7, PhCHtfO), 5.88-5.90 (2 H, m, 4-H, 5-H), 7.08-7.52 (11 H, m, 
aromatic CH), 7.87-7.96 (4 H,-m, 2-H and 6-H of benzoyl rings); 6c (CDC13; 100MHz)
48.10 (2-C), 66.22, 66.48 (0CH2CH20), 71.50 (CH), 72.65 (PhCH20), 73.85 (CH),
81.98 (6-C), 105.77 (3-C), 127.79, 128.00, 128.22, 128.43 (aromatic CH), 128.86,
129.27 (2 x 1-C of benzoyl rings), 129.74, 133.06, 133.36 (2 x 4-C of benzoyl rings),
136.86 (1-C of benzyl rings), 165.13, 165.34 (2 x PhC02), 199.69 (1-C); mlz: (FAB+) 
503 [(M+l)+, 90%].
6.2.18 Reduction of (171) with (R)-Alpine-Hydride
To a solution of (171) (150mg, 0.3mmol) in THF (5cm3) at -78°C was added (R)- 
Alpine-Hydride (1.2cm3 of a 0 .5 m  solution in THF, 0.6mmol) and the system was kept 
at -78°C for 1 h. After dropwise addition of 1m  aqueous HC1 (0.5cm3), the mixture 
was evaporated to dryness. The residue was extracted with chloroform (50cm3) and the 
organic extract was washed with water (50cm3), dried (MgS04), filtered and 
concentrated. Flash chromatography (eluent hexane : ethyl acetate 2:3) gave exclusively 
(168) (129mg, 88%); m.p. and m.m.p. 128-130°C.
6.2.19 D-l,6-Di-0-benzoyI-5-0-benzyl-3-deoxy-myo-inositol (176) and D-l,2-di-0- 
benzoyl-3-0-benzyI-5-deoxy-scy//o-inositol (177)
To a solution of (147) (533mg, 1.2mmol) in dioxane (15cm3) was added sodium 
borohydride (132mg, 3.5mmol). This mixture was stirred at room temperature for 1 h, 
when TLC (ethyl acetate) indicated consumption of starting material (R{ 0.65) to give a 
minor product (R{ 0.52) and a major product (Rf 0.44). After dropwise addition of 1m 
aqueous HC1 (0.5cm3), the system was evaporated to dryness. The residue was
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extracted with chloroform (2 x 50cm3) and the combined organic extracts were washed 
with water (50cm3), dried (MgS04), filtered and concentrated. The residue was 
subjected to flash chromatography (eluent hexane : ethyl acetate 1:1) to give (176) as a 
waxy solid (115mg, 22%); [cc]D -61.1 (c 2.0, CHC13); ^  (CDC13; 400MHz) 1.69 (1 H, 
ddd, 2J  14.0, V 11.9, 2.4, 3 -H J, 2.34 (1 H, dt, 2J  14.0,3/4 .3 , 3-H^), 2.43, 2.53 (2 H, 2 
br s, exch. D20 , 2 x OH), 3.62 (1 H, t, J  9.5, 5-H), 4.24 (1 H, ddd, J  4.9, 9.2, 11.9, 4-H), 
4.36 (1 H, br m, 2-H), 4.66, 4.75 (2 H, AB, JAB 11.3, PhCtf20), 5.26 (1 H, dd, J  2.8, 
10.1, 1-H), 5.99 (1 H, t, J  9.8, 6-H), 7.16-7.50 (11 H, m, aromatic CH), 7.91-8.07 (4 H, 
m, 2-H and 6-H of benzoyl rings); mlz (FAB+) 463 [(M+l)+, 80%].
Further elution gave (177) (376mg, 70%); m.p. 82-87°C (ethyl acetate-hexane); [a]D 
-65.0 (c 1.4, CHC13); (Found: C, 70.1; H, 5.68. Calc, for C27H26O7 :C, 70.10; H, 
5.67%); 5h (CDC13; 400MHz) 1.65 (1 H, q, 2J  = 37=11.9, 5 -H J, 2.34 (1 H, dt, 2J  12.8, 
V  4.6, 5-Hgq), 2.51, 2.60 (2 H, 2 br s, exch. D20, 2 x OH), 3.58 (1 H, t, J  9.3, 3-H), 3.71 
(1 H, br m, simplifies to ddd on D20  exch., J  4.6, 9.2, 11.6, 4-H), 3.85 (1 H, br m, 
simplifies to ddd on D20  exch., J  4.6, 9.5, 11.8, 6-H), 4.53, 4.64 (2 H, AB, 11.2, 
PhC/J20), 5.25 (1 H, t, J  9.8, 1-H), 5.47 (1 H, t, J  9.8, 2-H), 7.06-7.43 (11 H, m, 
aromatic CH), 7.82-7.87 (4 H, m, 2-H and 6-H of benzoyl rings); 5C (CDC13; 100 MHz)
36.66 (5-C), 68.15, 68.44, 72.94 (3 x CH), 75.19 (PhCH2), 77.55, 83.77 (2 x CH),
128.02, 128.33, 128.39, 128.54 (aromatic CH), 128.99, 129.29 (2 x 1-C of benzoyl 
rings), 129.62, 129.82 (aromatic CH), 133.22, 133.33 (2 x 4-C of benzoyl rings), 137.50 
(1-C of benzyl ring), 165.66, 166.96 (2 x PhC02); mlz (FAB+) 463 [(M+l)+, 30%].
6.2.20 D-l-0-benzyl-3-deoxy-scy//o-inositol (138)
To a solution of (177) (370mg, 0.8mmol) in methanol (25cm3) was added sodium 
hydroxide (128mg, 3.2mmol) and this mixture was heated under reflux for 1 h, when 
TLC (ethyl acetate : methanol 4:1) indicated conversion of starting material (R{ 0.82) to 
a product (R{ 0.43). The solution was cooled and concentrated. The residue was 
purified by flash chromatography (eluent ethyl acetate : methanol 9:1) to give the title 
compound as a white solid (174mg, 86%); m.p. 119-121°C; [a]D -3.3 (c 1.2, CHC13);
8h (D20 ; ref. int. D20; 400MHz) 1.47 (1 H, q, 2J  = V3.Hax,2-H = V3-Ha*.4-H = 12.2, 3 -H J,
2.17 (1 H, dt, 2J  12.2,37 4.6, 3-H*,), 3.22-3.34 (3 H, m, 1-H, 5-H, 6-H), 3.50 (1 H, ddd,
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J  4.6, 9.7, 12.2, 2-H or 4-H), 3.63 (1 H, br m, 2-H or 4-H), 4.82 (2 H, s, PhC//20), 7.35- 
7.65 (5 H, m, aromatic CH); 8C (D20; 67.8 MHz) 35.66 (3-C), 67.07, 67.14, 72.63 
(inositol CH), 73.70 (PhCH20), 75.68, 84.02 (inositol CH), 127.14, 127.47, 127.64,
128.31 (aromatic CH), 136.43 (1-C of benzyl ring); mlz (FAB+) 255 [(M+l)+, 10%], 
(FAB-) 253 [(M-l)-, 30%], 407 [(M+NBA)-, 30%].
6.2.21 D-4-0-Benzyl-l,2,3,5-tetrakis(di-p-chlorobenzylphospho)-6-deoxy-scy//o- 
inositol (178)
A mixture of lH-tetrazole (139mg, 1.98mmol), dry dichloromethane (5cm3) and bis(p- 
chlorobenzyloxy)(diisopropylamino)phosphine242 (546mg, 1.32mmol) was stirred at 
room temperature for 20 min, whereupon (138) (42mg, 0.17mmol) was added and 
stirring was continued for a further 30 min. TLC (ethyl acetate) indicated conversion of 
starting material (Rf  0.04) to a product (Rf  0.71-0.83). The mixture was cooled to 
-78°C and m-chloroperoxybenzoic acid (900mg) was added. The solution was allowed 
to warm to room temperature and after 10 min TLC (ethyl acetate : hexane 3:2) showed 
a new product (Rf  0.10). The solution was diluted with ether (100cm3) and the organic 
extract was washed with 50cm3 each of 1 0 % w/v Na2S203 solution, 1m aqueous HC1, 
saturated aqueous NaHCC>3 solution and saturated aqueous NaCl solution. The organic 
solution was dried (MgS04), filtered and concentrated. Purification of the residue by 
flash chromatography (eluent hexane : ethyl acetate 7:3 then 1:1) gave the title 
compound as a waxy solid (140mg, 54%); [a]o -4-5 (c 5.3, CHCI3); (Found: C, 52.9; H, 
3.95. Calc, for C69H62O17P4CI8 :C, 52.87; H, 3.99%); 8H (CDC13; 400MHz) 1.81 (1 H, 
q, 2/ =  3J = 11.9,6-Ha,), 2.88 (1 H, ddd, V 11.9,3/4 .6 ,4.8,6-He,), 3.61 (1 H, t, J  8.9,4- 
H), 4.29-4.61 (4 H, m, 1-H, 2-H, 3-H, 5-H), 4.70-5.01 (18 H, m, 9 x ArCH20  AB 
systems), 6.85-7.30 (37 H, m, aromatic CH); 8c (CDC13; 100MHz) 34.77 (6-C), 69.45, 
69.50, 69.54, 69.58, 69.63, 69.70, 69.76, 69.85 (8 x ArCH20), 73.40, 75.10 (2 x CH), 
75.41 (PhCH20), 78.10,79.73,81.94 (3 x CH), 127.15, 127.73, 128.39, 129.12, 129.45, 
129.52, 129.60, 129.69, 129.76, 129.94, 129.98, 130.02, 130.07, 130.16, 130.16 
(aromatic CH), 134.53, 134.61, 134.66, 134.74, 134.77, 134.86, 134.90, 134.94, 135.19,
135.27, 135.34, 135.39, 135.50, 135.54, 135.63 (1-C and 4-C of 8 x p- 
chlorobenzylphospho rings), 138.50 (1-C of benzyl ring); 5p (CDCI3; 162MHz)-2.25,
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-1.78, -1.73, -1.70 (4 s); m/z: (FAB+) 1567 (20%), 1569 (50%), 1571 (68%), 1573 
(45%), 1575 (18%), 1577 (6%) [all (M+l)+].
6.2.22 D-2-Deoxy-mj0-inositoM,3,4,5-tetrakisphosphate (78)
Ammonia was condensed into a three-necked flask at -78°C. An excess of sodium was 
added to dry the ammonia, about 30cm3 of which was then distilled into a second three­
necked flask and kept at -78°C. Sodium was added until the solution remained blue- 
black for 10 min. A solution of (178) (71mg, 45pmol) in dry dioxane (1.5cm3) was 
added and the mixture was stirred for 2 min. The reaction was quenched with methanol 
(lcm3), followed by water (1cm3). The solvents were evaporated and the residue 
dissolved in de-ionised water (400cm3) and purified by ion-exchange chromatography 
on Q Sepharose fast flow, eluting with a gradient of triethylammonium bicarbonate 
buffer ( 0 -1 m )  pH 9.0. The triethylammonium salt of the title compound eluted between 
250-280mM buffer; [oc]d 0.0 ( c  0.3, calc, for free acid, TEAB, pH 7.5); 5 h  ( D 2 O ; pH ca. 
6 ,400MHz) 1.55 (1 H, q, V  = V = 11.6, 2-H„), 2.37 (1 H, br m, 2-H*,), 3.44 (1 H, t, J
9.2, 6-H), 3.84-3.95 (4 H, ra, 1-H, 3-H, 4-H, 5-H); 8p (D20 ; pH ca. 6, 400MHz) (‘H- 
coupled) -0.27 (d, / h p  7.7), 0.05 (d, / h p  8.2), 0.72 (d, / Hp  8.2), 0.83 (d, 7 h p  9.0); mlz: 
(FAB ) 483 [(M-l)\ 100%]; (Found: M' 482.926. Calc, for QflieOnPi [M-H]' : 
482.926).
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6 .3  S y n th e s is  of (1/?, 2R, 3S , 4/?, 5 S )-3 -H y d r o x y -5 -h y d r o x y m e th y l-  
1 ,2 ,4 -tr is p h o sp h o c y c lo p e n ta n e
6.3.1 p-Methoxybenzaldehyde dimethyl acetal (187)
The method employed is a modification of that described by Johansson and 
Samuelsson.252 A 2 litre flask containing a stirring solution of p-methoxybenzaldehyde 
(272cm3, 304g, 2.24mol), trimethyl orthoformate (274cm3, 266g, 2.51mol) and PTSA 
(2.4g) was fitted with an air condenser, attached to a water pump via a three-way tap and 
evacuated. After 6 h the vacuum was broken, sodium carbonate (2.7g, 25mmol) was 
added and the suspension was stirred at ambient pressure for 1 h, then filtered. 
Distillation of the filtrate in vacuo gave the title compound as a colourless liquid (338g, 
83%); b.p. ca. 110°C at 0.2mbar [lit.252 ca. 100°C at 0.2mbar]; d  1.06gcnr3 [lit.252 
1.06gcnr3]; 5„ 3.31 (6 H, s, CH[OC//3]2), 3.81 (3 H, s, ArOCH3), 5.35 (1 H, s, 
C//[OCH3]2), 6.89 (2 H, d, J  8.6, 3-H, 5-H), 7.36 (2 H, d, J  8.6, 2-H, 6-H).
6.3.2 Methyl 4,6-0-(p-methoxybenzyIidene)-ot-D-glucopyranoside (186)
A 1 litre flask containing methyl a-D-glucopyranoside (103g, 0.53mol), p- 
methoxybenzaldehyde dimethyl acetal (96cm3, 0.56mol), PTSA (2g) and DMF 
(500cm3) was fitted with an air condenser, attached to a water pump via a three-way tap 
and evacuated. The system was stirred at 70°C until methanol ceased to condense (4 h). 
The solution was cooled and concentrated to give a white residue. Crystallisation from 
2%w/v aqueous NaHCC>3 solution gave the title compound as fine white needles (134g, 
81%); m.p. 202°C [lit.252 194°C]; [cc]D +88.4 (c 1.2, DMF) [lit.252 +97.4].
6.3.3 Methyl 2-0-benzyI-4,6-0-(p-methoxybenzylidene)-a-D-gIucopyranoside (188) 
and methyl 3-0-benzyl-4,6-0-(p-methoxybenzyIidene)-a-D-glucopyranoside (189)
A mixture of (186) (15.5g, 49.7mmol), dibutyltin oxide (13.6g, 54.6mmol) and 
tetrabutylammonium iodide (18.4g, 49.7mmol) was heated under reflux for 2 h in 
acetonitrile (600cm3) via a Soxhlet thimble containing 4A molecular sieves. The
161
solution was cooled to room temperature and benzyl bromide (6.5cm3, 54.6mmol) was 
added. The system was heated under reflux for a further 16 h, then cooled. 
Triethylamine (25cm3) was added and stirring was continued for 3 h. The solvents were 
evaporated and the orange residue was triturated with ether (500cm3). The ethereal 
extract was vigorously stirred with saturated aqueous NaHC03 solution (200cm3) for 2 
h, and the resulting suspension was filtered through Celite. The organic layer was 
collected, washed with water (200cm3) dried (MgS04), filtered and concentrated. The 
white residue thus obtained was subjected to flash chromatography (eluent hexane : 
ethyl acetate 7:3) to give (188) (9.6g, 48%); Rf 0.53 (hexane : ethyl acetate 2:3); m.p. 
135-136.5°C (from ethanol); [cc]D +31.9 (c 1.3, CHC13); (Found: C, 65.4; H, 6.47. Calc, 
for C22H260 7: C, 65.64; H, 6.52%); 5„ (CDC13; 400MHz) 2.65 (1 H, d, /2 .0 , exch. D20 , 
OH), 3.37 (3 H, s, OCH3), 3.44-3.49 (2 H, m, 2-H, 4-H), 3.68 (1 H, t, 27=37=10, 6-H J ,
3.78 (3 H, s, ArOCH3), 3.77-3.80 (1 H, m, 5-H), 4.13 (1 H, td, J  9.7, 2.0, simplifies to t 
on D20  exch., 3-H), 4.23 (1 H, dd, 2J 10,37 4.6, 6-H^), 4.60 (1 H, d, J  3.4, 1-H), 4.69,
4.78 (2 H, AB, J ^  12.2, C6H5C//20), 5.47 (1 H, s, 7-H), 6.87 (2 H, d, J  8.8, 3-H and 5- 
H of p-methoxyphenyl ring), 7.25-7.42 (7 H, m, aromatic CH); 8C (CDC13; 100.4 MHz) 
55.26, 55.31 (2 x OCH3), 61.97 (CH), 68.88 (6-C), 70.23 (CH), 73.20 (C6H5CH20),
73.31 (CH), 79.49 (2-C), 98.53 (1-C), 101.89 (7-C), 113.59 (3-C and 5-C of p- 
methoxyphenyl ring), 127.56, 127.64, 128.04, 128.10, 128.52 (aromatic CH), 129.56 (1- 
C of p-methoxyphenyl ring), 137.88 (1-C of benzyl ring), 160.14 (4-C of p- 
methoxyphenyl ring); mlz (FAB+) 403 [(M+l)+, 40%].
Further elution gave (189) (2.2g, 11%); R{ 0.35 (hexane : ethyl acetate 2:3); m.p. 176- 
178°C (from ethanol); [a]D +76.2 (c 1.7, CHC13); (Found: C, 65.5; H, 6.48. Calc, for 
C22H26°7: C’ 65 64; H’ 6-52%); Sh (CDC13; 270 MHz) 2.42 (1 H, d, J  7.3, exch. D20, 
OH), 3.43 (3 H, s, OCH3), 3.58-3.84 (8 H, m, 2-H, 3-H, 4-H, 5-H, 6-H.*, ArOCH3), 
4.34 (1 H, dd, V  3.8, 2J 9.3, 6-H*,), 4.75-4.96 (3 H, m, AB, J ^  11.5, C6U5CH20  
overlapping with 1-H), 5.51 (1 H, s, 7-H), 6.90 (2 H, d, J  8.8, 3-H and 5-H of p- 
methoxyphenyl ring), 7.24-7.42 (7 H, m, aromatic CH); 8C (CDC13; 67.8 MHz) 55.20,
55.29 (2 x OCH3), 62.53 (CH), 68.88 (6-C), 72.33 (CH), 74.67 (C6H5CH20), 78.78, 
81.82 (CH), 99.82 (1-C), 101.20 (7-C), 113.51 (3-C and 5-C of p-methoxyphenyl ring),
127.28, 127.60, 127.89, 128.28 (aromatic CH), 129.81 (1-C of p-methoxyphenyl ring),
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138.45 (1-C of benzyl ring), 159.95 (4-C of p-methoxyphenyl ring); mlz (FAB+) 403 
[(M+l)+, 30%].
6.3.4 Methyl 2-0-benzyl-3-0-(p-methoxybenzyl)-4,6-0-(p-methoxybenzylidene)-a- 
D-glucopyranoside (190)
A solution of (188) (9.6g, 23.8mmol) in dry DMF (50cm3) was sequentially treated with 
sodium hydride (857mg of an 80%w/w dispersion in mineral oil, 28.6mmol) and p- 
methoxybenzyl chloride (3.4cm3, 25.0mmol). The mixture was stirred at room 
temperature for 3 h. Methanol (10cm3) was added and stirring was continued for 1 h. 
The solvents were evaporated and the residue was extracted with chloroform (3 x 
150cm3). The combined organic extracts were washed with water (2 x 100cm3), dried 
(MgS04), filtered and concentrated to give crude (190) (11.8g). Crystallisation from 
ethanol gave pure (190) (10.9g, 87%); R{ 0.60 (hexane : ethyl acetate 2:3); m.p. 144- 
145°C; [a]D -30.0 (c 1.2, CHC13); (Found: C, 68.9; H, 6.67. Calc, for C30H34O8: C, 
68.94; H, 6.56%); 8h (CDC13;270 MHz) 3.40 (3 H, s, OCH3), 3.50-3.59 (2 H, m, 2-H,
4-H), 3.64-3.98 (8 H, m, 5-H, 6-H.*, 2 x ArOCH3), 4.02 (1 H, t, J  9.1, 3-H), 4.39 (1 H, 
dd, J  4.3, 9.8, 6-H*,), 4.57 (1 H, d, J 3.7, 1-H), 4.67-4.88 (4 H, m, 2 x ArCtf20  AB 
systems), 5.50 (1 H, s, 7-H), 6.82-6.92 (4 H, m, 3-H and 5-H of p-substituted rings), 
7.25-7.42 (9 H, m, aromatic CH); 8C (CDC13; 67.8 MHz) 55.24, 55.27, 55.31 (3 x 
OCH3), 62.34 (CH), 69.01 (6-C), 73.76, 74.99 (2 x ArCH20), 78.30, 79.18, 82.08 (CH), 
99.27 (1-C), 101.23 (7-C), 113.56, 113.72 (2 x 3-C and 5-C of p-substituted rings),
127.32, 127.86, 128.07, 128.41, 129.66, 129.97 (aromatic CH), 130.92 (1-C of p- 
substituted ring[s]), 138.22 (1-C of benzyl ring), 159.18, 159.99 (2 x 4-C of p- 
substituted rings); mlz (FAB+) 523 [(M+l)+, 10%].
6.3.5 Methyl 2-0-benzyl-3,6-di-0-(p-methoxybenzyl)-a-D-gIucopyranoside (194) 
and methyl 2-0-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D-glucopyranoside (185)
a) The method employed is a modification of that described by Johansson and 
Samuelsson.252 A solution, kept at 0°C, of trimethylsilyl chloride (12.5cm3, 98.4mmol) 
in dry acetonitrile (15cm3) was added dropwise under nitrogen to a vigorously stirred 
mixture of (190) (8.6g, 16.4mmol), sodium cyanoborohydride (6.2g, 98.4mmol), 3A
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molecular sieves and dry acetonitrile (150cm3) at 0°C. The suspension was allowed to 
warm to room temperature and was stirred under nitrogen for 3.5 h, when TLC (hexane : 
ethyl acetate 2:3) indicated conversion of starting material (R{ 0.62) into a minor product 
(Rf 0.51) and a major product (Rf 0.28). The suspension was filtered through Celite into 
ice-cold saturated aqueous NaHC03 solution (300cm3) and the residue was well washed 
with acetonitrile. The aqueous layer was extracted with ether (2 x 200cm3) and the 
combined organic extracts were washed with saturated aqueous NaHC03 solution 
(250cm3), dried (MgS04), filtered and concentrated. The yellow residue thus obtained 
was subjected to flash chromatography (eluent hexane : ethyl acetate 7:3) to give (194) 
as a colourless oil (2.4g, 28%); [a]D +12.6 (c 2.7, CHC13); (Found: C, 68.9; H, 6.91. 
Calc, for C30H36O8: C, 68.67; H, 6.92%); ^  (CDC13; 270 MHz) 2.36 (1 H, br s, exch, 
D20 , OH), 3.38 (3 H, s, OCH3), 3.48-3.79 (6 H, m, 2-H, 3-H, 4-H, 5-H, 6-H, 6-H’),
3.78, 3.79 (6 H, 2 s, 2 x OCH3), 4.43-4.93 (7 H, m, 1-H, 3 x Ai CH20  AB systems), 
6.83-6.90 (4 H, m, 3-H and 5-H of PMB rings), 7.22-7.36 (9 H, m, aromatic CH); 8C 
(CDC13; 67.8 MHz) 55.14, 55.17 (2 x OCH3), 69.18 (6-C), 69.82, 70.66 (4-C, 5-C), 
73.08, 73.16, 74.96 (3 x ArCH20), 79.53, 81.02 (2-C, 3-C), 98.12 (1-C), 113.70, 113.91 
(2 x 3-C and 5-C of PMB rings), 127.84, 128.02, 128.38, 129.21, 129.59 (aromatic CH),
130.02, 130.91 (2 x 1-C of PMB rings), 138.04 (1-C of benzyl ring), 159.14, 159.26 (2 x
4-C of PMB rings); mlz (FAB)' 523 [(M-l)', 70%], 677 [(M+NBA)',80%].
A sample of (194) was converted to its syrupy 4-O-benzoyl ester (195); [a]D -12.1 (c
2.2, CHC13); 6h (CDC13; 270 MHz) 3.43 (3 H, s, OCH3), 3.42-3.54 (2 H, m, 6-H, 6-H'), 
3.62-3.67 (4 H, m, OCH3, 2-H), 3.70 (3 H, s, OCH3), 3.94 (1 H, ddd, J  3.5, 9.2, 9.8, 5- 
H), 4.03 (1 H, t, J  9.5, 3-H), 4.37, 4.41 (2 H, AB, J ^  13.1, ArC/J20), 4.53-4.85 (5 H, 
m, 1-H, 2 x ArCHzO AB systems) 5.28 (1 H, t, J  9.7, 4-H), 6.59 (2 H, d, J  8 .6 , 3-H and
5-H of PMB ring), 6.71 (2 H, d, J  8.6 , 3-H and 5-H of PMB ring), 7.04 (2 H, d, J  8 .6, 2- 
H and 6-H of PMB ring), 7.15 (2 H, d, J  8.6, 2-H and 6-H of PMB ring), 7.25-7.56 (8 
H, m, aromatic CH), 7.90-7.94 (2 H, m, 2-H and 6-H of benzoyl ring); mlz (FAB+) 628 
[(M+l)+, 10%].
Further elution (eluent hexane : ethyl acetate 2:3) gave (185) as a pale yellow oil which 
solidified to a waxy solid (m.p. 50-51.5°C) on standing (4.1g, 48%); [a]D +7.5 (c 1.1,
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CHC13); (Found: C, 68.6; H, 7.05. Calc, for C30H36O8: C, 68.67; H, 6.92%); 5H (CDC13; 
400 MHz) 1.85 (1 H, br s, exch. D20 , OH), 3.35 (3 H, s, OCH3), 3.45-3.50 (2 H, m, 2- 
H, 4-H), 3.59-3.76 (3 H, m, 5-H, 6-H, 6-H’), 3.78, 3.79 (6 H, 2 s, 2 x ArOCH3), 3.97 (1 
H, t, J  9.3, 3-H), 4.55-4.99 (7 H, m, 1-H, 3 x ArC//20  AB systems), 6.84-6.88 (4 H, m, 
2 x 3-H and 5-H of PMB rings), 7.20-7.38 (9 H, m, aromatic CH); 8C (CDC13; 67.8 
MHz) 55.07, 55.19 (2 x OCH3), 61.84 (6-C), 70.64 (5-C), 73.35, 74.57, 75.35 (3 x 
ArCH20), 77.47, 79.98, 81.67 (2-C, 3-C, 4-C), 98.12 (1-C), 113.77, 113.83 (2 x 3-H 
and 5-H of PMB rings), 127.84, 128.02, 128.39, 129.55, 129.59 (aromatic CH), 130.29, 
130.94 (2 x 1-C of PMB rings). 138.12 (1-C of benzyl ring), 159.14, 159.29 (2 x 4-C of 
PMB rings); mlz (FAB") 677 [(M+NBA)", 60%].
A sample of (185) was converted to its 6-O-benzoyl ester (196), R{ 0.64 (hexane : ethyl 
acetate 2:3); m.p. 120.5°C (from isopropanol); [a]D +86.2 (c 1.2, CHC13); (Found: C, 
70.9; H, 6.30. Calc, for C37H40O9: C, 70.68; H, 6.41%); 8H (CDCI3; 270 MHz) 3.38 (3 
H, s, OCH3), 3.54-3.62 (2 H, m, 2-H, 4-H), 3.72, 3.81 (6 H, 2 s, 2 x ArOCH3), 3.92 (1 
H, dq, J  2, 9.6, 5-H), 4.03 (1 H, t, J 9.2, 3-H), 4.46-4.97 (9 H, m, 3 x Ai CH20  AB 
systems, 1-H, 6-H, 6-H'), 6.80 (2 H, d, J  8.6, 3-H and 5-H of PMB ring), 6.89 (2 H, d, J
8.6, 3-H and 5-H of PMB ring),7.17-8.14 (14 H, m, aromatic CH); mlz (FAB+) 628 
[M+, 5%].
b) To a solution of (190) (5.7g, 10.9mmol) in freshly distilled, dry THF (200cm3) was 
added LiAlH4 (2g) in one portion. The mixture was gradually brought to refluxing 
temperature. After 1 h, aluminium chloride (6g) was added portionwise over 30 min 
(care!). The mixture was stirred under reflux for a further 2 h, then cooled to 0°C. 
Excess LiAlH4 was destroyed by careful ^addition of ethyl acetate (20cm3) and 
aluminium hydroxide was precipitated by addition of water (30cm3). The system was 
extracted with ether (300cm3) and the combined organic extracts were washed with 
water (200cm3), dried (MgS04), filtered and concentrated. The syrup thus obtained was 
purified by flash chromatography (eluent hexane : ethyl acetate 7:3) to give exclusively 
(185) (4.2g, 73%).
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6.3.6 Methyl 2-0 -benzyI-3,4-di-O-(p-methoxybenzyl)-a-D-g/MC0-hexodialdo- 
pyranoside (1,5) (205)
Dry DMSO (0.33cm3) was added dropwise to a 2 m solution of oxalyl chloride in dry 
dichloromethane (1.25cm3 , 2.5mmol) at -60°C under an atmosphere of nitrogen. This 
mixture was stirred for 5 min, when a solution of (185) (1.2g, 2.3mmol) in dry 
dichloromethane (5cm3) was added dropwise over 5 min. The mixture was stirred at 
-60°C for 20 min when triethylamine (1.2cm3, 9.2mmol) was added. After a further 10 
min, the mixture was allowed to warm to room temperature. The solvents were 
evaporated and the residue was subjected to flash chromatography (eluent ethyl acetate : 
hexane 3:2) to give the crude product which showed OH stretching at Vmax 3480cm-1 in 
the IR spectrum. The product was dissolved in toluene (150cm3) and heated under 
reflux for 3 h with continuous azeotropic removal of water (Dean-Stark trap). The 
solution was cooled and concentrated to give the pure title compound as a pale yellow 
oil (l.Og, 84%); Rf 0.62 with streaking (ethyl acetate); [a]D +19.6 (c 4.0, CHC13); 
(Found: C, 68.7; H, 6.63. Calc, for C30H34O8: C, 68.94; H, 6.56%); 8H (CDC13;400 
MHz) 3.36 (3 H, s, OCH3), 3.47 (1 H, dd, J 3.4, 9.3, 2-H), 3.53 (1 H, dd, J  8.8, 10.3, 4- 
H), 3.79, 3.80 (6 H, 2 s, 2 x ArOCH3), 4.05 (1 H, t, J  9.3, 3-H), 4.13 (1 H, d, J  10.3, 5- 
H), 4.53-4.93 (7 H, m, 3 x ArC//20  AB systems, 1-H), 6.85-6.89 (4 H, m, 3-H and 5-H 
of PMB rings), 7.15-7.36 (9 H, m, aromatic CH), 9.62 (1 H, s, 6-H); 8C 
(CDC13;100MHz) 55.26, 55.74 (2 x OCH3), 73.63 (ArCH20), 74.25 (5-C), 74.73, 75.64 
(2 x ArCH20), 77.45, 79.30, 81.51 (2-C, 3-C, 4-C), 98.41 (1-C), 113.90 (3-C and 5-C of 
PMB rings), 128.11, 128.18, 128.47, 128.57, 129.04, 129.57, 129.68, 129.82 (aromatic 
CH), 129.88, 130.63 (2 x 1-C of PMB rings), 137.87 (1-C of benzyl ring), 159.31,
159.49 (2 x 4-C of PMB rings), 197.58 (6-C); m/z : (FAB') 677 [(M+NBA)', 60%]; vmax 
1745cm-1.
6.3.7 (IR, 2S, 3S, 4R, 5S)-3-Benzyloxy-4-hydroxy-5-hydroxymethyl-l,2-di-(p- 
methoxybenzyloxy)cyclopentane (206)
The method employed is a modification of that described by Chenede et al.260 To a 
0 .1 m  solution of samarium (II) iodide in dry THF (100cm3, lOmmol) under an 
atmosphere of nitrogen were added dry HMPA (5cm3) and freshly distilled, dry t-
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butanol (0.4cm3,4.3mmol). A solution of (205) (926mg, 1.8mmol) in freshly distilled, 
dry THF (20cm3) was then added dropwise over 15 min and the blue-black mixture was 
stirred under a stream of nitrogen for a further 1 h. 1m Aqueous HC1 (100cm3) was 
added and the mixture was extracted with ether (3 x 150cm3). The combined organic 
extracts were washed with 5%w/v aqueous Na2S203 solution (100cm3) and water 
(100cm3), dried (MgS04), filtered and concentrated. The residual orange oil was 
subjected to flash chromatography (eluent hexane : ethyl acetate 3:2) to give (185) 
(175mg, 19%);
Further elution with ethyl acetate gave (206) as a pale yellow oil (321mg, 37%); Rf 0.49 
(ethyl acetate); [a]D +19.5 (c 4.1, CHC13); (Found: C, 70.5; H, 6.57. Calc, for C29H3407: 
C, 70.41; H, 6.93%); 5H (CDC13;400MHz) 2.24 (1 H, m, 5-H), 2.50-3.40 (2 h, br s, 2 x 
OH), 3.72-3.77 (7 H, m, 2 x ArOCH3, 3-H), 3.78-3.83 (2 H, m, C//2OH), 3.90 (l H, t, J
5.4, 2-H), 3.97 (1 H, t, J  5.9, l-H), 4.24 (l H, dd, J  3.9, 6.8, 4-H), 4.47^1.65 (6 H, m, 3 
x A1 CH2O AB systems), 6.83-6.86 (4 H, m, 3-H and 5-H of PMB rings), 7.20-7.33 (9 
H, m, aromatic CH); 5C (CDC13;100MHz) 46.68 (5-C), 55.18 (OCH3), 60.93 (CH2OH), 
71.72, 71.81 (3 x AtCH20), 75.20, 81.66, 87.42, 87.90 (1-C, 2-C, 3-C, 4-C), 113.70 (3- 
C and 5-C of PMB rings), 127.68, 127.75, 128.35, 129.41, 129.54 (aromatic CH), 
130.05, 130.31 (2 x 1-C of PMB rings), 138.06 (1-C of benzyl ring), 159.13, 159.17 (2 x 
4-C of PMB rings); mlz: (FAB*) 493 [(M+l)*, 50%].
6.3.8 (1R, 25,35,4R, 55)-3-BenzyIoxy-5-benzyIoxymethyI-4-hydroxy-l,2-di-(p- 
methoxybenzyloxy)cyclopentane (208) and (1R, 25 ,35 ,4R, 55)-3,4-Dibenzyloxy-5- 
hydroxymethyI-l,2-di-(p-methoxybenzyIoxy)cycIopentane (207)
A solution of (206) (200mg, 0.4mmol) in dry DMF (3cm3) at 0°C was sequentially 
treated with sodium hydride (17mg of a 60% w/w dispersion in mineral oil, 0.4mmol) and 
benzyl bromide (0.05cm3, 0.45mmol). The mixture was stirred at 0°C for 1 h, when 
TLC (ethyl acetate : hexane 3:2) indicated two products (Rf 0.58 and 0.49) and 
unreacted starting material (Rf 0.15). Methanol (1cm3) was added and the solution was 
stirred for a further 5 min. The solvents were evaporated and the residue was extracted 
with chloroform (100cm3). The organic solution was washed with water (100cm3) and 
saturated aqueous NaCl solution (100cm3), dried (MgSCU), filtered and concentrated.
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The syrupy residue was subjected to flash chromatography (eluent chloroform : acetone 
30:1) to give (208) as a pale yellow oil (67mg, 28%); [a]D +30.4 (c 2.0, CHC13); 
(Found: C, 73.8; H, 7.00. Calc, for C36H40O7: C, 73.94; H, 6.90%); ^  (CDC13;400MHz)
2.31 (1 H, m, J  4.9, 9.3, 5-H), 3.32 (1 H, d, J  3.4, OH), 3.72-3.78 (2 H, m, 
CH2OCH2Ph), 3.77-3.81 (7 H, m, 2 x OCH3, 3-H), 3.90 (1 H, t, J  5.9, 2-H), 4.06 (1 H, 
dd, J  5.9, 9.3, 1-H), 4.25 (1 H, br m, 4-H), 4.40-4.70 (8 H, m, 4 x ArCtf20  AB 
systems), 6.81-6.87 (4 H, m, 2-H and 5-H of PMB rings), 7.15-7.37 (14 H, m, aromatic 
CH); 5C (CDC13;100MHz) 45.41 (5-C), 55.27 (OCH3), 67.98 (CH2OCH2Ph), 71.69,
71.78, 72.00, 73.52 (4 x ArCH20), 75.07, 81.32, 88.04 (4 x CH), 113.73 (2-C and 5-C 
of PMB rings), 127.63, 127.76, 127.82, 127.89, 128.36, 128.44, 128.49, 129.55, 129.63 
(aromatic CH), 130.38, 130.60 (2 x 1-C of PMB rings), 137.51, 138.24 (2 x 1-C of 
benzyl rings), 159.16, 159.20 (2 x 4-C of PMB rings); mlz: (FAB+) 463 [(M-PMB)+, 
65%].
Further elution gave (207) as a pale yellow oil (98mg, 41%); [a]D +27.9 (c 1.5, CHC13); 
(Found: C, 73.7; H, 6.92. Calc, for C36H40O7: C, 73.94; H, 6.90%); 5H (CDC13;400MHz) 
2.33 (1 H, m, J  5.9, 5-H), 2.57 (1 H, br m, exch. D20 , OH), 3.77, 3.78 (6 H, 2 s, 2 x 
OCH3), 3.82-3.87 (2 H, m, Ctf2OH), 3.88-3.91 (1 H, br m, 3-H), 3.95 (1 H, t, J  5.9, 2- 
H), 4.00-4.03 (1 H, br m, 1-H), 4.12 (1 H, dd, J  5.9, 8.8, 4-H), 4.46^.66 (8 H, m, 4 x 
ArCtf20  AB systems), 6.84-6.87 (4 H, m, 3-H and 5-H of PMB rings), 7.23-7.35 (14 
H, m, aromatic CH); ); 8C (CDC13;100MHz) 46.78 (5-C), 55.25 (OCH3), 60.95 
(CH2OH), 71.78,71.85, 72.19 (4 x ArCH20), 82.24, 82.42, 85.77, 88.37 (1-C, 2-C, 3-C, 
4-C), 113.77 (3-C and 5-C of PMB rings), 127.63, 127.74, 127.96, 128.42, 128.49, 
128.57, 129.44, 129.53, 129.63 (aromatic CH), 130.27, 130.47 (2 x 1-C of PMB rings), 
137.64, 138.04 (2 x 1-C of benzyl rings), 159“.20, 159.23 (2 x 4-C of PMB rings); mlz: 
(FAB+) 463 [(M-PMB)+, 15%].
Further elution with ethyl acetate gave starting material (50mg, 25%).
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6.3.9 (12?, 25,35,42?, 52?)-3-BenzyIoxy-5-benzyIoxymethyl-l,2,4-trihydroxycyclo- 
pentane (202)
A solution of (208) (90mg, 0.15mmol) in ethanol-lM aqueous HC1 (2:1, 30cm3) was 
heated under reflux for 2.5 h, when TLC (ethyl acetate) indicated consumption of 
starting material (Rf  0.79) to give a product (Rf  0.31) The solution was cooled, the 
solvents were evaporated and the residue was triturated with ether (3 x 50cm3). The 
combined organic solutions were washed with saturated aqueous NaHCC>3 solution 
(50cm3) and saturated aqueous NaCl solution (50cm3), dried (MgS04), filtered and 
concentrated. The residue was purified by flash chromatography (eluent hexane : ethyl 
acetate 1:1) to give the title compound as a waxy solid (38mg, 72%); [a]D +30.0 (c 1.7, 
CHC13); 5h (CDCI3;400MHz) 2.16-2.23 (1 H, br m, 5-H), 3.14 (1 H, br s, OH), 3.43 (1 
H, br s, OH), 3.61 (1 H, dd, J  3.4, 6.1, 3-H), 3.67-3.74 (3 H, m, C/72OCH2Ph, OH), 3.82 
(1 H, br t, J  6.5, 2-H), 3.95 (1 H, br dd, J  7.6, 1-H), 4.14-^4.18 (1 H, br m, 4-H), 4.46,
4.48 (2 H, AB, JAB 11.9, PhC7/20), 4.60, 4.67 (2 H, AB, 7 Ab  1 1.6, PhC/720), 7.23-7.35 
(10 H, m, aromatic CH); 5C (CDC13;100 MHz) 45.90 (5-C), 68.05 (CH2OCH2Ph),
71.96, 73.52 (2 x PhCH20), 74.47, 75.97, 81.02 (1-C, 2-C, 4-C), 89.19 (3-C), 127.76,
127.91, 128.00, 128.44, 128.58 (aromatic CH), 137.45, 138.02 (2 x 1-C of benzyl 
rings); m/z:(FAB+) 345 [(M+l)\ 15%], (FAB') 343 [(M-l)\ 38%], 497 [(M+NBA)', 
98%].
6.3.10 (12?, 22?, 35, 42?, 55)-3-Hydroxy-5-hydroxymethyI-l,2,4-trisphospho-
cyclopentane (200)
A mixture of bis(benzyloxy)(diisopropylamino)phosphine (211mg, 6.1mmol), 1 /7 -  
tetrazole (64mg, 9.2mmol) and dry dichloromethane (2cm3) was vigorously stirred at 
room temperature for 15 min, whereupon a solution of (202) (35mg, O.lmmol) in dry 
dichloromethane (1cm3) was added and stirring was continued for 30 min. 31P NMR' 
spectroscopy indicated phosphite triester signals at 5p 140.3 (s) and 140.2, 139.9 (AB, 
7ab 7.0). The mixture was cooled to -78°C, MCPBA (312mg) was added and the 
system was allowed to warm to room temperature. After a further 10 min, ethyl acetate 
(50cm3) was added and the organic solution was washed with 50cm3 each of 1 0 % w/v  
aqueous Na2S2C>3 solution, 1m aqueous HC1, saturated aqueous NaHCCb solution and
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saturated aqueous NaCl solution. The organic fraction was dried (MgSC>4), filtered and 
concentrated. Flash chromatography with chloroform : acetone 20:1 and recolumning 
with ethyl acetate : hexane 7:3 then 1:1 failed to remove all impurities. 31P NMR 
spectroscopy showed three peaks at 5p -2.47, -2.16 and -2.08 and this crude product 
was used for deprotection.
Ammonia (ca. 100cm3) was condensed into a three-necked flask at -78°C. An excess 
of sodium was added to dry the liquid ammonia, about 20cm3 of which was then 
distilled into a second three-necked flask and kept at -78°C. Sodium was added until 
the solution remained blue-black for 10 min. A solution of the crude product above in 
dry dioxane (1cm3) was added. The mixture was stirred for 2 min then the reaction was 
quenched with methanol (1cm3) and water (1cm3). The solvents were evaporated. The 
residue was dissolved in de-ionised water (300cm3) and purified by ion-exchange 
chromatography on Q Sepharose fast flow, eluting with a gradient of triethylammonium 
bicarbonate buffer ( 0 - 1 m ) ,  pH 7 .3 .  The triethylammonium salt of the title compound 
eluted between 610-640mM buffer; [a]D -11.0 (c 0.4 calc, for free acid, TEAB, pH 8.6); 
8h (D20 , pH ca. 4, 400 MHz) 2.29 (1 H, br quintet, J  7.3, 5-H), 3.65 (1 H, ABX, 27AB 
12,37 6, CHHOH), 3.71 (1 H, ABX, 2JAB 12,3/7 .3 , CHHOH), 3.94(1 H ,t,74 .6 , 3-H), 
4.16-4.31 (3 H, m, 1-H, 2-H, 4-H); 6P (D20 , pH ca. 4,400 MHz) (’H-coupled) 0.36 (d, 
7hp 9.3), 0.49 (d, JHp 8.8), 0.66 (d, Jm  9.2); mlz: (FAB-) 403 [(M-l)’ , 100%]; (Found: 
M \ 402.962. Calc, for C6H,20 i4P3 [M-H]': 402.960).
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6.4 A tte m p te d  P r e p a r a t io n  o f  a  V e r s a t i l e  C h ir a l  In te r m e d ia te  f o r  
S y n th e s is  o f  A n a lo g u e s  o f  Ins(l,4,5)P3
6.4.1 Methyl 2-0-(p-methoxybenzyl)-a-D-glucopyranoside (214)
a) The method employed is a modification of that described by Haque et al.262 A 
mixture of methyl a-D-glucopyranoside (20.0g, 103mmol) and dibutyltin oxide (25.6g, 
103mmol) was heated under reflux in methanol (500cm3) until solution was effected 
(3.5 h). The solution was cooled and concentrated. To the foamy residue was added 
tetrabutylammonium iodide (38.0g, 103mmol), acetonitrile (500cm3) and p- 
methoxybenzyl chloride (15.5cm3,123mmol). This mixture was heated under reflux via 
a Soxhlet thimble containing 4A molecular sieves for 16 h, whereupon more p- 
methoxybenzyl chloride (3.0cm3, 23.8mmol) was added, and heating was continued for 
a further 5 h. The solution was cooled and concentrated. Without further purification 
the residue was fractionated by flash chromatography (eluent ethyl acetate : hexane 4:1 
then ethyl acetate) to give a less polar fraction (Rf>0.55 in ethyl acetate : methanol 4:1) 
and a more polar fraction (Rf 0.35-0.48 in the same solvent system). The latter was 
collected and the title compound was isolated by fractional crystallisation from ethanol 
(yield 11.8g, 36%); R{ 0.40 (ethyl acetate : methanol 4:1); m.p. 136-138°C; [a]D +61.3 
(c 0.8, CHC13); (Found: C, 57.1; H, 7.13. Calc, for C15H220 7: C, 57.32; H, 7.05%); 5h 
(CDC13; 270 MHz) 2.20 (1 H, br s, exch. D20 , OH), 2.74 (1 H, br s, exch. D20 , OH),
3.32 (3 H, s, OCH3), 3.45-3.55 (2 H, m, 6-H, 6-H'), 3.67 (1 H, br s, exch. D20 , OH),
3.79 (3 H, s, ArOCH3), 3.81-3.95 (4 H, br m, 2-H, 3-H, 4-H, 5-H), 4.53^1.67 (3 H, m, 
Ai CH20  AB system overlapping 1-H), 6.87 (2 H, d, J  8.7, 3-H and 5-H of PMB ring), 
7.28 (2 H, d, J  8.7, 2-H and 6-H of PMB ring); 5C (CDC13; 67.8 MHz) 55.29 (OCH3), 
61.74 (6-C), 70.14, 70.86 (CH), 72.75 (ArCH20), 79.01 (2-C), 97.97 (1-C), 113.98 (3-C 
and 5-C of PMB ring), 129.79 (2-C and 6-C of PMB ring), 130.07 (1-C of PMB ring),
159.53 (4-C of PMB ring); mlz (FAB") 313 [(M-l)‘, 90%].
b) A solution of (163) (16.2g, 39.8mmol) in 80%v/v acetic acid in water (100cm3) was 
heated under reflux for 30 min. The solution was rapidly cooled (ice bath) and the 
solvents were evaporated and co-evaporated with toluene (3 x 100cm ). The residue
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thus obtained was extracted with water (3 x 200cm3) and the combined aqueous extracts 
were washed with light petroleum (100cm3) to remove benzaldehyde, and concentrated 
to give the title compound as a white solid (11.6g, 93%).
6.4.2 Methyl 4,6-0-isopropyIidene-2-0-(p-methoxybenzyl)-a-D-gIucopyranoside 
(215)
A solution of (214) (1.2g, 3.7mmol) in acetone was treated with PTSA (52mg) and 2- 
methoxypropene (3.5cm3, 37mmol) and stirred for 5 min. The solvents were evaporated 
and the dark brown residue was extracted with ether (200cm3). The organic extract was 
washed with saturated aqueous NaHC03 solution (70cm3) and water (70cm3), dried 
(MgS04), filtered and concentrated to give an orange oil which was purified by flash 
chromatography (eluent hexane : ethyl acetate 7:3 then 2:3) to give the title compound 
as a pale yellow oil (920mg, 71%); R{ 0.52 (ethyl acetate); [a]D +25.0 (c 2.4, CHC13); 
(Found: C, 60.8; H, 7.63. Calc, for C18H260 7: C, 61.00; H, 7.39%); 8H (CDC13; 
400MHz) 1.44, 1.50 (6 H, 2 s, 2 x isopropylidene CH3), 2.58 (1 H, br s, exch. D20 , 
OH), 3.34 (3 H, s, OCH3), 3.39 (1 H, dd, J  3.4, 9.3, 2-H), 3.53 (1 H, t, J  9.3, 4-H), 3.62 
(1 H, td, V4.H, 5-H = 3- W  5-H = 9.3,376_Heq, 5-H = 4.9, 5-H), 3.71 (1 H, t, 3 / ^  = ^  
Hax, 6-Heq = 9.8, 6-H J , 3.81-3.86 (4 H, m, ArOCH3, 6-H*,), 3.96 (1 H, br t, J  9.3, 3-H),
4.53 (1 H, d, J  3.9, 1-H), 4.61, 4.68 (2 H, AB, / AB 12, ArCH20), 6.89 (2 H, d, J  8.3, 3-H 
and 5-H of PMB ring), 7.30 (2 H, d, J 8.7, 4-H and 6-H of PMB ring); 8C (CDC13; 67.8 
MHz) 19.07 (axial CH3 of isopropylidene), 29.07 (equatorial CH3 of isopropylidene),
55.22 (OCH3), 62.37 (6-C), 62.87, 70.29 (CH), 72.83 (ArCH20), 73.72, 79.35 (CH), 
98.52 (1-C), 99.67 (Cq of isopropylidene), 113.94 (3-C and 5-C of PMB ring), 129.70 
(2-C and 6-C of PMB ring), 129.93 (1-C of PMB ring), 159.52 (4-C of PMB ring); mlz 
(FAB") 353 [(M-H)", 40%].
6.4.3 Methyl 3,4-0-isopropylidene-2-0-(p-methoxybenzyl)-a-D-glucopyranoside 
(210)
A solution of (214) (17.lg, 54.5mmol), DMAP (280mg, 2.3mmol) and t- 
butyldiphenylsilyl chloride (14.9cm3, 57.2mmol) in dry pyridine (100cm3) was left at 
room temperature for 16 h, when TLC (ethyl acetate) indicated consumption of starting
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material (R{ 0.11) to give a single product (R{ 0.53). The solvents were evaporated and 
co-evaporated with toluene (3 x 250cm3) to remove remaining traces of pyridine. To the 
residue was added acetone (200cm3), PTSA (lOOmg) and 2-methoxypropene (26cm3, 
273mmol). After 4 h, TLC indicated the presence of a single product (Rf 0.68 in ethyl 
acetate). The solvents were evaporated and the residue was heated under reflux in a 
1.1m solution of tetrabutylammonium fluoride in THF (240cm3, 218mmol) for 16 h, 
when TLC indicated a single product (R{ 0.44 in ethyl acetate). The solution was cooled 
and poured into a separating funnel containing water (350cm3). The resulting emulsion 
was extracted with ether (3 \  250cm3) and the combined organic extracts were dried 
(MgS04), filtered and concentrated. The resultant orange oil was subjected to flash 
chromatography (eluent hexane : ethyl acetate 1:1 then 1:4) to give the title compound 
as a pale yellow oil (18.2g, 95%); [a]D -5.9 (c 0.9, CHC13); (Found: C, 60.9; H, 7.61. 
Calc, for C18H260 7: C, 61.00; H, 7.39%); ^  (CDC13; 400MHz) 1.45, 1.46 (6 H, 2 s, 2 x 
isopropylidene CH3), 2.02 (1 H, br s, exch. D20 , OH), 3.25 (1 H, t, J  9.3, 4-H), 3.36 (3 
H, s, OCH3), 3.63 (1 H, dd, J  3.4, 9.4, 2-H), 3.73 (1 H, br m, sharpens on D20  exch., 6- 
H), 3.81 (3 H, s, ArOCH3), 3.82-3.89 (2 H, m, 5-H, 6-H’), 3.96 (1 H, t, J  9.3, 3-H), 4.58 
(1 H, AB, 7AB 12.2, ArC//HO), 4.65 (1 H, d, J  3.4, 1-H), 4.81 (1 H, AB, JAB 12.2, 
ArCH/ZO), 6.89 (2 H, d, J  8.8, 3-H and 5-H of PMB ring), 7.31 (2 H, d, J  8.8, 2-H and 
6-H of PMB ring); 8C (CDC13; 100MHz) 26.52, 26.96 (2 x isopropylidene CH3), 55.52,
55.29 (2 x OCH3), 62.55 (6-C), 71.60 (CH), 71.78 (ArCH20), 74.45, 77.40, 77.61 (CH),
99.07 (1-C), 111.01 (Cq of isopropylidene), 113.81 (3-C and 5-C of PMB ring), 129.88 
(2-C and 6-C of PMB ring), 130.03 (1-C of PMB ring), 159.40 (4-C of PMB ring); mlz 
(FAB+) 355 [(M+l)+, 2%].
6.4.4 (E,Z)-Methyl 6-<9-acetyI-3,4-0-isopropylidene-2-0-(p-methoxybenzyI)-a-D- 
xy/o-hex-5-enopyranoside (216ab) and methyl 6-C-acetoxy-6-0-acetyl-3,4-0- 
isopropyIidene-2-0-(p-methoxybenzyl)-a-D-glucopyranoside (217)
a) Dry DMSO (1.6cm3, 22.6mmol) was added dropwise to a 2 m solution of oxalyl 
chloride in dry dichloromethane (6.2cm3, 12.4 mmol) at -60°C (C02(s) /CHC13 bath) 
under an atmosphere of nitrogen. After 5 min a solution of (210) (4.0g, 11.3mmol) in 
dry dichloromethane (5cm3) was added over about 5 min. The mixture was stirred at 
-60°C for 15 min, then A^A-diisopropylethylamine (7.9cm3, 45.2mmol) was added over
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5 min. The system was allowed to warm to room temperature and the solvents were 
evaporated. To the residue was added anhydrous potassium carbonate (9.4g, 67.8mmol, 
dried in vacuo over P2Os at 75°C for 6 h), acetic anhydride (10.7 cm3, 113mmol) and 
dry acetonitrile (30cm3), and this mixture was heated under reflux under an atmosphere 
of nitrogen for 6 h, then cooled. The mixture was extracted with ether (2 x 200cm3) and 
the combined organic extracts were washed with saturated aqueous KC1 solution 
(200cm3) and water (200cm3), dried (MgS04), filtered and concentrated. The brown oil 
thus obtained was subjected to flash chromatography (eluent hexane : ethyl acetate 7:3) 
to give (216ab) as a pale yellow solid (1.2g, 26%); R{ 0.75 (ethyl acetate); [a]D -45.1 (c
1.6, CHC13); (Found: C, 60.8; H, 6.69. Calc, for C20H26O8: C, 60.89; H, 6.65%); 5H 
(major isomer) (CDC13; 270 MHz) 1.47,1.49 (6 H, 2 s, 2 x isopropylidene CH3), 2.16 (3 
H, s, CH3C02), 3.47 (3 H, s, OCH3), 3.74-3.80 (2 H, m, 2-H, 4-H), 3.81 (3 H, s 
ArOCH3), 3.96 (1 H, t, J  9, 3-H), 4.57-4.87 (3 H, m, Ai CH20  AB system overlapping 
with 1-H), 6.89 (2 H, d, J  8.8, 3-H and 5-H of PMB ring), 6.95 (1 H, d, J  1.7, 6-H), 7.31 
(2 H, d, J  8.8, 4-H and 6-H of PMB ring); 8C (major isomer) (CDC13; 68MHz) 20.54 
(CH3CO2), 26.41, 26.98 (2 x CH3 of isopropylidene), 55.29, 56.38 (2 x OCH3), 71.98 
(AtCH20), 73.39, 76.86, 77.94 (2-C, 3-C, 4-C), 101.32 (1-C), 112.18 (Cq of 
isopropylidene), 113.86 (3-C and 5-C of PMB ring), 118.93 (6-C), 129.90 (1-C of PMB 
ring), 129.96 (2-C and 6-C of PMB ring), 133.70 (5-C), 159.49 (4-C of PMB ring),
167.21 (CH3CO2); mlz (FAB') 393 [(M-l)’, 40%].
Further elution gave (217) as a colourless oil (2.2g, 43%); Rf 0.70 (ethyl acetate); [a]D 
-21.1 (c 1.8, CHC13); (Found: C, 58.2; H, 6.83. Calc, for C22H30O10: C, 58.13; H, 
6 .66%); 5h (CDC13; 400MHz) 1.42, 1.43 (6 H, 2 s, 2 x isopropylidene CH3), 2.08, 2.11 
(6 H, 2 s, 2 x CH3C02), 3.27 (1 H, t, J  9.8, 4^H), 3.35 (3 H, s, OCH3), 3.64 (1 H, dd, J
3.4, 10.5, 2-H), 3.80 (3 H, s, ArOCH3), 3.90-3.97 (2 H, m, 3-H, 5-H), 4.56 (1 H, AB, 
7ab 12.2, ArCHHO), 4.65 (1 H, d, 73.4, 1-H), 4.80 (1 H, AB, / AB 12.2, ArCHtfO), 6.88 
(2 H, d, J  8.8, 3-H and 5-H of PMB ring), 6.95 (1 H, d, J  4.9, 6-H), 7.30 (2 H, d, J  8.8,
2-H and 6-H of PMB ring); 8C (CDC13; 100 MHz) 20.67, 20.70 (2 x CH3C 02), 26.74, 
26.85 (2 x isopropylidene CH3), 55.27, 55.49 (2 x OCH3), 70.28 (CH), 71.91 (ArCH20), 
74.45, 76.77, 77.70, 87.93 (4 x CH), 98.96 (1-C), 111.12 (Cq of isopropylidene), 113.83 
(3-C and 5-C of PMB ring), 129.02 (1-C of PMB ring), 129.88 (2-C and 6-C of PMB
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ring), 159.44 (4-C of PMB ring), 168.47, 168.62 (2 x CH3C02); m/z: (FAB+) 455 
[(M+l)+, 2%].
b) Compound (210) (4.5g, 12.7mmol) was oxidised as above. The residue present after 
evaporation of the solvents was subjected to flash chromatography (eluent hexane : ethyl 
acetate 1:1) and the partially purified aldehyde was dissolved in toluene (250cm3). The 
solution was heated under reflux for 1.5 h with continuous azeotropic removal of water 
(Dean-Stark trap), then cooled and concentrated. The residue was treated as in a) to 
give (216ab) only (3.5g, 70%).
6.4.5 Attempted Ferrier rearrangement of (216ab)
To a solution of (216ab) (395mg, l.Ommol) in acetone : water 4:1 (25cm3) was added 
mercury (II) acetate (351 mg, 1.1 mmol). After 30 min TLC (ethyl acetate) indicated 
consumption of starting material (R{ 0.75) to give a baseline product. Sodium chloride 
(3.4g, 57mmol) was added and the suspension was stirred for 22 h. TLC indicated a 
single product (R{ 0.70 in ethyl acetate). The mixture was partially evaporated and 
diluted with chloroform (50cm3). The organic extract was washed with water (30cm3), 
dried (MgS04), filtered and concentrated. The residue was purified by flash 
chromatography (eluent hexane : ethyl acetate 7:3) to give 6-O-acetyl-3,4-0- 
isopropylidene-2-(9-(p-methoxybenzyl)-D-jcy/0-5-hexosulose (219) as a pale yellow oil 
(124mg, 33%); [a]D +23 (c 0.3, CHC13); 8H (CDC13; 400MHz) 1.43, 1.45 (6 H, 2 s, 2 x 
isopropylidene CH3), 2.17 (3 H, s, CH3C02), 3.80 (3 H, s, ArOCH3), 3.94 (1 H, dd, J
1.3, 2.9, 2-H), 4.46 (1-H, ABX, J  2.9, 7ab 7.6, 3-H), 4.54 (1 H, AB, 7ab 7.6, 4-H), 4.61, 
4.70 (2 H, AB, Jkg 11.6, ArC/f20), 4.86, 5.05 .(2 H, AB, JAB 18.0, 6-H, 6-H’), 6.88 (2 H, 
d, J  8.5, 3-H and 5-H of PMB ring), 7.28 (2 H, d, J  8.5, 2-H and 6-H of PMB ring), 9.64 
(1 H, d, J  1.2, 1-H); 5C (CDC13; 100MHz) 21.05 (CH3C 02), 26.26, 26.30 (2 x 
isopropylidene CH3), 55.27 (ArOCH3), 66.24 (6-C), 73.46 (ArCH20), 77.49, 79.02, 
81.35 (3 x CH), 112.00 (Cq of isopropylidene), 114.04 (3-C and 5-C of PMB ring),
128.67 (1-C of PMB ring), 129.99 (2-C and 6-C of PMB ring), 159.75 (4-C of PMB 
ring), 171.18 (CH3C02), 201.39 (1-C), 202.56 (5-C); m/z (FAB") 533 [(M+NBA)", 
30%].
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6.4.6 (E,Z)-Methyl 6-0-acetyl-2-0-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D-jcy/o- 
hex-5-enopyranoside (224ab)
Compound (185) (12.6g, 24.0mmol) was oxidised to (205) as described in section 6.3.6. 
The crude aldehyde thus obtained was dissolved in dry acetonitrile (100cm3) under an 
atmosphere of nitrogen. Potassium carbonate (20g) and acetic anhydride (24cm3, 
240mmol) were added and this suspension was heated under reflux for 12 h, then 
cooled. The system was extracted with ether (3 x 200cm3) and the combined organic 
extracts were washed with saturated aqueous KC1 solution (200cm3), dried (MgS04), 
filtered and concentrated. The brown residue was purified by flash chromatography 
(eluent hexane : ethyl acetate 7:3) to give the title compound as a pale yellow syrup 
(11.7g, 86%); Rf 0.58 (hexane : ethyl acetate 2:3); [a]D -39.4 (c 1.8, CHCI3); (Found: C, 
67.8; H, 6.36. Calc, for C32H36O9: C, 68.06; H, 6.43%); 8h (major isomer) (CDC13; 
400MHz) 2.15 (3 H, s, COCH3), 3.46 (3 H, s, OCH3), 3.55 (1 H, dd, J  3.5, 9, 2-H), 3.79,
3.80 (6 H, 2 s, 2 x ArOCH3), 3.89-3.94 (2 H, m, 3-H, 4-H), 4.63-4.86 (7 H, m, 3 x 
ArC/^O AB systems, 1-H), 6.85-6.89 (4 H, m, 2 x 3-H and 5-H of PMB rings), 7.16 (1 
H, d, J  1, 6-H), 7.25-7.35 (9 H, m, aromatic CH); 6c (major isomer) (CDCI3; 68 MHz)
20.58 (CH3CO2), 55.16, 56.10 (OCH3), 73.68, 74.13, 75.35 (3 x ArCH20), 79.01, 80.96 
(CH), 99.75 (1-C), 113.73, 113.83 (2 x 3-C and 5-C of PMB rings), 122.95 (6-C),
123.03, 127.94, 128.04, 128.44, 129.61, 129.74 (aromatic CH), 130.71 (1-C of PMB 
ring[s]), 135.04 (5-C), 137.98 (1-C of benzyl ring), 159.18, 159.32 (2 x 4-C of PMB 
rings), 167.28 (CH3CO2); mlz (FAB+) 564 [M+, 5%].
6.4.7 D-l-0-Acetyl-3-0-benzyI-4,5-di-0-(p-methoxybenzyl)-my0-inos-6-ose (225)
A solution of (224ab) (11.2g, 19.9mmol) and mercury (II) trifluoroacetate (8.9g, 
20.9mmol) 3:2 (300cm3) was stirred at room temperature for 30 min, when sodium 
chloride (35g) was added and stirring was continued for 18 h. The system was partially 
evaporated and the gummy residue was extracted with chloroform (3 x 150cm ). The 
combined organic extracts were washed with water (100cm ), dried (MgS04), filtered 
and concentrated. The residue was subjected to flash chromatography (eluent hexane : 
ethyl acetate 7 :3) and the crude product was crystallised from ethanol to give the title 
compound (5.3g, 36%); m.p. 150.5-153°C; [a]D -44 (c 1.1, CHCI3); (Found: C, 67.8;
176
H, 6.16. Calc, for C31H34O9: C, 67.61; H, 6.23%); ^  (CDC13; 400MHz) 2.23 (3 H, s, 
CH3CO2), 2.63 (1 H, s, exch. D20 , OH), 3.79-3.85 (7 H, m, 2 x OCH3, 3-H), 4.04 (1 H, 
t, J  9, 4-H), 4.12 (1 H, d, J  9.4, 5-H), 4.32 (1 H, br t, J  2.4, 2-H), 4.44-4.49 (1 H, AB, 
Ja b  11.0, ArCtfHO), 4.69^1.87 (5 H, m, 3 x A1 CH2O AB systems), 5.15 (1 H, d, J  2.4,
1-H), 6.84-6.86 (4 H, m, 2 x 3-H and 5-H of PMB rings), 7.22-7.34 (9 H, m, aromatic 
CH); 5c (CDCI3; 100MHz) 20.54 (CH3CO2), 55.27 (OCH3), 69.28 (CH), 73.23, 73.37 
(2 x ArCH20), 74.93 (CH), 75.82 (ArCH20), 78.91, 81.49, 83.21 (3-C, 4-C, 5-C),
113.75, 113.83 (2 x 3-H and 5-H of PMB rings), 127.98, 128.18, 128.62 (aromatic CH),
129.45 (1-C of PMB ring), 129.77, 129.94 (aromatic CH), 130.43 (1-C of PMB ring), 
137.43 (1-C of benzyl ring), 159.29, 159.42 (2 x 4-C of PMB rings), 169.91 (CH3CO2),
198.00 (6-C); mlz (FAB") 703 [(M+NBA)", 100%].
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6.5 S y n th e s is  o f  In te r m e d ia te s  and  A n a lo g u e s  o f  Ins(l,4,5)P3 B a sed  
o n  A d e n o p h o stin  A
6.5.1 Methyl 3,4-di-0-benzoyl-2,6-di-0-benzyl-a-D-glucopyranoside (249)
The method employed is a modification of that described by Garegg et a /..281 Hydrogen 
chloride in diethyl ether was added at room temperature under an atmosphere of 
nitrogen to a mixture of (144) (502mg, l.lmmol), sodium cyanoborohydride (876mg, 
13.9mmol), 3 A molecular sieves and dry THF (10cm3) until the evolution of gas ceased. 
The system was stirred at room temperature for 20 min, when TLC (ethyl acetate : 
hexane 3:2) indicated complete consumption of starting material (Rf 0.66) to give a 
product (R{ 0.63). The suspension was diluted with ether (100cm3) and filtered. The 
filtrate was washed with water (100cm3) and saturated aqueous NaHC03 solution 
(100cm3), dried (MgS04), filtered and concentrated to give a pale yellow oil, which was 
subjected to flash chromatography (eluent hexane : ethyl acetate 7:3). The product was 
dissolved in dry pyridine (5cm3) and stirred with DMAP (25mg) and benzoyl chloride 
(0.25cm3,2.2mmol) for 1 h. Methanol (1cm3) was added and stirring was continued for 
15 min. The solvents were evaporated and the residue was extracted with ether 
(100cm3). The organic extract was washed with 5m  aqueous HC1 (50cm3), saturated 
aqueous NaHC03 solution (50cm3) and saturated aqueous NaCl (50cm3), dried 
(MgS04), filtered and concentrated. The oil thus obtained was purified by flash 
chromatography (eluent hexane : ethyl acetate 4:1) to give (249) as a colourless oil 
(482mg, 79% from 144); R{ 0.74 (ether); m.p. 123-123.5°C (ethyl acetate-hexane); [a]D 
-27.5 (c 3.8, CHC13); (Found: C, 71.8; H,.5.66. Calc, for C35H34Og: C, 72.14; H, 
5.89%); 6h (CDC13; 270MHz) 3.47 (3 H, s, OCH3), 3.55 (1 H, ABX, 2JAB 13.7, V  4.4, 
6-H), 3.61 (1 H, dd, 2J^  13.7, V 2.8, 6-H’), 3.78 (1 H, dd, J  3.5, 9.9, 2-H), 4.12 (1 H, 
ddd, J  2.8,4.4, 9.8, 5-H), 4.48,4.54 (2 H, AB, J ^  12.1, PhCtf20), 4.60, 4.62 (2 H, AB, 
JAb 12.0, PhCtf20), 4.80 (1 H, d, J  3.5, 1-H), 5.49 (1 H, t, J  9.9, 3-H), 5.92 (1 H, t, J 
9.9, 4-H), 7.15-7.52 (16 H, m, aromatic CH), 7.86-7.94 (4 H, m, 2-H and 6-H of 
benzoyl rings); 8C (CDC13; 67.8MHz) 55.43 (OCH3), 68.41 (6-C), 68.63, 69.54, 72.14 
(3-C, 4-C, 5-C), 72.95, 73.59 (2 x PhCH20), 76.81 (2-C), 97.89 (1-C), 127.50, 127.70, 
127.86, 127.94, 128.18, 128.31, 129.91, 129.50 (aromatic CH), 129.67 (1-C of benzoyl
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ring), 129.71 (aromatic CH), 129.77 (1-C of benzoyl ring), 132.82, 133.08 (aromatic 
CH), 137.49, 137.54 (2 x 1-C of benzyl rings), 165.32, 165.56 (2 x PhC02); m/z: 
(FAB+) 583 [(M+l)+, 11%].
6.5.2 Acetolysis of (249)
The method employed is a modification of that described by Come.216 A solution of 
(249) (480mg, 0.8mmol) in acetic anhydride (10cm3) was stirred with freshly distilled, 
dry boron trifluoride etherate (0.1cm3) at 0°C under an atmosphere of nitrogen for 20 
min, when TLC (ether) indicated complete consumption of starting material (Rf 0.74) to 
give a minor product (R{ 0.68) and a major product (R{ 0.62). The reaction was 
quenched with saturated aqueous NaHC03 solution (5cm3) and the mixture was 
extracted with ethyl acetate (200cm3). The organic extract was washed with saturated 
aqueous NaHC03 solution (50cm3) and water (50cm3), dried (MgS04), filtered and 
concentrated. The pale yellow oil thus obtained was subjected to flash chromatography 
(eluent hexane : ethyl acetate 4:1) to give l,6-di-O-acetyl-3,4-di-0-benzoyl-2-Obenzyl- 
D-glucopyranose (251) as a pale yellow oil which ran as a single spot on TLC (ether) but 
which was shown by *H NMR to be a ca. 3:1 a:p anomeric mixture (31mg, 7%); 5H 
(CDC13; 270MHz) 2.02, 2.26 (6 H, 2s, 2 x CH3C02), 3.87 (0.7 H, dd, J  3.7, 10.0, 2-HJ, 
4.09-4.34 (3.3 H, m, 2-Hp, 5-H, 6-H, 6-H’), 4.51, 4.64 (2 H, AB, 7AB 12.2, PhC//20),
5.48 (1 H, t, J  9.7, 3-H), 5.82 (0.3 H, d, J 7.4, 1-Hp), 5.90 (1 H, t, J  9.8, 4-H), 6.48 (0.7 
H, d, J  3.7, 1-HJ, 7.12-7.57 (11 H, m, aromatic CH), 7.85-7.97 (4 H, m, 2-H and 6-H 
of benzoyl rings). The a  and P subscripts denote signals arising from the a- and P- 
anomers respectively.
Further elution gave methyl 6-0-acetyl-3,4-di-0-benzoyl-2-0-benzyl-a-D- 
glucopyranoside (250) as a colourless oil which spontaneously crystallised on standing 
(283mg, 64%); m.p. 76-78.5°C; [a]D -23.5 (c 2.3, CHC13); (Found: C, 67.3; H, 5.56. 
Calc, for C30H30O9: C, 67.39; H, 5.66%); 8H (CDC13; 270MHz) 2.05 (3 H, s, CH3C 02),
3.48 (3 H, s, OCH3), 3.77 (1 H, dd, J  3.7, 10.0, 2-H), 4.12^1.29 (3 H, m, 5-H, 6-H, 6- 
H'), 4.60, 4.63 (2 H, AB, 7 ^  12.0, PhC//20), 4.79 (1 H, d, 7 3.5, 1-H), 5.40 (1 H, t, J
9.7, 3-H), 5.94 (1 H, t, J  9.7, 4-H), 7.26-7.58 (11 H, m, aromatic CH), 7.80-7.98 (4 H, 
m, 2-H and 6-H of benzoyl rings); 5C (CDC13; 67.8MHz) 20.71 (CH3C02), 55.63
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(OCH3), 62.58 (6-C), 67.45, 69.49, 71.88 (3-C, 4-C, 5-C), 73.06 (PhCH20),76.58 (2-C),
98.05 (1-C), 127.99, 128.28, 128.38, 128.44 (aromatic CH), 129.00 (1-C of benzoyl 
ring[s]), 129.74, 129.84, 132.98, 133.34 (aromatic CH), 137.49 (1-C of benzyl 
ring),165.48, 165.58 (2 x PhC02),170.61 (CH3C02); m/z (FAB+) 535 [(M+l)+, 6%].
6.5.3 Allyl a-D-glucopyranoside (254a)
The method employed is a modification of that described by Lee and Lee.290 A mixture 
of D-glucose (18g, 0.1 mole), Dowex 50X2-100 (lOg) and allyl alcohol (200cm3) was 
heated under reflux for 90 min. The suspension was cooled, filtered and the residue was 
well washed with ethanol (30cm3). The combined filtrate and washings were 
concentrated and the syrupy residue was subjected to flash chromatography (loading 
solvent and eluent ethyl acetate : methanol 9:1). The eluate was concentrated to give a 
white solid (254ab), which was shown by *H NMR (D20; 270MHz; ref. int. HDO) to be 
a ca. 7:3 a:p anomeric ratio (1-Ha, 8 4.92, J 3.7; 1-Hp 8 4.46, J  7.9). Fractional 
crystallisation from ethyl acetate-ethanol (ca. 1:1) gave the pure cc-anomer (254a) (3.1g, 
14%); m.p. 99-100°C [lit.288 100.5-101.5°C]; [a]D +140.6 (c 1.4, H20) [lit.288 +151.1].
6.5.4 Allyl 2,6-di-0-benzoyl-a-D-glucopyranoside (261)
A mixture of (254ab) (5.0g, 22.7mmol) and dibutyltin oxide (5.9g, 23.8mmol) was 
heated under reflux in dry toluene (150cm3) for 2h with continuous azeotropic removal 
of water (Dean-Stark trap). The solution was cooled to 0°C and triethylamine (1cm3) 
and benzoyl chloride (5.5cm3, 47.7mmol, dropwise) were added. The solution was 
allowed to warm to room temperature and was stirred for a further 16 h, when TLC 
(ethyl acetate) indicated a major product (Rf 0.63) and several minor products. 
Methanol (10cm3) was added and stirring was continued for 5 min. The solvents were 
evaporated and the residue was taken up in ether (250cm3). The solution was stirred 
with saturated aqueous NaHC03 solution (150cm3) for 30 min and the resulting 
suspension was filtered through Celite. The ethereal layer was dried (MgS04), filtered 
and concentrated to give an orange oil, which was subjected to flash chromatography 
(eluent hexane : ethyl acetate 7:3). The eluate was concentrated and the residue was
180
crystallised from ethanol to give the title compound (3.4g, 35%); m.p. 135-136°C 
[lit »* 136-137°C]; [a]D +70.1 (c 4.3, CHC13) [lit.29» +74].
6.5.5 Allyl 2,6-di-0-benzoyI-3,4-0-isopropylidene-a-D-glucopyranoside (262)
A solution of (261) (1.2g, 2.8mmol) in acetone (30cm3) was stirred with p- 
toluenesulphonic acid (30mg) and 2-methoxypropene (1.5cm3, 15.7mmol) at room 
temperature for 5 min, when TLC (hexane : ethyl acetate 3:2) indicated complete 
conversion of starting material (R{ 0.13) to a product (Rf 0.48). The solvents were 
evaporated and the residue dissolved in ether (50cm3). The organic extract was washed 
with saturated aqueous NaHC03 solution (30cm3), dried (MgS04), filtered and 
concentrated. The residue was purified by flash chromatography (eluent hexane : ethyl 
acetate 19:1 then 17:3) to give the title compound as a pale yellow oil (774mg, 59%); 
[a]D +69.4 (c 2.2, CHC13); (Found: C, 66.9; H, 6.20. Calc, for C26H28Og: C, 66.64; H, 
6.03%); 5h (CDC13; 400MHz) 1.47, 1.50 (6 H, 2 s, 2 x isopropylidene CH3), 3.54 (1 H, 
t, J  9.3,4-H), 4.03 (1 H, m, C//HCH=CH2), 4.19-4.32 (3 H, m, CH//CH=CH2 , 3-H, 5- 
H), 4.48 (1 H, ABX, 12.2,37 6.3, 6-H), 4.68 (1 H, ABX, 2/ AB 12.2, 37 2.4, 6-H'),
5.10 (1 H, m, 3J  10.3, 2J 1.0, CH2CH=C/fc/jH/raJ ,  5.19-5.25 (2 H, m, 
CH2CH=CHcbHtnua, 2-H)» 5 36 0  H» d»J  3-4> i-K). 5 80 0  H* m* CH2C//=CH2), 7.43-
7.59 (6 H, m, aromatic CH), 8.06-8.11 (4 H, m, aromatic CH); 8C (CDC13; 100MHz) 
26.56, 26.82 (2 x isopropylidene CH3), 64.01 (6-C), 69.12 (CH2CH=CH2), 70.01, 73.20, 
74.76, 75.45 (4 x CH), 95.74 (1-C), 111.56 (Cq of isopropylidene), 117.85 
(CH2CH=CH2), 128.38, 128.44 (aromatic CH), 129.48 (1-C of benzoyl phenyl ring),
129.68 (aromatic CH), 129.94 (1-C of benzoyl phenyl ring), 129.99 (aromatic CH), 
133.16 (aromatic CH), 133.34 (CH2CH=CH2),-133.47 (aromatic CH), 165.95, 166.19 (2 
x PhC02); m/z (FAB+) 469 [(M+l)+, 74%].
6.5.6 Allyl 3,4-0-isopropylidene-a-D-glucopyranoside (263)
Sodium hydroxide (514mg, 12.9mmol) was added to a solution of (262) (1.5g, 
3.2mmol) in methanol (100cm3) and the mixture was heated under reflux for 1 h. After 
cooling, carbon dioxide was bubbled through the cooled solution for 16 h. The solvent 
was evaporated and the glassy residue was extracted with chloroform (2 x 100cm3). The
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combined organic extracts were washed with water (100cm3), dried (MgS04), filtered 
and concentrated. The resultant residue was purified by flash chromatography (eluent 
hexane : ethyl acetate 7:3 then 1:1) to give the title compound as a colourless oil 
(779mg, 93%); R{ 0.35 (ethyl acetate); [a]D +114.0 (c 1.3, CHC13); (Found: C, 55.2; H,
8.05. Calc, for C12H20O6: C, 55.36; H, 7.75%); 8H 1.45, 1.46 (6 H, 2 s, 2 x 
isopropylidene CH3), 2.07 (1 H, br s, exch. D20, 6-OH), 2.40 (1 H, d, J  10.4, exch. D20,
2-OH), 3.30 (1 H, t, J 9.2, 4-H), 3.73-3.92 (5 H, m, 2-H, 3-H, 5-H, 6-H, 6-H'), 4.04-
4.11 (1 H, m, C/fHCH=CH2), 4.23-4.30 (1 H, m, CH/fCH=CH2), 5.01 (1 H, d ,/3 .8 , 1- 
H), 5.25 (1 H, m, V 10.3, 2/.1.4, CH2CH=C//aJH/raJ ,  5.32 (1 H, m, 37 17.2, 27 1.5, 
CH2CH=CHcisHtrans), 5.92 (1 H, m, CH2CH=CH2); 8C (CDC13; 67.8MHz) 26.42, 26.79 
(2 x isopropylidene CH3), 62.40 (6-C), 69.07 (CH2CH=CH2), 71.83, 72.39, 73.98, 78.75 
(4 x CH), 97.97 (1-C), 111.12 (Cq of isopropylidene), 118.19 (CH2CH=CH2), 133.34 
(CH2CH=CH2); m/z (FAB+) 261 [(M+l)+, 78%].
6.5.7 Allyl 2,6-di-0-benzyl-a-D-gIucopyranoside (265)
A mixture of (254a) (2.0g, 9.1 mmol) and dibutyltin oxide (5.7g, 22.7mmol) was heated 
under reflux in dry toluene (300cm3) for 4 h with continuous azeotropic removal of 
water (Dean-Stark trap). The solution was cooled and concentrated to give a white 
residue which was dried on a vacuum line for 2 h. Benzyl bromide (18cm3, 151.4mmol) 
was added and this mixture was stirred under an atmosphere of nitrogen at 100-110°C 
for 2 days. The pale yellow solution thus obtained was cooled, diluted with ether 
(100cm3) and vigorously stirred with saturated aqueous NaHC03 solution (75cm3) for 
30 min. The resultant suspension was filtered through Celite and the organic layer was 
dried (MgS04), filtered and concentrated. Flash chromatography (eluent hexane : ethyl 
acetate 8:2 to remove benzyl bromide then 1:1) gave a mixture of benzylated products 
(2.8g, Rf 0.30-0.51 in ethyl acetate). Crystallisation from diisopropyl ether gave 
exclusively the title compound (1.6g, 44%); R{ 0.22 (ethyl acetate : hexane 3:2); m.p. 
74_77°C; [tx]D +76.4 (c 0.8, CHC13); (Found: C, 68.8; H, 7.08. Calc, for C23H280 6: C, 
68.97; H, 7.05%); 8H (CDC13; 270MHz) 3.12 (2 H, br s, exch. D20 , 2 x OH), 3.37 (1 H, 
dd, J  3.7, 9.7, 2-H), 3.58 (1 H, t, J 9.2, 4-H), 3.68-3.78 (3 H, m, 5-H, 6-H, 6-H'), 3.88- 
3.98 (2 H, m, 3-H, CtfHCH=CH2), 4.10-4.15 (1 H, m, CHtfCH=CH2), 4.54,4.59 (2 H,
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AB, 12.2, PhCtf20), 4.62,4.67 (2 H, AB, 7^  12.1, PhCtf20), 4.81 (1 H, d, 73.5, 1- 
H), 5.18 (1 H, m, 37 10.3, 27 1.0, CH2CH=C//njHfrflJ ,  5.29 (1 H, m, 37 17.2, 27 1.0, 
CH2CH=CHdj/ftra/w), 5.89 (1 H, m, CH2C/f=CH2), 7.25-7.33 (10 H, m, aromatic CH); 8 
c (CDC13; 67.8MHz) 68.29 (CH2CH=CH2), 69.44 (6-C), 70.03, 70.74, 72.72 (3 x CH),
72.75, 73.49 (2 x PhCH20), 79.08 (2-C), 95.46 (1-C), 117.87 (CH2CH=CH2), 127.58,
127.96, 128.05, 128.31, 128.46 (aromatic CH), 133.71 (CH2CH=CH2), 137.90, 137.96 
(2 x 1-C of benzyl rings); m/z: (FAB") 553 [(M+NBA)", 100%]
A sample of (265) was converted to its 3,4-dibenzoate (266) with benzoyl chloride in 
pyridine in the usual way, Rf 0.72 (ethyl acetate : hexane 3:2); [a]D -10.0 (c 1.4, 
CHC13); 5h (CDC13; 400MHz) 3.57-3.61 (2 H, m, 6-H, 6-H’), 3.80 (1 H, dd, 7 3.9, 10.1,
2-H), 4.08 (1 H, m, CHHCH=CH2), 4.19 (1 H, ddd, 7 5.7, 9.3, 9.8, 5-H), 4.25 (1 H, m, 
CHtfCH=CH2), 4.45-4.60 (4 H, m, 2 x PhC//20  AB systems), 5.00 (1 H, d, 7 3.4, 1-H), 
5.25 (1 H, m, 37 10.3, 27 1.5, CH2CH=C//djH,rflJ ,  5.38 (1 H, m, 37 17.6, 27 1.5, 
CH2CH=CHcisHtrans), 5.52 (1 H, t, 7 10.3, 4-H), 5.95-6.00 (2 H, m, t of 3-H overlapping 
with CH2CH=CH2), 7.14-8.13 (20 H, m, aromatic CH).
The mother liquor of the benzylation mixture was reacted with 2-methoxypropene and 
p-toluenesulphonic acid in acetone as described for (262). A single new product was 
formed by TLC (Rf 0.71 in ethyl acetate : hexane 3:2). Purification and flash 
chromatography as for (262) gave allyl 2,3-di-0-benzyl-4,6-CMsopropylidene-a-D- 
glucopyranoside (267) as a pale yellow oil (480mg, 12% from 254a); [a]D +26.5 (c 0.7, 
CHC13); (Found: C, 71.1; H, 7.40. Calc, for C26H320 6: C, 70.89; H, 7.32%); ^  (CDC13; 
400MHz) 1.43, 1.48 (6 H, 2 s, 2 x isopropylidene CH3), 3.50 (1 H, dd, 7 3.9, 9.3, 2-H), 
3.61-3.72 (3 H, m, 4-H, 5-H, 6 -H J, 3.83 (1 H, dd, 7 3.4, 8.3, 6-H*,), 3.90 (1 H, 7 9.3,
3-H), 3.97-4.03 (1 H, m, CHHCH=CH2), 4.14-4.18 (1 H, m, CH//CH=CH2), 4.65,4.81 
(2 H, AB, 7 ^  12.2, PhCtf20), 4.75 (1 H, d, 7 3.4, 1-H), 4.80, 4.85 (2 H, AB, 7 ^  11.7, 
PhCtf20), 5.23 (1 H, m, 37 10.3, 27 1.0, CH2CH=CHcisi l trans), 5.32 (1 H, m, 37 17.1, 27
1.0, CH2CH=CHCIJ//,rflJ ,  5.93 (1 H, m, CH2Ctf=CH2), 7.24-7.39 (10 H, m, aromatic 
CH); 8C (CDC13; 67.8MHz) 19.18 (axial CH3 of isopropylidene), 29.22 (equatorial CH3 
of isopropylidene), 62.58 (6-C), 63.37 (CH), 68.36 (CH2CH=CH2), 73.57 (PhCH20), 
74.91 (CH), 75.07 (PhCH20), 78.99, 79.11 (2-C, 3-C), 96.78 (1-C), 99.34 (Cq of
183
isopropylidene), 118.23 (CH2CH=CH2), 127.43, 127.78, 127.85, 128.02, 128.22, 128.36 
(aromatic CH), 133.69 (CH2CH=CH2), 138.29, 139.08 (2 x 1-C of benzyl rings); m/z 
(FAB+) 441 [(M+l)+, 40%].
6.5.8 Allyl 2,6-di-0-benzyl-3,4-0-isopropylidene-a-D-gIucopyranoside (264)
a) A solution of (263) (717mg, 2.8mmol) in dry DMF (5cm3) was stirred with sodium 
hydride (215mg of an 80%w/w dispersion in mineral oil, 6.9mmol) and benzyl bromide 
(0.7cm3, 6.1 mmol) at room temperature for 3 h. Methanol (5cm3) was added and 
stirring was continued for 15 min. The solvents were evaporated and the residue was 
dissolved in ether (100cm3). The ethereal extract was washed with water (50cm3), dried 
(MgS04), filtered and concentrated. The residual oil was purified by flash 
chromatography (eluent hexane : ethyl acetate 19:1) to give the title compound as a pale 
yellow oil (922mg, 76%); R{ 0.68 (hexane:ethyl acetate 2:3); [a]D +27.8 (c 2.0, CHC13); 
(Found: C, 70.9; H, 7.38. Calc, for C26H320 6: C, 70.89; H, 7.32%); 8** (CDC13; 
400MHz) 1.45, 1.47 (6 H, 2 s, 2 x isopropylidene CH3), 3.34 (1 H, t, J  9.8,4-H), 3.61 (1 
H, ABX, Vab 10.7,37 5.4, 6-H), 3.70 (1 H, dd, J  2.4, 10.3, 2-H), 3.74 (1 H, ABX, VAB
10.7, 3J  2.4, 6-H’), 3.97-4.03 (3 H, m, 3-H, 5-H, CtfHCH=CH2), 4.13-4.21 (1 H, m, 
CHtfCH=CH2), 4.59,4.60 (2 H, AB, J ^  12.7, PhC//20), 4.63,4.84 (2 H, AB, J ^  12.2, 
PhCtf20), 4.92 (1 H, d, J  3.4, 1-H), 5.19 (1 H, m, 3J  10.7, V 1.4, CH2CH=CHcisHtr(ms),
5.33 (1 H, m, V 17.1, V  1.5, CH2CH=CHCIJtf,raJ ,  5.92 (1 H, m, CH2Ctf=CH2), 7.25-
7.58 (10 H, m, aromatic CH); 8C (CDC13; 100MHz) 26.54, 26.92 (2 x isopropylidene 
CH3), 68.65 (CH2CH=CH2), 69.42 (6-C), 71.01 (CH), 71.96, 73.41 (2 x PhCH20),
74.32, 77.60, 77.83 (3 x CH), 96.80 (1-C), 110.75 (Cq of isopropylidene), 117.90 
(CH2CH=CH2), 127.47, 127.56, 127.74, 1-28.02, 128.35 (aromatic CH), 133.83 
(CH2CH=CH2), 138.11 (1-C of benzyl ring[s]); m/z: (FAB+)441 [(M+l)+, 12%].
b) Using the method for the preparation of (262) from (261), the title compound was 
prepared in 71% yield from (265).
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6.5.9 Allyl 2,6-di-0-benzyI-3,4-di-0-(p-methoxybenzyI)-a-D-gIucopyranoside (257)
A solution of (265) (1.9g, 4.7mmol) in dry DMF (10cm3) was stirred with sodium 
hydride (326mg of an 80%w/w dispersion in mineral oil, 10.4mmol) and p- 
methoxybenzyl chloride (1.4cm3, lO.Ommol) at room temperature for 3 h, when TLC 
(ethyl acetate : hexane 3:2) indicated consumption of starting material (Rf 0.27) to give a 
product (R{ 0.71). Methanol (5cm3) was added and stirring was continued for 15 min. 
The solvents were evaporated and the residue was dissolved in chloroform (200cm3). 
The organic solution was washed with water (100cm3), dried (MgS04), filtered and 
concentrated. The residual oil was purified by flash chromatography (eluent hexane : 
ethyl acetate 19:1) to give the title compound as a pale yellow oil (2.2g, 72%); [a]D 
+13.8 (c 1.9, CHC13); (Found: C, 73.4; H, 6.88. Calc, for C39H4408: C, 73.09; H, 
6.93%); 6h (CDC13; 400MHz) 3.55 (1 H, dd, J 3.7, 9.7, 2-H), 3.57-3.64 (2 H, m, 4-H, 6- 
H), 3.68-3.80 (2 H, m, 5-H, 6-H’), 3.77, 3.80 (6 H, 2 s, 2 x OCH3), 3.95^1.18 (3 H, m,
3-H, CH2CH=CH2), 4.36-4.94 (9 H, m, 4 x Ai CH20  AB systems, 1-H), 5.19 (1 H, m, 37 
10.4, V 0.9, CH2CH=C//dJHfrflJ ,  5.29 (1 H, m, 3J  17.2, V  1.0, CH2CH=CHa/ / fmJ ,  
5.90 (1 H, m, CH2CZf=CH2), 6.78-6.88 (4 H, m, 2 x 3-H and 5-H of PMB rings), 7.04 
(2 H, d, J  8.5, 2-H and 6-H of PMB ring), 7.24-7.38 (12 H, m, aromatic CH); 5C 
(CDC13; 67.8MHz) 55.24 (OCH3), 68.15, 68.45 (6-C and CH2CH=CH2), 70.27 (5-C), 
73.17, 73.40, 74.63, 75.36 (4 x ArCH20), 77.39, 79.94, 81.88 (2-C, 3-C, 4-C)), 95.72 
(1-C), 113.75, 113.78 (3-C and 5-C of PMB rings), 118.06 (CH2CH=CH2), 127.60,
127.78, 127.83, 128.02, 128.31, 128.36, 129.48, 129.53 (aromatic CH), 131.13 (1-C of 
PMB ring[s]), 133.79 (CH2CH=CH2), 137.99, 138.27 (2 x 1-C of benzyl rings), 159.19,
159.14 (2 x 4-C of PMB rings); m/z: (FAB+) 641 [(M+l)+, 10%].
6.5.10 (cis-Prop-1-eny I) 2,6-di-0-benzyI-3,4-di-0-(p-methoxybenzyI)-(x-D-gluco-
pyranoside (269a)
A solution of (257) (2.0g, 3.1mmol), and freshly sublimed potassium f-butoxide (1.8g, 
15.6mmol) in diy DMSO (20cm3) was stirred at 50°C under an atmosphere of nitrogen 
for 3 h, when TLC (CHC13 : acetone 10:1) indicated total consumption of starting 
material (Rf 0.66) to give a product (Rf 0.71). The dark brown solution was cooled, 
water (20cm3) was added and the system was extracted with ether (3 x 100cm3). The
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combined organic extracts were washed with saturated aqueous KC1 solution (2 x 
150cm3), dried (MgS04), filtered and concentrated. The pale yellow oil thus obtained 
was purified by flash chromatography (eluent hexane : ethyl acetate 4:1) to give a 
mixture of trans and cw-prop-l-enyl isomers (269ab) (1.7g, 85%). A portion was 
recolumned twice with the same solvent system to provide an analytical sample of the 
pure cis isomer (269a) as a pale yellow oil; [a]D +2.9 (c 1.4, CHC13); (Found: C, 73.2; 
H, 6.89. Calc, for C39H4408: C, 73.09; H, 6.93%); 5H (CDC13; 270MHz) 1.63 (3 H, dd, 
4J  1.5,37 6.8, CH=CHC/f3), 3.56-3.80 (5 H, m, 2-H, 4-H, 5-H, 6-H, 6-H'), 3.77, 3.80 (6 
H, 2 s, 2 x OCH3), 4.02 (1 H, t, J  9.2, 3-H), 4.39-4.94 (10 H, m, 4 x ArCtf20  AB 
systems, 1-H, CH=CtfCH3), 6.00 (1 H, dd, V  1.5, V 3.6, C//=CHCH3), 6.78-6.89 (4 H, 
m, 2 x 3-H and 5-H of PMB rings), 7.05 (2 H, d, J  8.6, 2-H and 6-H of PMB ring), 
7.24-7.34 (12 H, m, aromatic CH); 5C (CDC13; 100MHz) 9.62 (CH=CHCH3), 55.27 
(OCH3), 68.16 (6-C), 70.75 (5-C), 73.23, 73.37, 74.78, 75.40 (4 x ArCH20), 77.12, 
79.61, 81.73 (2-C, 3-C, 4-C), 97.46 (1-C), 104.46 (CH=CHCH3), 113.81 (3-C and 5-C 
of PMB ring[s]), 127.69, 127.87, 127.96, 128.35, 128.46, 129.52, 129.59, 129.63 
(aromatic CH), 130.39, 131.03 (2 x 1-C of PMB rings), 137.89, 138.24 (2 x 1-C of 
benzyl rings), 142.21 (CH=CHCH3), 159.18, 159.25 (2 x 4-C of PMB rings); m/z: 
(FAB+) 641 [(M+l)+, 20%].
6.5.11 2,6-Di-0-benzyl-3,4-di-O-(p-methoxybenzyl)-D-glucopyranose (240)
A solution of (269ab) (1.5g, 2.3mmol) in acetone (50cm3) was heated to 50°C (oil 
bath). Aqueous 1m HC1 (5cm3) was added and stirring was continued for 20 min, when 
TLC (chloroform : acetone 10:1) indicated total consumption of starting material (Rt 
0.70) to give a product (/?f 0.28). Solid NaHC03 (2g) was added and stirring was 
continued as the suspension was allowed to cool to room temperature. The solvents 
were evaporated and the residue was extracted with ether (3 x 100cm3). The combined 
organic extracts were washed with saturated aqueous NaHC03 solution (150cm3) and 
water (150cm3), dried (MgS04), filtered and concentrated. Recrystallisation from a 
minimum of ether gave the title compound (l.lg , 77%), which reduced Fehling’s 
solution; m.p. 120-131°C; [oc]D +5.1 (c 1.4, CHC13, 2 h); (Found: C, 71.8; H, 6.66. Calc, 
for C36H40O8: C, 71.97; H, 6.72%); 5H (CDC13; 270MHz) 1.64 (0.5 H, s, exch. D20 , OH
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p), 3.09 (0.5 H, d, J 2.6, exch. D20 , OHa), 3.37 (0.5 H, dd, J  7.6, 9.9, 2-Hp), 3.48-3.80 
(4.5 H, m, 2-Ha, 3-Ha or 3-Hp, 5-Ha or 5-Hp, 4-H, 6-H, 6-H'), 3.78, 3.80 (6 H, 2 s, 2 x 
OCH3), 3.94 (0.5 H, t, J  9.2, 3-Ha or 3-Hp), 4.01 (0.5 H, ddd overlapping with t at 
3.94ppm, 5-Ha or 5-Hp), 4.39-4.93 (8.5 H, 1-Hp, 4 x ArCtf20  AB systems), 5.21 (0.5 
H, t, J  2.6, simplifies to d on D20  exch., 1-Ha), 6.79-6.88 (4 H, m, 2 x 3-H and 5-H of 
PMB rings), 7.02-7.07 (2 H, m, 2-H and 6-H of PMB ring), 7.21-7.34 (12 H, m, 
aromatic CH). The a  and p subscripts denote signals arising from the a- and p-anomers 
respectively; mlz: (FAB- ) 753 [(M+NBA)', 100%].
6.5.12 (2-HydroxyethyI) 2,6-di-O-benzyl-a-D-glucopyranoside (270)
The method employed is a modification of that described by Ferrier and Stiitz.185 A 
saturated aqueous solution of sodium metaperiodate (20cm3) containing osmium 
tetraoxide (80mg, 0.3mmol) was added to a solution of (264) (392mg, 0.9mmol) in ether 
(20cm3) and the mixture was vigorously stirred at room temperature for 5 h, when TLC 
(ethyl acetate : hexane 2:3) indicated consumption of starting material (R{ 0.56) to give a 
product (R{ 0.08-0.18). The mixture was diluted with ether (100cm3) and water (50cm3) 
and the organic layer was dried (MgS04), filtered and concentrated to give a dark grey 
residue which was dissolved in methanol (30cm3) and cooled to 0°C. Sodium 
borohydride (480mg, 12.7mmol) was added and the suspension was stirred for 1 h. The 
mixture was concentrated and the residue partitioned between ether (100cm3) and water 
(50cm3). The organic layer was dried (MgS04), filtered and concentrated. Purification 
by flash chromatography (eluent hexane : ethyl acetate 1:1 then ethyl acetate) gave the 
title compound as a colourless oil (203mg, 56%); R{ 0.52 (ethyl acetate : MeOH 4:1); [a 
]D +48.2 (c 2.6, CHC13); (Found: C, 65.6; H, 7.12. Calc, for C22H280 7: C, 65.32; H, 
6.98%); 5h (400MHz; CDC13) 3.35 (1 H, dd, J  3.4, 9.8, 2-H), 3.38-3.43 (1 H, m, 
-C//HCH2-), 3.45 (1 H, t, J  9.3, 4-H), 3.58-3.69 (6 H, m, simplifies to 5 H, m, on D20  
exch, OH, 6-H, 6-H’, -CHHCH2-), 3.74 (1 H, ddd, J  2.4, 4.9, 9.8, 5-H), 3.83 (2 H, br s, 
exch D20, 2 x OH), 3.97 (1 H, t, J 9.8, 3-H), 4.50, 4.55 (2 H, AB, JAB 12.2, PhCtf20), 
4.56 (1 H, AB, JAb 12.2, PhCtfHO), 4.66 (1 H, d, J 3.9, 1-H), 4.73 (1 H, AB, JAB 12.2, 
PhCH/ZO), 7.23-7.36 (10 H, m, aromatic CH); 8C (100MHz; CDC13) 61.47 (2'-C), 69.37 
(6-C), 70.28 ( l’-C), 70.50, 70.63, 72.88 (3-C, 4-C, 5-C), 73.55 (2 x PhCH20), 79.52 (2-
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C), 97.15 (1-C), 127.67, 127.71, 128.33, 128.38, 128.44, 128.66 (aromatic CH), 137.54,
138.00 (2 x 1-C of benzyl rings); m/z (FAB") 403 (M -l)', 50%; 557 (M+NBA)", 100%.
6.5.13 (2-Hydroxyethyl) 2,6-di-0-benzyl-2',3,4-tris(dibenzyIphospho)-a-D- 
glucopyranoside (271)
A mixture of bis(benzyloxy)(diisopropylamino)phosphine (565mg, 1.6mmol), dry 
dichloromethane (3cm3) and 1 /f-tetrazole (220mg, 3.1mmol) was stirred at room 
temperature for 15 min, whereupon a solution of (270) (106mg, 0.26mmol) in dry 
dichloromethane (2cm3) was added and stirring was continued for a further 30 min. 
TLC (ethyl acetate) indicated complete conversion of starting material (R{ 0.17) to a 
product (Rf 0.76 with streaking) and 31P NMR spectroscopy showed phosphite triester 
signals at 140.72, 141.31 (AB, 7AB 4.9) and 139.05ppm. The system was cooled to -  
78°C, m-chlorperoxybenzoic acid (900mg) was added and the system was warmed to 
room temperature. After 10 min TLC showed conversion of the trisphosphite to a new 
product (R{ 0.46). The mixture was extracted with ethyl acetate (100cm3) and the 
organic extract was washed with 50cm3 each of 1 0 % w/v aqueous Na2S03 solution, 1m 
HCl, saturated aqueous NaHC03 solution and saturated aqueous NaCl solution. The 
organic solution was dried (MgS04), filtered and concentrated to give a pale yellow 
solid, which was purified by flash chromatography (eluent CHC13 : acetone 20:1 then 
10:1) to give the title compound as a colourless oil (247mg, 80%); [a]D +12.5 (c 1.2, 
CHC13); (Found: C, 65.1; H, 5.62. Calc, for C ^ H ^ O ^ :  C, 64.84; H, 5.70%); ^  
(CDC13; 400MHz) 3.45-3.51 (1 H, m, OC//HCH2OP[0][OBn]2), 3.56 (1 H, dd, J  3.4,
9.3, 2-H), 3.65-3.70 (2 H, m, 6-H, 0CHtfCH20P[0][0Bn]2), 3.73-3.77 (1 H, ABX, 
VAB 10.7, 3J 3.9, 6-H'), 3.89 (1 H, ddd, J  3.9, 9.3, 9.8, 5-H), 4.09-4.17 (2 H, m, 
0CH2Ctf20P[0][0Bn]2), 4.32,4.45 (2 H, AB, / AB 11.7, PhCtf20), 4.43-^1.48 (1 H, AB, 
PhCtfHO), 4.61-4.68 (3 H, m, PhCH/fO, 3-H, 4-H), 4.86-5.07 (13 H, m, 6 x PhC/J20  
AB systems, 1-H), 7.12-7.32 (40 H, m, aromatic CH); 8C (CDC13; 100MHz) 66.10, 
66.95 (2'-C[with C-P coupling]), 68.00 (6-C or l ’-C), 66.94, 69.15 (POCH2Ph [with C-P 
coupling]), 69.35, 69.40, 69.73 (6 x POCH2Ph), 73.08, 73.21 (2 x PhCH20), 74.40,
77.91, 78.42, 78.46 (4 x CH), 96.69 (1-C), 127.50, 127.61, 127.74, 127.85, 127.91,
128.00, 128.03, 128.24, 128.31, 128.40, 128.47, 128.58 (aromatic CH), 135.72, 135.79, 
135.86,135.92,136.15,136.23 (6 x 1-C of benzylphospho rings), 137.95, 138.07 (2 x 1-
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C of benzyl rings); 5P (CDC13; 162MHz) -2.29 (sextet, 7HP 8.0), -1.85 (sextet, / HP 7.6), 
-0 .89 (septet, 7HP 7.9, 0CH 2CH2 0P [0][0B n ]2); m/z: (FAB+) 641 [(M+l)+, 10%].
6.5.14 (2-Hydroxyethyl) a-D-glucopyranoside 2',3,4-trisphosphate (235)
Ammonia was condensed into a three-necked flask at -78°C. An excess of sodium was 
added to dry the liquid ammonia, about 30cm3 of which was then distilled into a second 
three-necked flask and kept at -78°C. Sodium was added until the solution remained 
blue for 10 min. A solution of (271) (106mg) in dry dioxane (2cm3) was added. The 
mixture was stirred for 90 sec, then the reaction was quenched with methanol (1cm3), 
followed by water (1cm3). The solvents were evaporated. The residue was dissolved in 
de-ionised water (300cm3) and purified by ion-exchange chromatography on Q 
Sepharose fast flow, eluting with a gradient of triethylammonium bicarbonate buffer (0 -  
1 m ) ,  pH 8.0 . The triethylammonium salt of (235) eluted between 470-550 mM buffer; 
[a]D +90.5 (c 0.8 calc, for free acid, TEAB, pH 8 .6 ); 5h (D2 0 , pH ca. 4; 400MHz) 3.54-
3.60 (1 H, m, 5-H), 3.55 (1 H, dd, J  3.9, 9.8, 2-H), 3.67-3.74 (4 H, m, 0C tf2 CH2 0 P 0 3 2-,
6 -H, 6 -H'), 3.82-3.91 (3 H, m, 3-H or 4-H, OCH2C //2 OP032), 4.26 (1 H, ddd, J  8 .8 , 9.3,
3-H or 4-H), 4.85 (1 H, d, J  3 .9 ,1-H); 8 P (D2 0 , pH ca. 4; 36MHz) 0.32,0.45,0.52 (3 s); 
m/z: (FAB”) 463 [(M-l)-, 100%]; (Found: M“, 462.983. Calc, for C8H 180 16P3 [M-H]- 
462.981).
6.5.15 Allyl 2,6-di-0-benzyl-3,4-bis(di-p-chIorobenzyIphospho)-a-D-gluco- 
pyranoside (278)
A mixture of bis(p-chlorobenzyloxy)(diisopropylamino)phosphine2 4 2  (8 .8 g, 21.3mmol), 
dry dichloromethane (10cm3) and l//-tetrazole (2.2g, 32.0mmol) was stirred at room 
temperature for 20 min, whereupon (265) (2.1g, 5.3mmol) was added and stirring was 
continued for a further 40 min. 31P NMR spectroscopy showed a bisphosphite triester 
AB system at SP 141.55 and 140.93ppm (7 5.5Hz), and excess tetrazolide at 126.26ppm. 
The system was cooled to -78°C and MCPBA (7.3g) was added. Stirring was continued 
for 10 min, when 31P NMR spectroscopy revealed consumption of phosphites to give a 
new product at 8 P ca. -2ppm. The mixture was extracted with ether (200cm3) and the 
organic extract was washed with 100cm3 each of 1 0 % w/v aqueous Na2 S 0 3 solution, 1m
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HC1, saturated aqueous NaHC03 solution and saturated aqueous NaCl solution. The 
organic solution was dried (M gS04), filtered and concentrated to give a waxy solid 
which was purified by flash chromatography (eluent chloroform : acetone 2 0 :1 ) to give 
(278) as a colourless oil (4.7g, 85%); R{ 0.56 (chloroform : acetone 10:1); [a]D +15.2 (c
2.6, CHC13); 8 h (CDC13; 400MHz) 3.58 (1 H, dd, J  3.4, 9.8, 2-H), 3.70 (1 H, ABX, V AB
11.0, V  1 .8 , 6 -H), 3.77 (1 H, ABX, 2/ AB 11.0, V  4.0, 6 -H'), 3.87-3.93 (2 H, m, 5-H, 
C//HCH=CH2), 4.10-4.15 (1 H, m, CHtfCH=CH2), 4.42, 4.50 (2 H, AB, JAB 11.9, 
PhCtf2 0 ), 4.52, 4.67 (2 H, AB, JAB 12.0, PhC//2 0 ), 4.78 (1 H, d, J  3.4, 1-H), 4.82-5.00 
(10 H, m, 4 x Ai CH20  AB systems, 3-H, 4-H), 5.21 (1 H, m, 3J  10.4, 2J  0.9, 
CH2 CH=C//d,HfraJ ,  5.31 (1 H, m, 37 17.1, CH2CH=CHdJ//,raJ ,  5.89 (1 H, m, 
CH2 C//=CH2), 7.05-7.34 (26 H, m, aromatic CH); 5C (CDC13; 100MHz) 68.03 
(CH2CH=CH2), 68.43, 68.67, 68.94 (P[0]OCH2Ar with CP coupling, 7=3-6Hz), 69.20 
(CH), 72.95, 73.30 (2 x PhCH2 0), 74.63, 77.87, 78.63 (3 x CH), 95.21 (1-C), 118.27 
(CH2 CH=CH2), 127.52, 128.00, 128.29, 128.44, 128.55, 128.62, 128.71, 129.06, 
129.15, 129.26, 129.33 (aromatic CH), 133.34 (CH2 CH=CH2), 134.12, 134.20, 134.34,
134.49 (4 x 1 -C of p-chlorobenzylphospho rings), 137.65, 137.98 (2 x 1-C of benzyl 
rings); 5P (CDCI3 ; 162MHz) (^-coupled) -2.38 (sextet, 7hp 8.2), -2 .00 (sextet 7hp 7.8); 
m/z (FAB+) 1057 (6 6 %), 1059 (90%), 1061 (52%), 1063 (16%) [all (M+l)+].
6.5.16 (2-Hydroxyethyl) 2,6-di-0-benzyl-3,4-bis(di-/?-chlorobenzylphospho)-a-D- 
glucopyranoside (279)
To a saturated aqueous solution of sodium metaperiodate (50cm3) containing osmium 
tetraoxide (lOOmg, 0.4mmol) was added a solution of (278) (2.0g, 1.9mmol) in ether 
(50cm3). The mixture was stirred at room temperature for 20 h, when TLC (chloroform 
: acetone 10:1) indicated consumption of starting material (/?f 0.56) to give a product {R{ 
0.05-0.15). The mixture was diluted with ether (100cm3) and the organic layer was 
washed with saturated aqueous NaCl solution (50cm3), dried (M gS04), filtered and 
concentrated. The grey residue thus obtained was subjected to flash chromatography 
(eluent chloroform : acetone 10:1). The product was dissolved in methanol (50cm3) and 
this solution was stirred with sodium borohydride (176mg, 4.7mmol) at room 
temperature for 30 min. The solvent was evaporated and the residue extracted with 
ether (200cm3). The organic extract was washed with 50cm3 each of 1m aqueous HC1,
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water and saturated aqueous NaCl solution, dried (M gS04), filtered and concentrated. 
The residue was purified by flash chromatography (eluent chloroform : acetone 9:1) to 
give (279) as a colourless oil (922mg, 46%); [a]D +17.3 (c 1.3, CHC13); (Found: C, 
56.4; H, 4.81. Calc, for C5 0H5 0Cl4 O13P2: C, 56.60; H, 4.75%); 8 H (CDC13; 400MHz) 
1.90-2.40 (1 H, br s, exch. D2 0 , OH), 3.48-3.52 (1 H, m, CtfHCH2), 3.57 (1 H, dd, J  
3.4, 9.8, 2-H), 3.66-3.74 (5 H, m, CHHCH2, 6 -H, 6 -H’), 4.00 (1 H, ddd, J  2.9, 9.8, 9.9, 
5-H), 4.41-4.58 (4 H, m, 3 x PhCHH AB protons, 4-H), 4.65-4.70 (2 H, m, PhCH//, 1- 
H), 4.83-5.01 (9 H, m, 4 x ArC/f20  AB systems, 3-H), 7.05-7.32 (26 H, m, aromatic 
CH); 8 C (CDC13; 100MHz) 6L54 (2'-C), 68.11, 68.51, 68.64, 68.75, 68.95, 69.26 (4 x 
P[0]OCH2Ar with CP coupling, 7=3-6Hz, l'-C, 6 -C), 71.01 (CH), 73.35, 73.39 (2 x 
PhCH2 0), 74.78, 78.09, 78.47 (3 x CH), 96.89 (1-C), 127.63, 127.71, 128.05, 128.22, 
128.36, 128.60, 128.64, 128.77, 129.11, 129.30, 129.39 (aromatic CH), 134.25, 134.34, 
134.42, 134.60 (4 x 1-C of p-chlorobenzylphospho rings) 137.47, 137.73 (2 x 1-C of 
benzyl rings); 8 p (CDCI3 ; 109MHz) (‘H-coupled) -2 .00 (sextet 7hp 6 .8 ), -1.47 (sextet, 
7h p  10.0); m/z (FAB+) 1061(45%), 1063 (50%), 1065 (30%) [all (M+l)+].
6.5.17 (2-Hydroxyethyl) 2,6-di-0-benzyl-3,4-bis(di-p-chlorobenzylphospho)-2'-(di- 
p-chlorobenzylphosphorothio)-a-D-glucopyranoside (280)
The method employed is a modification of that described by Mills et al. 101 A mixture of 
bis(p-chlorobenzyloxy)(diisopropylamino)phosphine2 4 2  (454mg, 1.1 mmol), dry
dichloromethane (5cm3) and l//-tetrazole (117mg, 1.7mmol) was stirred at room 
temperature for 15 min, whereupon a solution of (279) (590mg, 0.6mmol) in dry 
dichloromethane (5cm3) was added and stirring was continued for a further 30 min. 31P 
NMR spectroscopy showed a phosphite peak at 8 P 139.45ppm and phosphate peaks at 8 p 
-1 .82 and -2.35ppm. The solvents were evaporated and the residue was redissolved in 
dry DMF-dry pyridine 2:1 (3cm3). Sulphur (28mg, 0.9mmol) was added and the system 
was stirred for 30 min, when 31P NMR spectroscopy indicated major peaks at 8 P ca. 
67.8, -2 .2  and -2.6ppm. The suspension was filtered and the solvents were evaporated 
from the filtrate. The residue was extracted with dichloromethane (100cm3) and the 
organic extract was washed with 50cm3 each of 0 .1 m  aqueous HC1, 5 % w/v aqueous 
NaHC03 solution and water, dried (MgS04), filtered and concentrated. The residue was
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purified by flash chromatography (eluent chloroform : acetone 10:1) to give (280) as a 
colourless oil (509mg, 61%); [cc]D +19.7 (c 7.5, CHC13); ^  (CDC13; 400MHz) 3.03- 
3.77 (5 H, m, 2-H, 6-H, 6-H’, OCtf2CH2OP[S][OPCB]2), 3.93 (1 H, ddd, J  3.4, 11.9, 5- 
H), 4.14-4.19 (2 H, m, OCH2Ctf2OP[S][OPCB]2), 4.36-5.02 (19 H, m, 1-H, 3-H, 4-H, 
8 x ArC//20  AB systems), 7.01-7.32 (34 H, m, aromatic CH); 5C (CDC13; 100MHz) 
66.73 (2'-C [with C-P coupling]), 67.92 ( l ’-C or 6-C), 68.63, 68.96, 69.02 (POCH2Ar 
[with C-P coupling, 7=3-7Hz], l ’-C or 6-C), 69.23 (CH), 72.93, 73.28 (2 x PhCH20 ), 
74.41, 77.27, 77.83, (3 x CH), 96.40 (1-C), 127.50, 127.58, 127.94, 128.03, 128.31, 
128.47, 128.53, 128.60, 128.71, 128.80, 129.00, 129.11, 129.24, 129.33, 129.44, 129.48 
(aromatic CH), 134.03, 134.14, 134.34, 134.38, 134.42, 134.53 (6 x 1-C of /?- 
chlorobenzylphospho rings), 137.60, 137.89 (2 x 1-C of benzyl rings); 8P (CDC13; 
162MHz) -2.33 (sextet, 7hp 8, ring phosphate), -1.89 (sextet, 7hp 7.7, ring phosphate), 
68.76 (septet, JH? 10, P[S][OPCB]2); m/z (FAB+) 1406 (47%), 1408 (75%), 1410 
(57%), 1412 (17%), 1414 (9%) [all (M+l)+].
6.5.18 (2-HydroxyethyI) a-D-glucopyranoside 3,4-bisphosphate-2'-phosphoro- 
thioate (276)
Ammonia was condensed into a three-necked flask at -78°C. An excess of sodium was 
added to dry the liquid ammonia, about 30cm3 which was then distilled into a second 
three-necked flask and kept at -78°C. Sodium was added until the solution remained 
blue for 10 min. A solution of (280) (125mg, 89pmol) in dry dioxane (2cm3) was 
added. The mixture was stirred for 2 min, then the reaction was quenched with 
methanol (1cm3), followed by water (10cm3). The solvents were evaporated. The 
residue was dissolved in de-ionised water (700cm3) and purified by ion-exchange 
chromatography on Q Sepharose fast flow, eluting with a gradient of triethylammonium 
bicarbonate buffer (0-1 m ) ,  pH 8.1.  The triethylammonium salt of (276) eluted between 
610-660 mM buffer; [a]D +34.2 (c 0.6 calc, for free acid, TEAB, pH 9.0); 8H (D20 , pH 
ca. 4; 400MHz) 3.52-3.89 (9 H, m, 2-H, 3-H or 4-H, 5-H, 6-H, 6-H’, 0C H 2CH20 ) f 4.23 
(1 H, q, J  9, 3-H or 4-H), 4.87 (1 H, d, J  3.7, 1-H); 8P (D20 , pH ca. 4; 162MHz) 0.94 (d, 
7 hp 8.3, ring phosphate), 1.43 (d, /hp 9.8, ring phosphate), 45.50 (t, J  7.5,
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OCH2CH2OP[S]02); m/z: (FAB~) 479 [(M -1)-, 100%]; (Found: M‘, 478.957. Calc, for 
C8H ,8015SP3 [M-H]*: 478.958).
6.5.19 Fluorescent Labelling of (276)
An aliquot of (276) equivalent to 8|imol by Briggs phosphate assay was freeze-dried 
then dissolved in degassed ethanol (0.05cm3). A solution of N-(4,4-difluoro-5,7- 
dimethyl-4-bora-3a,4a-diaza-5-indacene-3-propionyl)-Ar-iodoacetyl ethylenediamine 
(275) (5mg, lO.Opmol, Cambridge BioScience) in degassed ethanol (0.45cm3) was 
added and the resultant orange suspension was stirred at room temperature for 2 h, when 
3IP NMR spectroscopy showed peaks at 8p 16.5, 1.3 and 0.9ppm. The system was 
diluted with de-ionised water (50cm3) and purified by ion-exchange chromatography on 
Q Sepharose fast flow, eluting with a gradient of triethylammonium bicarbonate buffer 
(0-1m), pH 7.5. The triethylammonium salt of S-[7V-(4,4-difluoro-5,7-dimethy 1-4-bora- 
3a,4a-diaza-j-indacene-3-propionyl)-AT-acetyl ethylenediamine]-(2-hydroxyethyl) a-D- 
glucopyranoside 3,4-bisphosphate-2'-phosphorothioate (277) eluted at 580-650mM 
buffer; 5P (D20 , pH ca. 5, 162MHz) 0.55 (d, 7hp 8.8, ring phosphate), 3.72 (d, 7hp 10.3, 
ring phosphate), 18.71 (quintet, 7Hp ca. 7, 0CH2CH20 P [0 ]2SCH2); 5F (D20 ,  pH ca. 5, 
376 M Hz)-122.58 (s).
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APPENDIX
NOMENCLATURE AND NUMBERING OF INOSITOLS, 
CARBOHYDRATES AND CYCLOHEXANONE FERRIER
PRODUCTS
A .1  I n o sit o l s
The IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) has 
issued two documents concerned with nomenclature of cyclitols, the Tentative Cyclitol 
Nomenclature Rules,312 and the updated 1973 Recommendations for Cyclitol.313
Under these recommendations, a cyclitol is defined as a cycloalkane containing one 
hydroxyl group on each o f three or more ring atoms. The 1,2,3,4,5,6-cyclohexanehexols 
are termed generically “inositols,” and are differentiated by an italicised prefix. There 



















Fig. A.1 The Nine Inositols
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Only d -  and L-c/z/ro-inositol are chiral, the other seven being meso compounds. 
However, on substitution the symmetry of these compounds may be disrupted. In this 
case usual (additive) rules for naming the derivative are followed,314 and the compound 
is numbered such that substituents receive the lowest possible locants; anticlockwise 
numbering gives a substituted inositol with a d -  prefix, clockwise with an l-  prefix. This 










(anticlockwise numbering) (clockwise numbering)
Often, particularly in metabolic sequences, systematic nomenclature is not applied, for 
reasons of clarity. For example, describing the dephosphorylation of D-myoinositol 
1,3,4-trisphosphate to L-myo-inositol 1,6-bisphosphate is somewhat more confusing than 
to D-myo-inositol 3,4-bisphosphate. This relaxation of systematic rules has been 
accepted by the Nomenclature Committee of the International Union of Biology (NC- 
IUB).315
A widely adopted notation for referring to inositol polyphosphates and 
phosphorothioates, which has been accepted by the NC-IUB,315 uses “Ins” to denote 
myo-inositol, followed by substituted positions in brackets and Px (for x phosphate 
groups). Phosphorothioate groups are denoted by S. Absence of a configurational 
prefix implies the D-enantiomer. Thus, (3a) is represented as Ins(l,4,5)P3, d-myo- 
inositol-l,4,5-trisphosphorothioate as Ins(l,4,5)PS3> and D-myo-inositol-1,4- 
bisphosphate-5-phosphorothioate as Ins(l,4,5)P3-5S. Such notation is used throughout 
this thesis.
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A.2 C a r b o h y d r a te s
The nomenclature of carbohydrates is the subject of the CNOC document ‘Tentative 
Rules for Carbohydrate Nomenclature.”316 These comprehensive rules specify that 
substituted glycosides shall be named from the parent monosaccharide with the suffix 
“pyranoside” to denote a six-membered ring, and shall be numbered from the anomeric 
carbon.
A.3 C y c lo h e x a n o n e  F e r r ie r  P r o d u c t s
Under the 1973 Recommendations for Cyclitol,313 products of the Ferrier rearrangement 
such as (148) are named as derivatives of cyclohexanone. Numbering commences at the 
carbonyl carbon and proceeds in the direction to give substituents lowest possible 
locants. Thus, in (148) the deoxy position becomes position 6. Several methods are 
acceptable to specify the configuration of substituents in the ring. In this thesis, the 
Cahn-Ingold-Prelog RS nomenclature314 is used for each position (the same convention 








Products of the modified Ferrier rearrangement, which give non-deoxy inososes such as 
(225) are named from the parent inositol and usual additive rules for substituents are 
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